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ABSTRACT 
Study of Multifactorial Eye Disorders in Pakistan 
The aim of the current study was to investigate the underlying genetic cause in the 
Pakistani population of common multifactorial eye disorders including glaucoma and 
age-related macular degeneration. For this purpose linkage analysis of the families 
suffering from these diseases as well as case-control association analysis of sporadic 
cases of reported single nucleotide polymorphisms (SNPs) was performed. The 
genotyping was done by Sanger sequencing, SNP microarray analysis, exome 
sequencing and Taqman/KASPar SNP genotyping assays. The preliminary analysis of 
glaucoma families was carried out by sequencing candidate genes MYOC, OPTN, 
WDR36 and CYP1B1, which resulted in the identification of a disease-causing mutation 
(c.868dup; p.Arg290Profs*37) in CYP1B1 in a large family with primary congenital 
glaucoma (PCG). 250K microarray analysis of families with PCG and juvenile-onset 
open angle glaucoma (JOAG) resulted in the identification of a possible novel locus on 
chromosome 7 in one family. Exome sequencing revealed possible trigenic inheritance 
(variants in three genes MYO18A; c.2071G>A; p.Arg691Cys, ENOX1; c.171C>T; 
p.Met57Ile and COL9A2; c.1061C>T; p.Pro354Leu) in a family with JOAG, and 
another variant (c.724C>T; p.Val242Met) in NCOA7 segregating with the disease in 
the same family among individuals with late onset of the disease. Moreover in another 
family a possible disease-causing variant was found in the PHKG1 gene (c.125 C>T; 
p.Thr42Met). In the AMD families, sequencing of the complement factor H (CFH) gene 
revealed no mutations. 
Association analysis was performed of polymorphisms previously reported to be 
associated with glaucoma and AMD, in 1000 samples with glaucoma comprising of 
500 samples of primary open angle glaucoma (POAG), 200 samples of primary angle 
closure glaucoma (PACG) and 300 pseudoexfoliation glaucoma (PEXG) samples, as 
well as 300 unaffected controls. In addition, 300 samples of AMD patients and 250 
unaffected age and gender-matched controls were screened. Of the 11 polymorphisms 
screened in the glaucoma cohort, significant association of HSP70 (rs1043618) and 
NOS3 (27bp VNTR in intron 4) polymorphisms with all three types of glaucoma were 
found, whereas association of BIRC6 (rs2754511) and P450 (c.-2805T>C) 
polymorphisms were found only for PEXG. 16 polymorphisms in genes of the 
apoptotic, oxidative stress, complement and inflammatory pathways were screened in 
xi 
 
the AMD cohort. Significant association was found for polymorphisms in MMP2 
(rs243866) and CX3CR1 (rs3732378 and rs3732379) with dry AMD, for NOS3 (27bp 
VNTR in intron 4), and ARMS2 (rs10490924) with wet AMD and for ILβ (rs16944) 
both with wet and dry AMD. 
In conclusion, in the present study possible novel genetic causes of familial glaucoma 
were identified, which included a possible novel locus in a PCG family, a possible 
trigenic pattern of inheritance in a JOAG family involving three genes (MYO18A, 
ENOX1, COL9A2), and in the same family a variant in the NCOA7 gene possibly 
responsible for late-onset glaucoma in a separate loop. Furthermore, in another family 
with JOAG, a variant in the PHKG1 gene was found to segregate with the disease. 
Moreover, SNPs in oxidative stress and apoptosis components were found to be to be 
associated with sporadic glaucoma. In addition, AMD-associated genes were for the 
first time screened in the Pakistani population, which resulted in the identification of 
variants in the complement and inflammatory pathway to be associated with AMD in 
the Pakistani population. 
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Chapter 1 
Introduction
2 
 
1 Introduction 
1.1 Multifactorial Diseases 
Diseases involving multiple causative factors are known as multifactorial diseases. These 
factors can be environmental, metabolic, functional or genetic, with strong interactions 
between them. Several organs of the human body might be affected because of the complex 
interactions of these factors.  
There are many diseases of the eye that are multifactorial in nature e.g. myopia, diabetic 
retinopathy, dry eye disease, age-related macular degeneration (AMD), glaucoma, etc. 
According to the global data on visual impairment, 16 million people around the globe are 
visually impaired, while 37 million are blind due to the presence of different eye diseases, 
and, in addition, 137 million people have low vision. Of the visually impaired, glaucoma 
and age-related macular degeneration are the major cause after cataract (Resnikoff et al., 
2004). The main focus of the current study was to explore the genetics of the multifactorial 
eye diseases glaucoma and AMD. 
1.2 Anatomy of the Eye with Reference to Glaucoma and AMD 
Vision is one of the five most widely used senses that enable human beings to see their 
surroundings. The eye is the organ that is involved in the vision process, which can be 
divided into three segments namely outer, interior and posterior segments and it also 
consists of the optic nerve head (ONH).  
1.2.1 Outer Segment 
The outer segment of the eye includes the eye lid, orbit and sclera; these parts protect the 
eye from external hazards.  
1.2.2 Interior Segment 
The interior segment consists of the cornea, iris, aqueous humor, lens, ciliary body, stroma 
and pupil, which are mostly involved in focusing the light coming from an object and 
maintaining the pressure in the eye (Fig.1.1). The cornea is the transparent portion of the 
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Figure 1.1 Cross sectional view of Eye (Patel and Lundy 2002)  
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eye with no blood supply and allows the light rays to enter the eye through it. Corneal 
transparency is lost at the ends where it merges into the sclera; this point of merging is 
called the limbus. There is a fluid filled chamber between the lens and the cornea, which 
is known as the aqueous chamber. The fluid in the aqueous chamber is secreted by the 
ciliary body and is known as aqueous humor (Riordan-Eva and Whitcher 2007). This fluid 
provides nutrients to the cornea and the lens, and provides the path to the light rays entering 
the eye. Aqueous humor is also involved in maintaining the pressure inside the eye 
(Agarwal et al., 2003; Morrison and Pollack 2011). Once the nutrients from the fluid are 
extracted, it is secreted from the chamber via the drainage system i.e the trabecular 
meshwork (TM) that lies behind the limbus. The fluid passes through the angle between 
the cornea and anterior iris which is known as angle of the anterior chamber or iridocorneal 
angle. Almost 80% of the fluid is secreted through this passage and empties into the 
episcleral venous pathway; the remaining 20% of the fluid is secreted via the Schlemm’s 
canal through the uveoscleral pathway (Distelhorst and Hughes 2003). The fluid outflow 
is hindered to maintain the intraocular pressure (IOP) between 15-21 mmHg, which thus 
maintains the proper shape of the eye and keeps all tissues in their proper position 
(Morrison et al., 2005). The iris is the colored portion of the eye and can be viewed from 
the cornea. This structure controls the amount of light entering the eye via a small opening; 
the pupil (Michael 2005). 
1.2.3 Posterior Segment 
The posterior segment of the eye consists of the vitreous and retina. The vitreous is a clear 
gel like fluid, which fills the posterior segment of the eye and also provides protection to 
it. At the anterior side, the vitreous is in contact with the ciliary body and the lens, whereas 
on the posterior side it comes in contact with the retina (Corina 1999). 
The retina is a thin, almost transparent tissue, which is specialized in capturing the light 
photons and initiates the process of image formation by the brain. It is composed of ten 
layers of neurons interconnected by synapses and supporting cells. The deepest layer of the 
retina is composed of the retinal pigment epithelium (RPE). The RPE is a single layer of 
pigmented cells and is crucial for normal metabolic and supportive functions of the retina 
(De Jong 2006). It serves as an obstruction in flow of ions, nutrients, metabolic products, 
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and water between the retina and the choriocapillaries. It is also responsible for the 
restoration of the visual cycle (conversion of excited trans-retinal to 11-cis retinal and 
recycling it back to the photoreceptors). The photoreceptors shed their tips, which are 
degraded by the lysosomes through the phagocytic activity of the RPE. The regeneration 
of the rod cells occurs at the base by the addition of the membrane of the outer segment, 
whereas in the case of the cone cells replacement of lipids, proteins and membranes occurs 
all over the individual cell rather than just at the base. This regeneration function of the 
RPE is performed by the secretion of growth factors that maintain the photoreceptors, 
endothelium and the choriocapillaries (Ehrlich et al., 2008). Moreover, 
immunosuppressive factors are also secreted by the RPE that help to maintain the immune 
functions of the eye (Strauss 2005). 
The rest of the nine layers of the retina are involved in the conversion of light into 
electrochemical signals and subsequently transmission of these signals to the brain via the 
optic nerve for image formation. The macula lutea is the central yellow portion of the retina 
with a diameter of about 6mm and is responsible for central vision. Central to the macula 
is a depression known as the fovea, which has the highest concentration of cone 
photoreceptor cells and thus is responsible for sharp image formation and color vision. The 
yellowish appearance of the macula is caused by the presence of different pigments 
consisting of antioxidants (xynthophill, carotenoids, lutein, zeaxanthin). Although only 
0.5% of the retina is occupied by the fovea, 50% of the nerve fibers carry the information 
from the fovea due to its dense concentration of the photoreceptor cells. 
The rod and cone photoreceptors convert light into an electrical impulse. Their distribution 
throughout the retina varies. The concentration of cones is highest in the fovea (199,000 
cones/mm2) and decreases towards the periphery, whereas the concentration of the rods is 
highest in the area at 20o from the fovea (160,000 rods/mm2). The photoreceptor density 
also decreases towards the periphery. The cones contain a visual pigment known as opsin, 
which is sensitive to a wide range of wavelengths, depending on the structure of the opsin 
molecule. ‘L’ cones are sensitive to light with long wavelengths (red light, 564 nm), ‘M’ 
cones are sensitive to light with medium wavelengths (green light, 533 nm) and ‘S’ cones 
to light with short wavelengths (blue light, 437 nm). The rods contain visual pigment called 
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rhodopsin, and are sensitive to blue-green light (500 nm). Rods enable vision in dim light, 
are sensitive enough to even detect a single photon of light and are able to detect contrast, 
motion and brightness (Provencio et al., 2000). 
The Bruch’s membrane (BM) is a three-layer connective tissue sandwiched between two 
basement membranes: the RPE basement membrane and choriocapillary basement 
membrane (Figure 1.2). The three layers of BM are the inner collagenous layer adjacent to 
the RPE known as the RPE basement membrane, an elastic central layer, and the outer 
collagenous layer adjacent to the choriocapillaries basal lamina (Sivaprasad et al., 2005; 
De Jong 2006). BM plays two important functions in the eye; structural support and 
transport facilitation. It covers more than half of the eye and whenever extra pressure is 
exerted due to raised IOP or increasing blood volume in the choroid, BM adjusts with it, 
stretching along with the corneoscleral envelope, and when the pressure is lowered the 
membrane reverts back to its original position (Beers and Heijde 1994;  Charman 2008). 
The choriocapillaries lie just behind the BM and provide the choroidal vasculature for the 
transport of nutrients and waste products to and from the photoreceptors via the RPE and 
BM (Nowak 2006). The transport of nutrients takes place from the choriocapillaries to the 
RPE, and waste product removal occurs in the opposite direction via the BM. Certain 
factors necessary for the proper functioning of the photoreceptors such as signalling 
molecules and vitamins are carried to the RPE in the form of lipoproteins passing through 
the BM. The fluid in the eye is moved from the RPE to the BM, which then passes to the 
capillary bed and is subsequently taken away to the main blood stream. With advancing 
age, significant changes occur in the BM that hinder its transport function, resulting in 
accumulation of the waste material in the BM (Curcio and Johnson 2013). The retina 
requires more oxygen as compared to any other tissue (Nowak 2006). In dark conditions 
the photoreceptors are anoxic and thus are dependent upon the choriocapillaries for the 
provision of oxygen, which provides 90% of it. Any harm to the capillaries can prove to 
be fatal to the photoreceptors (Jong 2006). To fulfill the energy requirements of the retina, 
it is enriched by two systems of the vasculature, the retinal vessels and the choriocapillary 
bed. The retinal vessels provide nutrients to the inner retina, whereas the choroid provides
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Figure 1.2 A schematic diagram of the retina is shown in the figure. The inset shows the choroid and layers of the retina, including the 
retinal pigment epithelium (RPE) Bruch’s membrane (BM) choroid, rod cells & cone cells and basement membranes [modified; Zhang 
et al., 2012]   
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nutrients to the outer retina, which is completely devoid of vessels (Campochiaro 2004; 
Das and Mcguire 2003). 
1.2.4 Optic Nerve Head 
The optic nerve head (ONH) is a central convergence point for all retinal ganglion cells, 
comprised of 1.2 million ganglion cell axons (Morrison and Pollack 2011). The nerve fibers 
of these ganglion cells leave the eye at the optic disc where it forms a depression called the 
cup, whereas the outer rim of this region is known as the disc (Quigley 2011). The optic 
disc is 1.5 mm in diameter and the cup is 0.3 mm, with the ratio between the two in a 
normal eye around 1:3 (Morrison and Pollack 2011; Karen 2006). The optic disc consists 
of nerve fiber layers only and thus is not involved in any excitatory visual process; therefore 
it is also referred to as the blind spot of the eye. Some ganglion cells have a pigment known 
as melanopsin, which is not involved in image formation but is involved in the rapid 
adjustment of the pupil size (Provencio et al., 2000). 
Damage to the ONH or macula due to the interplay of multiple factors results in glaucoma 
and AMD, respectively.  
1.3 Glaucoma 
Glaucoma is a group of nurodegenerative eye disorders, generally characterized by optic 
nerve damage in one or both eyes, subsequently resulting in gradual narrowing of the visual 
field. The damage is a result of the death of the retinal ganglion cells and axons in the optic 
nerve (Quigley 2011). It is the second major cause of blindness worldwide (Resnikoff et 
al., 2004), affecting mostly Asians (Stein et al., 2011) and Africans (Ntim-Amponsah et 
al., 2004). More than 67 million people are estimated to suffer from glaucoma at present 
(Quigley 1996), and the number is expected to rise to 80 million by the year 2020 (Varma 
et al., 2011).  
1.3.1 Types of Glaucoma 
Glaucoma can be divided into primary glaucoma and secondary glaucoma. In primary 
glaucoma the etiology of the disease is unknown.  This form of glaucoma can be divided 
into three subclasses: primary open angle glaucoma (POAG), primary angle closure 
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glaucoma (PACG) and primary congenital glaucoma (PCG). In secondary glaucoma the 
etiology is usually known, and most often this category is named after the causative factor. 
Secondary glaucoma consists of pseudoexfoliative glaucoma (PEXG), steroid induced 
glaucoma (SIG), neovascular glaucoma, and pigmentary glaucoma. 
1.3.1.1 Primary Open Angle Glaucoma 
The most common type of glaucoma is POAG; a progressive chronic neuropathy of the 
eye, in which many factors play a role in initiation, progression and damage to the optic 
nerve with irreversible vision loss (Center 2007). POAG is a complex disease and its 
classification is based on the age of onset (0-3 years primary congenital glaucoma; 10-35 
years, juvenile-onset glaucoma, JOAG; 36 years and above adult glaucoma) (Gemenetzi et 
al., 2012). POAG is not always associated with raised IOP and hence can also be classified 
into NTG and high tension glaucoma (HTG), which classification is based upon the 
pressure in the eye. In NTG the pressure remains in the normal range (less than 21mmHg), 
but lowering the pressure further protects the ONH from further damage (Valk et al., 2005). 
The patient becomes aware of the problem only when considerable damage has occurred 
(Hewitt et al., 2006; Mukesh et al., 2002). Although the IOP is not raised in NTG, the loss 
to the ONH and loss of vision is at the same level as in HTG. The reason for the occurrence 
of POAG even at low pressure is still unclear, but genetic and environmental factors are 
postulated to play a combined role in POAG (Fan et al., 2006). 
The risk factors associated with POAG other than raised IOP (Tielsch et al., 1994), are 
family history of the disease, hypertension and cigarette smoking (Wilson et al., 1987). 
1.3.1.2 Primary Angle Closure Glaucoma 
PACG anatomically is characterized by closure of the angle of drainage between the 
trabecular meshwork (TM) and the iris (Tarongoy et al., 2009; Kim and Jung 1997). The 
American Academy of Ophthalmology classifies the primary group of angle closure into 
primary angle closure suspect, primary angle closure without damage and the final stage 
of PACG (Tarongoy et al., 2009). PACG is more aggressive as compared to POAG, and 
patients suffer from an acute and sudden attack resulting in loss of vision, but this condition 
is preventable. The blockage in PACG occurs via two mechanisms; papillary block 
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mechanism and angle crowding, both of which result in abrupt elevation of IOP leading to 
glaucomatic changes in the eye. The aqueous humor flows from its site of production into 
the posterior chamber and then to the anterior chamber, flowing from underneath the iris, 
above the lens, passing through the pupil and finally flows out from the TM. There is a 
pressure difference of 0.23 mmHg in the posterior chamber and the anterior chamber (Heys 
et al., 2001). In pupillary blockage, this pressure increases to 10-15 mmHg, which results 
in the increased convexity of the iris, resulting in iris bombe´ that blocks the TM and thus 
the drainage route of the aqueous humor. The eye anatomy is the strongest risk factor for 
the development of PACG. The shape and the size of iris, placement of the lens and 
anatomy of the ciliary body are the usual factors for the pupillary block. The other mode 
of development of PACG is the mechanism of angle crowding, in which the iris is 
sandwiched between the TM and the ciliary body forming a raised iris arrangement called 
plateau iris, which then blocks the drainage of the aqueous humor and results in the raised 
IOP (Wand et al., 1977; Tarongoy et al., 2009). Patients suffering from PACG also 
experience pain in the eyes, vision blurring, headache, eye redness, vomiting, nausea and 
circles of rainbow color around a light source. The pain radiates to the head and sinuses 
and might cause corneal edema as well (Morrison and Pollack 2011). Family history, age, 
and female gender are risk factors of PACG (Coleman 1999; Karen 2006) 
1.3.1.3 Pseudoexfoliative Glaucoma 
PEXG is a secondary form of glaucoma, occurring in the eye(s) mostly with an age-related 
systemic disorder known as exfoliation syndrome (Viso et al., 2010). The syndrome is 
present in almost 25% patients of open angle glaucoma (OAG) worldwide (Ritch and 
Schlotzer-Schrehardt 2001). PEXG is characterized by the deposition of fibrillar 
exfoliative material on the aqueous bathed surfaces of the eye including the lens, the non-
pigmented iris epithelium and trabecular and corneal endothelium (Naumann et al., 1998; 
Ritch and Schlotzer-Schrehardt 2001). The disease usually manifests when the normal 
passage of aqueous humor is blocked in the TM due to the accumulation of fibrillar 
material, which leads to raised IOP causing OAG (Johnson et al., 2008), which is 
considered to be the primary cause of the development of glaucoma in PEX syndrome. 
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1.3.1.4 Syndromic Forms of Glaucoma 
There are various systemic disorders that involve ocular abnormalities. Several with 
abnormalities of the anterior segment result in glaucomatic changes in the ONH and are 
known as glaucoma syndromes (Wiggs 2007). These syndromes include for example Nail 
patella syndrome, Alfred Reiger’s syndrome, aniridia pigment dispersion syndrome, an 
Marfan’s syndrome.    
1.3.2 Prevalence 
Being the second most prevalent disease responsible for causing bilateral blindness, 
glaucoma affects 16 million people worldwide, ¾ of whom suffer from POAG. Females 
are mostly affected, comprising 55% of POAG patients, 70 % of PACG and 59% of other 
types of glaucoma. Among various ethnic groups of the world, Asians are more prone to 
develop glaucoma after Africans, who have the highest chance of developing glaucoma. 
Among Asians, Chinese have a higher incidence of PACG patients, whereas the Japanese 
have higher number of normal tension glaucoma (NTG) patients. The prevalence of POAG 
is similar among various populations of the world, with the exception of Africans, where 
it is the highest (Cook and Foster 2012).  
1.3.3 Pathophysiology of Glaucoma 
The pathophysiological features of glaucoma revolve around the TM, outflow of the 
aqueous humor, the retinal ganglion cells and the optic nerve. 
The TM is the vital drainage pathway for the normal outflow of the aqueous humor (Tamm 
2009). Pressure is built up inside the anterior chamber of the eye in response to any 
resistance in the outflow of aqueous humor from the TM (Gabelt and Kaufman 2005). A 
normal pressure is necessary to maintain the normal shape of the eye and keep various 
tissues in their respective positions. At stable IOP, the production rate of aqueous humor 
in the ciliary body and its outflow is balanced due to a basal resistance, which helps 
maintain the pressure around 20-21 mmHg. With advancing age, various physiological 
changes occur in the TM. As a result, the resistance increases hindering the normal outflow 
of the aqueous humor and raising the IOP (Gabelt and Kaufman 2005). The TM outflow is 
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responsible for 80% of the aqueous humor drainage, while the rest of it is done by the 
uveoscleral pathway (Alm and Nilsson 2009)  
A raised IOP results in disturbances in the microcirculation of nutrients to the ganglion 
cells. In addition, a raised IOP can also directly damage these cells by triggering apoptosis 
(Osborne et al., 2001). Moreover the TM cells have the capability of producing 
extracellular matrix (ECM) components and when these components attach to the ECM, it 
starts generating various cellular signals thus acting as a signaling molecule (Zhou et al., 
2000). These cells also act as phagocytes and thus have the ability to detach from the site 
of formation and move around. With advancement in age these cells become committed to 
phagocytosis more than any other function; once they detach from their place of origin they 
may be lost via Schlemm’s canal. The TM cells are lost at a rate of 12,000 cells/ year as a 
result of their movement (Gabelt et al., 2003). This decrease in the TM cells resultantly 
hinders the catabolic organization of the cellular matrix (Grierson et al., 1982). Besides, 
accumulation of debris in the TM blocks the drainage of the TM, and thus the nutrients 
present in the aqueous humor do not reach the TM cells. In addition this also blocks the 
toxic metabolites that are needed to be removed (Kaufman., 1995). Another mechanism 
for the loss of retinal nerve fibers in glaucoma is accumulation of plaques that covers the 
fine fibrils, which connect the ciliary epithelium and matrix of the TM thus thickening it 
(Gottanka et al., 1997). The exact relationship of loss of the retinal nerve fibers with the 
accumulation of the sheath particles is not known but it is postulated that the factors that 
affect the formation of the sheath are the same that result in the death of the retinal fibers, 
moreover, they may act in combination with IOP or by themselves may be enough to cause 
the damage (Gabelt and Kaufman 2005). This accumulation results in disruption of the 
cellular arrangement and death of astrocytes (neurosupportive cells; a type of glial cells 
present in abundance in retina) leading to optic cupping. The death of the cells in the ONH 
results in its progressive thinning till the ratio between optic rim (disc) and optic cup 
decreases to 1 (Hernandez 2000). The primary damage to the optic nerve is also thought to 
be due to compliance, a phenomenon in which the ONH is pushed back due to the raised 
IOP, reverting to its original position when the pressure is reduced (Burgoyne et al., 1995), 
this phenomenon results in disorganization of the ONH structure. If the pressure remains 
high for a longer period of time, it results in reduced compliance, which then causes the 
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initial insult to the axons, besides resulting in the accumulation of the ECM material 
(Johnson et al., 2000). The raised IOP also interferes with the transfer of nutrients 
(neurotrophins) to the axons of the ganglion cells, and results in neuronal cell death 
(Quigley 1999). Moreover, cellular apoptosis of the retinal ganglion cells is also one of the 
mechanisms that can lead to pathophysiological changes of glaucoma (Quigley et al., 
1995). 
1.3.4 Signs, Symptoms and Diagnosis 
Raised IOP is considered to be the most important sign of glaucoma but this is not always 
the case. Lower elevation in IOP indicates suspicion of glaucoma and higher eye pressure 
clearly indicates the development of the disease (Coleman 1999). Rapid elevation to 
extreme levels (which is mostly the case in PACG) results in sudden and chronic insult to 
the ONH and rapid loss of vision. In the case of POAG, the IOP remains between 20-30 
mmHg, thus causing progressive damage over a number of years (Karen 2006). A 
tonometer is used to measure the IOP, to assess the individuals at risk of developing 
glaucoma. 
Cupping of the ONH is another symptom of glaucoma, which refers to the disturbance of 
the cup-to-disc ratio.  With the maximum number of axons dying, the ratio falls to 1:1, 
resulting is maximum damage of the ONH (Coleman 1999; Adatia and Damji 2005). 
Vision tunneling is an obvious sign of glaucoma and occurs due to the loss of ganglion 
cells in the ONH (Arthur and Jan 2005). The progressive loss of the peripheral vision leads 
to tunneling of the vision, and the patient remains unaware of the damage until only the 
central vision is left (Buckingham et al., 2008). The visual field damage starts appearing 
when 50 percent of the axons of the ganglion cells are dead (Cook 2009). Visual field 
testing is done to measure the entire field of vision in both eyes individually in order to 
estimate the damage to the field of vision as a result of glaucoma. 
In addition, ophthalmic tests are conducted to differentiate between open angle and angle 
closure glaucoma. A gonioscope is used to measure the angle of the anterior chamber of 
the eye (Fraser and Manvikar 2005). Gonioscopy also helps to differentiate between 
primary and secondary glaucoma (Morrison and Pollack 2011).  
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1.3.5 Risk Factors for Glaucoma 
1.3.5.1 Raised Intraocular Pressure 
Elevated IOP is the most important risk factor for glaucoma, and damage caused as a result 
of elevated IOP is associated with disease progression. However, the role of IOP in 
glaucoma is controversial in the case of NTG, as the pressure is normal. The disease 
remains unnoticed until substantial damage has occurred (Rao 2014). 
1.3.5.2 Age 
Age is also a potential risk factor for glaucoma, although the disease can affect all age 
groups (Drance 2008; Fraser and Manvikar 2005). The usual age range is from 10 years to 
70 years for POAG, with the majority being affected after the age of 40 years (Alward et 
al., 1998).  
1.3.5.3 Ethnicity  
The risk of development of glaucoma is higher among the Afro-Caribbean’s as compared 
to white people. Africans are the most POAG susceptible ethnic group followed by Asians 
(Quigley and Broman 2006) 
1.3.5.4 Miscellaneous Factors 
Gender is also a risk factor; females have been found to be more susceptible than males 
(Quigley and Broman 2006). Vascular abnormalities, vasospasm, migraine, and diabetes 
are also associated with glaucoma (Leske 2007; Fraser and Manvikar 2005). Family history 
of glaucoma increases the risk many fold (Adatia and Damji 2005; Taylor and Keeffe 
2001).  
1.3.6 Treatment of Glaucoma 
Glaucoma treatment involves only the management of IOP as it is the only treatable factor 
known till date (Wilensky 1999). Once glaucoma is confirmed, controlling IOP can help 
stop/slow down the progression of the disease (Lichter 2002). In the past, leeching 
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procedures were used to lower the IOP, but now medications are used to lower it. These 
medications can be administered orally or in the form of ophthalmic drops.  
These drops given to the patient are of different types. Miotics facilitate the flow of aqueous 
humor out of the drainage system by opening it wider. Beta-blockers decrease the rate of 
flow of the aqueous humor into the anterior chamber (Zimmerman and Kaufman 1977). 
Lantoprost increases the flow of the aqueous humor out of the eye (Alm 2014). 
Apraclonidine is used during surgeries and otherwise, to stop the sudden increase in IOP. 
Sometimes when the IOP cannot be controlled with eye drops alone, a combination with 
oral medication is prescribed, which targets the production of the aqueous humor. 
Surgery for the treatment of glaucoma involves trabeculectomy, a procedure in which a 
portion of the TM is removed surgically to facilitate the outflow of aqueous humor. 
Although this procedure relieves the patient from pain and glaucoma medication, cataract 
develops as an after effect of surgery mostly within 5 years. Laser surgery is becoming 
more and more popular because of its fewer post-operative complications and also as it is 
a painless procedure. In this procedure a laser beam is used to shrink the TM muscles, 
resulting in widening of the path for the aqueous humor outflow. 
1.4 Age-Related Macular Degeneration  
Initial cases of age-related macular degeneration (AMD) were seen in 1875 by two 
clinicians, Hutchinson and Tay, who explained the condition in aged patients due to 
different changes in the fundus. Ten years later, in 1885, this condition was clinically 
recognized and was known as “senile macular degeneration” by Otto Haab. Today it is 
alternatively called AMD or age-related maculopathy (ARM) (Mcconnell and Silvestri 
2005).  
It is mainly a disease of the RPE layer of the retina that leads to various age-related changes, 
causing deterioration of the photoreceptors primarily in the macular region resulting in loss 
of central vision (Chen et al., 2010b). This loss of central vision adversely affects normal 
daily chores of a person, such as reading, driving and facial recognition (Ehrlich et al., 
2008). 
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1.4.1 Prevalence of AMD 
The usual age of onset of AMD is 50 years. Above the age of 65 years the disease 
occurrence increases to 35%, and being prevalent mostly in people of 80 years of age. 
Therefore, for AMD-based epidemiological studies, 50 years is chosen as the minimum 
patient inclusion criterion (Bird et al., 1995). AMD is more prevalent in Caucasians as 
compared to other populations (Chen et al., 2010b). AMD is common in the female gender 
above the age of 75 years, and the prevalence of wet AMD is twice as high in females as 
compared to males (Smith et al., 1997). Epidemiological studies in the U.S. have shown 
that there are 8 million people suffering from intermediate AMD, whereas 2 million have 
the advanced stages of the disease (Owen et al., 2003). 
1.4.2 Clinical Classification of AMD  
Changes in the macula are used to clinically diagnose AMD (Jong 2006), which can be 
grouped into two classes: dry and wet AMD.  
1.4.2.1 Dry AMD 
Dry AMD can be classified as early, intermediate and late dry AMD. Characteristic 
features of early AMD are the accumulation of small drusen without any significant loss 
of vision. In intermediate AMD, accumulation of drusen occurs (both basal laminar and 
basal linear deposits). Moreover, lipofuscin accumulation, thickening and disturbance in 
the architecture of the BM and hyper- or hypo-pigmentation in the macular region also 
takes place. The first sign of late dry AMD is the appearance of the geographic atrophy of 
the RPE cells, and thus it is also known as geographic AMD or non-exudative AMD. This 
results in the degeneration of the photoreceptor cells and thinning of the retinal layer, and 
consequently, deterioration of vision. The retinal atrophy also moves to the other layers of 
the retina, thus worsening the condition. Hyperpigmentation of the peripheral regions of 
the patchy areas occurs in response to apoptosis of the RPE cells (Ding et al., 2009). Dry 
AMD is responsible for loss of vision in 20% of the AMD patients (Ferris et al., 1984).  
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1.4.2.2 Wet AMD 
A characteristic feature of wet AMD is the formation of new vessels in the sub-retinal 
space, and therefore it is also known as neovascular AMD or exudative AMD. The classical 
pattern of growth of these vessels is across the BM and into the sub-retinal space (Ding et 
al., 2009). Vision is severely compromised, primarily due to hemorrhage and exudate 
formation, and secondly due to the cellular apoptosis. The CNV can cause detachment of 
the RPE or the retina. As the CNV progresses to the macular region, the elastic layer of the 
BM becomes thin in the foveal region. This results in reduction of the foveal region to 
55nm, also increasing the porosity of the foveal region to up to 35% (Ambati et al., 2003). 
The end stage of wet AMD is disciform scar formation, vascularised by the choroid and 
sometimes by the retinal blood supply as well. The bigger the scar is, the greater the loss 
of the RPE and photoreceptors (Green and Enger 2005). People with wet AMD may also 
develop blind spots. 
1.4.3 Pathophysiology of AMD 
The outer surface of the retina, which is a combination of RPE, photoreceptor cells (rods 
and cones) and Bruch’s membrane (BM), faces the choroid and hence is dependent on the 
choriocapillaries for nutrition, while the internal surface faces the vitreous chamber. All 
these parts together are called Ruysch’s complex and are responsible for retinal function 
(Jong 2006). With advancing age, degenerative changes in RPE, BM and choriocapillaries 
(in the case of wet AMD) are the characteristic features of AMD (Coleman et al., 2008). 
The pathological features of AMD involve changes in the RPE cells, Bruch's membrane 
and photoreceptor cells (Fig. 1.3) and the mechanisms leading to AMD are formation of 
the drusen, formation of lipofuscin, choroidal neovascularisation and inflammation. 
1.4.3.1 Formation of Drusen 
The clinical hallmark of AMD is the formation of deposits or drusen, which can vary in 
color (white to yellow) and size (De Jong 2006; Nowak 2006). The particles of drusen 
lump together as a result of the aging process, which in turn is due to many factors including 
physiological changes, oxidative stress, inflammation and the activity of the immune 
system, which all play a central role in the formation of drusen (Anderson et al., 2010). 
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Figure 1.3 Differences between an RPE cell of a 3-year old child and an 80-year old person. 
The outer segments of the rods and cones are embedded in the interphotoreceptor matrix 
(blue-gray areas) and partially surrounded by apical pseudopodial RPE processes). The 
figure shows the shed disks (right-hand panel); digested by the RPE. The right-hand panel 
shows enlarged lipofuscin granules, the thickened Bruch's membrane, and attenuation of 
the choriocapillaries. The central elastic lamina in Bruch's membrane becomes more 
porous in old age (De Jong 2006) 
 
  
19 
 
Drusen are generally composed of glycoproteins (central part), surrounded by 
apolipoproteins (A & E), chaperone proteins, inflammatory proteins, fibronectin, 
vitronectin and RPE debris (Jong 2006). The major components of drusen are lipids, which 
originate from the membrane debris of the shed photoreceptor discs (Malek et al., 2003). 
The RPE transports the membrane bound particles (secretary proteins, lipids, and 
cytoplasm), and malfunctioning of the RPE is thus thought to be involved in the formation 
of drusen in the BM. Moreover, ECM remodelling is also suggestive of drusen formation 
due to its presence in different regions in the BM (Hageman and Mullins 1999; Luibl et 
al., 2006). Moreover, drusen formation is probably an active and discriminatory process 
rather than just a slow build-up of lipid and protein debris in the BM, and thus not only age 
but also genetic components and environmental stress factors coalesce to cause the disease, 
which explains why not all elderly people have AMD (Ehrlich et al., 2008; Sivaprasad et 
al., 2005; Jong 2006). 
Drusen, on the basis of their aggregation site in the BM and composition are classified into 
two categories: basal laminar drusen and basal linear drusen. Basal laminar drusen are 
located between the RPE and basement membrane of RPE (Russell et al., 2000), whereas 
basal linear drusen are located between the RPE basement membrane and the inner 
collagenous layer of BM (Curcio and Millican 1999). Basal laminar drusen are considered 
as a histological finding of AMD, consisting mostly of collagen, fibronectin, laminin, and 
lipids, which are formed during advanced stages of the disease (Yamada et al., 2006; Reale 
et al., 2009). Basal linear drusen consist of lipoprotein particles and lipid aggregates that 
stack together forming a lipid wall (Curcio and Millican 1999).  
Based on the appearance of the boundary of drusen, they can be classified into ‘soft’ or 
‘hard’, drusen. Soft drusen are known to accumulate in the macular region, increasing the 
risk of AMD many-fold (Davis et al., 2005; Klein et al., 2007). Soft and basal linear drusen 
are fragile, oily and not easily isolatable particles, and the lipids present in the soft drusen 
are membranous debris (Rudolf et al., 2008). Hard drusen mostly accumulate in the 
peripheral region and are easily isolated. The major components of hard drusen are 
apolipoproteins and lipoproteins (Ryan et al., 2012) 
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1.4.3.2 Formation of Lipofuscin 
Yellowish brown cellular debris, known as age pigment or lipofuscin, accumulates over 
time in the RPE (Terman and Brunk 1998). It is composed of bisretinoids, lipids (~50%) 
and proteins (~44%) (Julien and Schraermeyer 2012) and shed membranes of the outer 
segments of photoreceptor cells (Saprunova et al., 2010). The accumulation of lipofuscin 
causes the death of RPE cells and result in dark patchy areas (geographic atrophy) that 
gives rise to dry AMD (Holz et al., 2007). Lipofuscin amassing in the RPE results in 
adverse effects on the RPE. Its component N-retinylidene-N-retinylethanolamine (A2E) 
seems to eliminate the acidic environment of the lysosome and thus hinders the degradation 
activity of the lysosome, in turn hindering the phagocytic property of the RPE cells (Godley 
et al., 2005). Moreover, A2E activates the complement system, which then results in 
activation of the immune system (Radu et al., 2011). It also has the ability to stimulate the 
production of reactive oxygen species (ROS) in response to light (Saprunova et al., 2010).    
1.4.3.3 Choroidal Neovascularization (CNV) and Inflammation 
Normally, endothelial cells control angiogenic signals, and thus a balance is maintained 
between the pro-angiogenic factors (VEGF) and anti-angiogenic factors (pigment 
epithelium derived factor, PEDF) (Das and Mcguire 2003). If this balance is disturbed as 
a result of ischemia or hypoxia, it results in upregulation of angiogenic growth factors 
(Campochiaro 2004). In the choriodal vasculature, besides ischemia and insult, also local 
inflammation and activation of the immune system are thought to play a significant role in 
the initiation and progression of CNV (Das and Mcguire 2003; Anderson et al., 2002). The 
immune cells, like mast cells and neutrophils, have the ability to disrupt the balance of pro- 
and anti-growth factors by releasing pro-angiogenic factors (Kijlstra et al., 2005). VEGF 
and PEDF have been postulated to play a very important role in the formation of CNV, and 
thus therapeutic strategies have been and are being developed to maintain the balance 
between VEGF and PEDF (Nowak 2006). The new vessels (neovascularisation) thus 
formed either remains under the RPE or they may break through the RPE cells and enter 
the sub-retinal tissue. The blood from these vessels may also seep out into the sub-retinal 
area giving it a grayish color (Ambati et al., 2003). 
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1.4.4 Risk Factors 
1.4.4.1 Age 
Age is a major risk factor for AMD. In the age group of 65-74 years, it is prevalent among 
approximately 20% of people, and in the 75-84 year age group it occurs in almost 35% of 
people (Bonnel et al., 2003). Major changes occurring with age are the accumulation of 
lipids and lipofuscin formation in the BM, which when exposed to daylight generate ROS 
that are potent in damaging the membranes (protein and lipid). A2E creates phototoxic 
environment (via blue light), disrupting the membrane integrity, and apoptotic death of the 
RPE cells. Similarly, lumping of drusen associated with AMD occurs with increasing age 
(Sparrow et al., 2000; Schutt et al., 2000). 
1.4.4.2 Smoking 
Smoking is a single, strong, modifiable risk factor of AMD that increases the risk of 
development of disease 2 to 4 times, and persists as a risk factor for even 20 years after 
cessation of smoking (Morris et al., 2007). There is a linear relationship in the number of 
cigarettes smoked and the progression of AMD (Coleman et al., 2008). Depletion of 
antioxidants and the resultant oxidative stress might be the result of smoking, but the exact 
mode of action of involvement of smoking in causing AMD is not known (Dhubhghaill et 
al., 2010; Cano et al., 2010). 
1.4.4.3 Diet 
A diet rich in fats and cholesterol has been associated with increased risk of developing 
AMD. A mineral- and antioxidant-rich diet decreases the risk of disease progression by 
25% (2001). Carotenoids are also found to have a protective role in AMD (Seddon et al., 
1994).  
1.4.4.4 Exposure to Sunlight 
Exposure to sunlight has been shown to be associated with increased risk of development 
of AMD but not its progression. Use of sunglasses or a hat have been seen to be protective 
against the development of AMD (Tomany et al., 2004a). The possible mechanism of 
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sunlight-induced damage is the creation of oxidative stress in the macular region (Taylor 
et al., 1992).   
1.4.5 Treatment of AMD 
There is no standard treatment of AMD that can revert the loss of vision. Therefore, 
prevention is the best mode of defense against the disease. Taking care of modifiable risk 
factors, such as smoking and diet, can help reduce the chances of developing the disease 
(Tomany et al., 2004b).  
Currently, there is no medication available for the cure of dry AMD or its prevention from 
advancing to the late stage. Usually, dietary supplements are used to reduce the chances of 
the disease entering into advanced stages. The Age Related Eye Disease Study (AREDS) 
found that a combination of antioxidant minerals and vitamins act as preventive agents, but 
this study could not establish a regimen for the cure of the disease, since the combination 
supplement could not prevent the disease from entering the advanced stages (Age-Related 
Eye Disease Study Research Group., 2001). In the next study trial, lutein and zeaxanthin 
were added to the supplementation, which further decreased the chances of development 
of advanced stages of the disease. It was found to be 20% more beneficial as compared to 
the previous supplement (Age-Related Eye Disease Study 2 Research Group., 2013). Beta-
carotene has been reported to be associated with lung cancer in smokers, and hence was 
removed from the final formulation of the supplement. The current supplement that is given 
to patients with dry AMD comprises of vitamin C (500 mg), vitamin E (400 IU), zinc (as 
zinc oxide 80 mg), copper (as cupric oxide 2mg), lutein (10mg)/zeaxanthin (2 mg), omega-
3 long-chain polyunsaturated fatty acids, docosahexaenoic acid (DHA-350 mg) and its 
precursor, eicosapentaenoic acid (EPA-650 mg) (Ratnapriya and Chew 2013). 
The most effective therapy for wet AMD is anti-VEGF therapy, which involves intravitreal 
injections of humanized monoclonal antibodies, Avastin (bevacizumab) and Lucentis 
(ranibizumab). The mode of action of this drug is neutralization of all active forms of 
VEGF and thus its angiogenic capacity. A new therapic compound, Aflibercept, is also 
given to the patients via intravitreal injections, and it acts as a soluble receptor that traps 
the VEGF family of proteins (Ratnapriya and Chew 2013).  
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1.5 Molecular Pathology of Glaucoma and AMD 
Many aspects of glaucoma and AMD are not fully understood, and the treatment options 
are thus very limited. Therefore, there is a need to study the molecular mechanism of the 
disease to gain a better understanding of the disease processes, and thus create the 
possibility of developing better treatments. Interactions of various molecular mechanisms 
involved in glaucoma and AMD are depicted in the flowchart in Figures 1.4 & 1.5.  
1.5.1 Role of Oxidative Stress in Glaucoma and AMD 
Oxidative stress can be described as the physiological production of ROS, and failure of 
scavenging enzymes to eliminate them thus creates an environment of stress. With 
advancement in age, the concentration of free radicals increases and results in oxidative 
stress and damage to various tissues of the body, especially post-mitotic tissues such as 
brain, heart, liver, and the retina. (Shigenaga et al., 1994). ROS include radical OH-, 
peroxyl radical ROO-, super anion of oxygen O2
-, hydrogen per oxide H2O2, hydroxyl and 
singlet oxygen 1O2 (Ferreira et al., 2004). Free radicals are involved in lipid per-oxidation 
of cell membrane components thus disrupting it, increasing the vulnerability of DNA, 
proteins and mitochondrial DNA. This mechanism is believed to play a general role in most 
degenerative diseases (Sacca et al., 2007). Under the influence of age, smoking, pollution, 
and inflammation, free radicals keep on leaking from the active sites of the enzymes 
(Borish et al., 1987). Oxidative stress has been reported in different ocular complications 
including glaucoma (Ferreira et al., 2004) and macular degeneration (Yildirim et al., 2004). 
Its role in glaucoma was postulated thirty years ago (Alvarado et al., 1981; Alvarado et al., 
1984). Subsequently, in vivo and in vitro experiments were conducted to determine the role 
of oxidative stress in glaucoma (Izzotti et al., 2006). In the in vitro studies, TM cells were 
treated with H2O2, which demonstrated that these cells lose their integrity and cell-to-cell 
adhesion capacity decreases in the presence of H2O2 (Zhou et al., 1999). In vivo studies on 
calf showed that perfusion with H2O2 resulted in a change in the drainage of aqueous humor 
from the interior chamber to the posterior chamber (Kahn et al., 1983). Moreover, 
treatment with anti-oxidants has been shown to provide protection to retinal ganglion cells 
in rats (Ko et al., 2000). Superoxide dismutase, glutathione oxidase and catalase act as 
antioxidant enzymes in eye tissues, in particular in the TM and aqueous humor, and provide  
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Figure: 1.4 Pathological mechanisms involved in glaucoma [modified (Vohra et al., 2013), (Sacca et al., 2007)]. IOP; Intra Ocular 
Pressure, NO; Nitric Oxide, ET1; Endothelin1, TBM; Trabecular Meshwork, RGC; Retinal Ganglion Cells.  
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      Figure: 1.5 Pathological mechanisms involved in AMD [modified (Anderson et al., 2010; Nowak 2006; Kopitz et al., 2004)]. 
RPE; Retinal Pigment Epithelium, NO; Nitric Oxide, CFH; Complement factor H, C3; complement 3, C2; Complement 2.  
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a defense mechanism against free radicals by scavenging them (Behndig et al., 1998). 
Carotenoids such as lutein and zeaxanthin are present in the macular region (macular 
pigments), where they provide the first line of defense to neurons, particularly from singlet 
oxygen (Frank 1996). It has been found that the level of glutathione is lower in glaucomatic 
eyes, suggesting that its protective role is compromised. Moreover, polymorphisms in 
Glutathione S Transferase Mu 1 (GSTM1; that catalyse reaction of glutathione with variety 
of organic compounds and is involved in detoxification process) have been associated with 
glaucoma (Izzotti et al., 2003). Although the enzyme is not directly involved in IOP 
management, it may protect aqueous-bathed surfaces from the possible damaging effects 
of H2O2 (Kahn et al., 1983). Most damaging changes due to H2O2 occur in the inner layers 
of the TM due to oxidative stress, which together with other factors can induce TM cell 
loss, the thickening of the fibrils in TM, which result in compromising the integrity of the 
TM (Sacca et al., 2007). The structural units of TM, glycosaminoglycans (GAGs) and 
hyaluronic acid, play an important role in the outflow of aqueous humor, and their integrity 
is disturbed in the presence of reduced quantities of ascorbate (Sacca et al., 2007). 
Moreover, due to elevated free radicals, nitric oxide (NO) has the capacity to generate toxic 
substances that can damage the TM and alter its properties (Lipton 1999). Endothelin levels 
have been seen to be elevated in glaucomatous eyes, which reduce the blood flow in the 
ONH and/or hinder the axonal transport and cause glaucomatic damage (Yorio et al., 
2002).  
The retina has the highest consumption of oxygen compared to all other tissues, and 
therefore accumulatess a high concentration of free radicals. The RPE contains many 
photosensitizers, such as in the outer segments of the photoreceptor cells that contain 
polyunsaturated fatty acids (PUFAs), which are continuously being shed and phagocytosed 
by the RPE cells (Beatty et al., 2000). The burden of phagocytosis by the RPE increases as 
a consequence of the above mentioned changes, which results in peroxidation of lipids that 
damages the RPE itself thus triggering apoptosis of the RPE. As a consequence, the 
apoptotic RPE cells and the undigested phagocytosed material pile up in BM and trigger 
drusen formation (Ishibashi et al., 1986; Cai et al., 2000). Lipofuscin present in the RPE 
cells acts as a photosensitizer, generating ROS and damaging the RPE. Moreover, the A2E 
compound of lipofuscin hinders the function of the RPE, reducing its capacity of 
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phagocytosis (Gaillard et al., 1995; Holz et al., 1999). Lipofuscin can also induce 
generation of ROS under the influence of light (Beatty et al., 2000). 
1.5.2 Role of Immune System in Glaucoma and AMD 
An inflammatory response is elicited in the eye in response to ischemia, vascular 
dysregulation, oxidative stress, hypoxia, and raised IOP (Ergorul et al., 2010). The immune 
system maintains the tissue architecture by helping the cells to overcome these stresses and 
thus maintain the tissue architecture, which otherwise would result into neurodegenerative 
changes (Schwartz and Ziv 2008). With advancing age and chronic increase in stress 
factors, the potential of the immune system to overcome the stress decreases. Initially 
providing a protective mechanism, the immune system overactivates the immune 
regulatory protection of the tissues and thus results in an autoimmune-triggered 
neurodegenerative process (Tezel 2009).  
The complement cascade, auto-antibodies and T-cell cytotoxicity have been found to be 
involved in the degeneration of RGC and axons in glaucoma (Wax et al., 2008). Heat shock 
proteins (HSPs) have an antigenic character, and their upregulation is taken as a signal for 
the removal of harmful and stressed cells thereby activating the immune response (Tezel 
et al., 2000). The vascular dysregulation, as a result of raised IOP and other stressors is 
also seen to play a role in activation of the immune response and ischemic injury to the 
ONH (Vohra et al., 2013). In response to these changes (raised IOP, ischemia, stressors), 
nitric oxide (NO) and endothelin 1 (ET-1) levels rise in the vasculature, resulting in 
lowering of the IOP. However ET-1 also lowers the blood flow to the ONH, with potential 
damaging consequences (Sugiyama et al., 1995). Ubiquitin-dependent proteosomal 
degradation system is also disrupted by the ET-1, which decreases the ubiquitination in the 
ONH and activates caspase-3, resulting in apoptosis (Dibas et al., 2008).  As a result of 
this disruption in the ocular blood flow, other inflammatory compounds are also 
upregulated, which include tumor necrosis factor (TNF), C reactive protein (CRP), 
vascular endothelial growth factor (VEGF), and interleukins (ILs) (Vohra et al., 2013). The 
overexpression of VEGF activates the major histocompatability complex (MHC-I and 
MHC-II), thus eliciting an immune response (Chintala et al., 2002). VEGF interaction with 
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ET-1 and involvement in VEGF has been previously reported in POAG and NTG (Iwabe 
et al., 2010).  
The most significant pathogenic mechanism of the immune system involved in AMD is 
the complement pathway (Parmeggiani et al., 2012). Macrophages and lymphocytes have 
also been reported to be present in the Ruysch's complex (Penfold et al., 1985; Dunaief et 
al., 2002), moreover the oxidative stress produced in the photoreceptors also influences the 
activation of the complement system, resulting in apoptosis of retinal cells in the Ruysch's 
complex and accumulation of drusen (Hollyfield et al., 2010). It has been reported that the 
retina and RPE can manufacture as well as transport lipoproteins, besides extracting them 
from the blood (Zheng et al., 2012). Apolipoprotein B (Apo-B) mediated transport of 
cholesterol has been observed to be the most important mechanism involved in the 
pathogenesis of AMD (Curcio et al., 2010). The particles (Apo-B) pile up in the BM, 
resulting in activation of drusenogenesis with advancing age (Curcio et al., 2009). Various 
genes in these pathways have been identified as pathogenic factors for AMD in genome-
wide association studies (GWAS), which include high density lipoprotein (HDL) related 
genes such as ATP binding cassette transporter 1 (ABCA1), hepatic lipase (LIPC), 
cholesteryl ester transfer protein (CETP), and lipoprotein lipase (LPL) (Neale et al., 2010). 
The accumulation of drusen in the BM and RPE is capable of triggering inflammation by 
triggering the complement system and cytotoxicity (Pauleikhoff et al., 1990). 
1.6 Genetic Etiology of Glaucoma and AMD 
Various DNA sequence variations with pathogenic consequences have been reported to be 
associated with the development of genetic disorders (Lai 2001). Advancement in 
statistical and bioinformatics tools as well as evolution of techniques such as GWAS, 
microarrays and advancement in sequencing techniques has enabled researchers in better 
understanding complex diseases such as glaucoma and AMD (Feero et al., 2008). These 
advancements have made the genetic analysis of these diseases somewhat easier (Fuse 
2010). As glaucoma and AMD are both mutlifactorial complex disorders, multiple genes 
can be involved in the pathogenicity of these diseases (Donoso et al., 2006). The current 
etiology of these disease mechanisms is not clearly understood due to the complex nature 
and involvement of a combination of factors in their manifestation. The interactions of 
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these multiple factors result in deviation from the Mendelian mode of inheritance of 
multifactorial diseases such as glaucoma and AMD (Fan et al., 2004; Libby et al., 2005).  
In addition, in the case of multifactorial diseases, more than one gene might interact with 
each other in disease manifestation (Faucher et al., 2002; Baird et al., 2003). Monogenic 
forms of glaucoma and AMD also exist such as PCG (Lopez-Garrido et al., 2013) and 
juvenile macular degeneration (Stargardt disease) (Tuo et al., 2004).  
1.6.1 Molecular Genetics of Glaucoma 
To date 20 loci (Table 1.1) (GLC1A to GLC1N, GLC3A to GLC3D) have been reported 
to be associated with familial glaucoma and three genes, myocillin (MYOC), optineurin 
(OPTN), and WD repeat domain 36 (WDR36), have been reported to be the causative 
factor in these loci (Fuse 2010). Cytochrome P450 (CYP1B1) has been found to be 
associated with PCG. These loci have been found by candidate gene analysis in which a 
plausible gene is screened in the family on the basis of its function (Fuse 2010). In total 
more than 20 genes (Table 1.2) have been reported to be associated with POAG (Fuse 
2010) and 9 genes associated with PACG were identified by GWAS (Vithana et al., 2012) 
and case-control association studies in different cohorts (Shastry 2013). 
Worldwide more than 70 point mutations in MYOC have been found to be associated with 
POAG (predominantly with JOAG), with a 3-5% overall association with POAG (Challa 
2011). MYOC encodes a 570 kDa protein, spans a 17 kb genome region and has 3 exons. 
The MYOC protein has a C-terminal alfactomedin-like domain and an N-terminal myosin-
like domain (Suzuki et al., 1997). In the eye it has been reported to be present in the TM, 
aqueous humor (Suzuki et al., 1997) and in the sheath of the optic nerve fibers (Tamm et 
al., 1999). Different mutations in MYOC have been reported to interfere with aqueous 
humor outflow and thus increase the IOP. However, the mechanism of the rise in IOP has 
not been clearly defined yet (Mackey et al., 2003; Wilkinson et al., 2003). 
In vivo studies of MYOC have shown that it does not seem to play a role in the pathogenesis 
of glaucoma, which could be a coincidental finding, or the gene might be acting in tandem 
with another gene. For examples, the. Gly399Val mutation in the the MYOC gene has been 
reported to cause late-onset POAG (mean age of 51 years), however, when it occurs in  
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Table: 1.1 Loci associated with glaucoma 
Locus name Gene Name Chromosomal 
location 
Characteristic  
Features 
Mode of inheritance Population 
studied 
References 
GLC1A Myocilin 1q23 JOAG; high IOP Autosomal dominant  Sheffield et al., 1993 
GLC1B - 2cen-q13 Late onset, moderate IOP   Stoilova et al., 1996 
GLC1C - 3q21-24 Late onset Autosomal dominant  Wirtz et al., 1997 
GLC1D - 8q23 Adult onset Medium IOP Autosomal dominant  Trifan et al., 1998 
GLC1E Optineurin 10p13 Adult onset NTG Variable pattern British Sarfarazi et al., 1998 
GLC1F ASB10 7q36 Late onset, low and high 
IOP 
Autosomal dominant U.S Wirtz et al., 1999 
GLC1G WDR36 5q22.1 POAG, NTG   Monemi et al., 2005 
GLC1H - 2p16-p15 Late onset, moderate to 
high IOP 
Variable segregation 
pattern 
British Suriyapperuma et al., 
2007 
GLC1I - 15q11-q13 Adult onset Complex segregation  Caucasian Allingham et al., 2005 
GLC1J - 9q22 JOAG Autosomal dominant  Wiggs et al., 2004 
GLC1K - 20p12 JOAG   Wiggs et al., 2004 
GLC1L - 3p22-p21? Late onset, autosomal dominant British Baird et al., 2005 
GLC1M - 5q22.1-q32 JOAG Autosomal dominant Filipino Pang et al., 2006 
GLC1N - 15q22-q24 JOAG Autosomal Dominant Chinese Wang et al., 2006a 
GLC1O NTF4 19q13.3 POAG, NTG  European Pasutto et al., 2009 
GLC1P TBK1* 12q14 NTG, early onset Autosomal dominant African-
American 
Fingert et al., 2011 
GLC3A CYP1B1 2p21 PCG, very high IOP Autosomal recessive  Sarfarazi et al., 1995 
GLC3B  1p36.2-p36.1 PCG, very high IOP Autosomal recessive  Akarsu et al., 1996 
GLC3C  14q24.3-31.1 PCG, very high IOP Autosomal recessive  Stoilov and Sarfarazi., 
2002 
GLC3D LTBP2 14q24 PCG, very high IOP Autosomal recessive Pakistani Firasat et al., 2008 
*300kb duplication in TBK1 gene 
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combination with the Arg368His mutation in CYP1B1, the age of onset of the disease 
decreases to a mean age of 27 years (Challa 2011). In vivo analysis of MYOC mutations in 
double mutant mice revealed that the gene is not associated with IOP maintenance, since 
no TM abnormalities were seen in transgenic mice after the introduction of these mutations 
(Liu and Neufeld 2003).  
The optineurin gene has been reported to be associated with a late age of disease onset, but 
it has been found to account for only about 1% of glaucoma mutations. Polymorphisms in 
the gene are associated with NTG, and the Glu50Lys variant has been reported in POAG 
cases (Leung et al., 2003). The Met98Lys variant is also associated with NTG (Craig et 
al., 2006). The gene encodes a 577-kDa protein expressed in the TM, ciliary muscle, and 
retina, and has been shown to have a protective role in the eye, being expressed in response 
to stress (Vittotow and Borras 2002).  
Mutations in WDR36 account for pathogenicity in less than 1% of glaucoma cases. 
Although initially associated with glaucoma, later studies have shown no involvement of 
the gene in glaucoma (Gemenetzi et al., 2012). 
PCG is a developmental disorder of infants, usually occurring in sporadic cases, but 
familial cases of the disease have also been reported. The disease is inherited as an 
autosomal recessive trait (Sarfarazi et al., 2003; Bejjani et al., 2000). Although to date four 
loci have been linked to the condition, GLC3A, GLC3B, GLC3C and GLC3D, only two 
genes have been found in these loci to be causative of the disease i.e. GLC3A (CYP1B1) 
and GLC3D (Latent transforming growth factor beta binding protein; LTBP2) 
(Mozaffarieh et al., 2008; Coleman 1999). Around 60 different mutations in CYP1B1 have 
been reported to be associated with PCG (Ressiniotis et al., 2005). To date, a single 
mutation in LTBP2 has been identified to cause PCG in a Pakistani family (Ali et al., 1999), 
which was also found homozygously later as a founder mutation in 12 Gypsy PCG 
probands (Azmanov et al., 2011). Besides the mutations, there is just one report of a single 
basepair deletion in the gene resulting in PCG (Narooie-Nejad et al., 2009).     
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Table: 1.2 Genes and polymorphisms associated with POAG and PACG 
Gene Disease type Population Original study 
AGTR2 POAG Japanese Hashizume et al., 2005 
ANP POAG Australian Tunny et al., 1996 
APOE POAG -- Copin et al., 2002 
CDH-1 POAG Chinese Lin et al., 2006 
EDNRA POAG Japanese Ishikawa et al., 2005 
GPDS1 POAG Japanese Nakamura et al., 2009 
GST POAG Estonian Juronen et al., 2000 
HSPA1A POAG Japanese Tosaka et al., 2007 
IGF2 POAG Chinese Tsai et al., 2003 
Ilβ POAG Chinese Lin et al., 2003b 
MFN1 POAG German Wolf et al., 2009 
MFN2 POAG Dutch Wolfs et al., 1998 
MTHFR POAG -- Junemann et al., 2005 
NCK2 POAG Japanese Akiyama et al., 2008 
NOS3 POAG Australian Tunny et al., 1998 
NTF4 POAG German Pasutto et al., 2009 
OCLM POAG -- Fujiwara et al., 2003 
OLFM2 POAG Japanese Funayama et al., 2006 
OPA1 POAG European Aung et al., 2002 
PARL POAG German Wolf et al., 2009 
PON1 POAG Japanese Inagaki et al., 2006 
TAP1 POAG -- Lin et al., 2004 
TLR4 POAG Japanese  Shibuya et al., 2008 
TNF POAG Chinese Lin et al., 2003a 
TP53 POAG Chinese Lin et al., 2002 
PLEKHA7 PACG Asian Vithana et al., 2012 
COL11A1 PACG Asian Vithana et al., 2012 
PCMTD1 PACG Asian Vithana et al., 2012 
MMP9 PACG Chinese 
Taiwanese 
Caucasian 
Qui 1990 
Wang et al., 2006b 
Awadalla et al., 2011a 
MFRP PACG Chinese Aung et al., 2008 
MTHFR PACG Pakistani Michael et al., 2008 
NOS3 PACG Pakistani Ayub et al., 2010 
HSP70 PACG Pakistani Ayub et al., 2010 
HGF PACG Nepalese  Awadalla et al., 2011b 
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1.6.2 Molecular Genetics of AMD 
The role of genetics in the pathogenesis of AMD has lately been reported in a number of 
genetic studies, which have been conducted to explore the underlying cause of the disease 
and its mechanisms (Edwards et al., 2005). Twin studies, combined linkage analysis and 
GWAS have contributed considerably in the understanding of the genetics of AMD 
(Spencer et al., 2011). Studies on smaller families has resulted in the identification of 
susceptible loci at 1q25-31, 9p13, 9p24, 10q26, 15q21 and 17q25 (Mancebo 1992; Klein 
et al., 1998; Weeks et al., 2004; Abecasis et al., 2004) and GWAS identified loci in the 
vicinity of  genes such as COL8A1/FILIP1L, IER3/DDR1, SLC16A8, TGFBR1, RAD51B, 
ADAMTS9, and B3GALTL (Fritsche et al., 2013). GWAS and candidate gene studies have 
highlighted the role of genes including complement factor H (CFH) (Zareparsi et al., 
2005), complement component 3 (C3) (Maller et al., 2007), complement component 2, 
complement factor B (C2-CFB) (Gold et al., 2006), complement factor I (CFI) (Fagerness 
et al., 2009), HTRA1/LOC387715/ARMS2 (Rivera et al., 2005; Kanda et al., 2007), CETP, 
TIMP3 (Chen et al., 2010a), hepatic lipase gene (LIPC) (Neale et al., 2010), VEGF-A, 
COL10A1 (Yu et al., 2011), TNFRSF10A (Arakawa et al., 2011) and APOE  (Mckay et al., 
2011).  
Rare variant studies and GWAS have shown upregulation of the alternative pathway of the 
complement system in AMD (Fritsche et al., 2013). Variants at two loci have been 
recurrently shown to be associated with AMD in several studies in the world. These two 
loci contain the genes complement factor H (CFH) and age-related maculopathy 
susceptibility 2/High temperature requirement A1 (ARMS2/HTRA1) (Sobrin et al., 2011). 
The C3 convertase enzyme and other components of the immune system are activated as a 
result of complement system activation, which can occur through any of the three pathways 
i.e. classical, lectin or alternative pathway, all of which act as a component of the 
membrane attack complex and cell lyses. CFH has been shown to be involved in controlling 
the alternative pathway of complement activation by inhibiting the activation of C3 to C3a 
and C3b (Klein et al., 2005). CFH is composed of 20 repeating units of 60 amino acids 
called short consensus repeats (SCRs) (Edwards et al., 2005). In SCR7 a change in the 
amino acid tyrosine to histidine at position 402 has mostly been found to be associated with 
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AMD (Klein et al., 2005). This polymorphism lies in the region of the protein critical for 
binding of CFH to heparin and C-reactive protein (CRP) ( Cordoba et al., 2004). 
Involvement of CFH in the incidence as well as progression to the end stages of AMD has 
been well established (Cao et al., 2013). 
Polymorphisms in ARMS2/HTRA-1 have also been reported to be associated with increased 
risk of AMD (Sundaresan et al., 2012). ARMS2 lies in the mitochondrial membrane and 
is hypothesized to cause AMD by interfering with energy metabolism of the photoreceptors 
as well as by activating apoptosis and reactive oxygen species (Kanda et al., 2007). The 
HTRA1 protein is located in the vascular endothelium and the polymorphisms in the gene 
are postulated to cause AMD by degrading the ECM by increasing the expression of the 
matrix metalloproteinases (Ding et al., 2009). The variant rs10490924 in HTRA1 is 
reported to be significantly associated with AMD (Sobrin et al., 2011). 
1.7 Study Overview 
The current study was based on investigating the underlying genetic causes of 
multifactorial eye diseases, glaucoma and AMD. Both diseases are complex inherited 
disorders and determination of their genetic basis is very difficult. Therefore, in order to 
better understand the genetic etiology in Pakistani glaucoma and AMD patients, we 
conducted genetic linkage analysis and case-control association studies. AMD familial 
cases are rare, therefore mostly sporadic cases were included for genetic investigation. The 
genetic analyses were conducted using high-throughput techniques, such as microarray 
analysis that led to the identification of a possible novel locus for PCG, and next generation 
sequencing analysis that revealed possible genetic causes in two glaucoma families with 
juvenile onset of the disease.  
In addition, polymorphisms in different genes were screened in sporadic cases of glaucoma 
and AMD, which had been previously reported to be significantly associated with the 
respective diseases in various populations. Restriction fragment length polymorphism 
(RFLP), Taqman® allelic discrimination assay, KASPar  assays and Sanger sequencing 
were employed to explore the genetic causes of glaucoma and AMD, which led to the 
identification of a number of genes involved in the pathogenesis of glaucoma and AMD in 
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the Pakistani population. However, there were also contradictory results for some of the 
previously reported associated variants. 
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2 Materials and Methods 
2.1 Ethics Statement 
The current study was approved by COMSATS Institute of Information Technology, 
Islamabad, Department of Biosciences, Ethics Review Board and conforms to all of the 
norms of the Helsinki Declaration. Informed written consent was obtained from all the 
participants recruited for the analysis prior to sampling.  
2.2 Participants of the Study  
In the current study, families with glaucoma and AMD, as well as sporadic cases of 
glaucoma and AMD were included.  
2.2.1 Families with Glaucoma and AMD 
Twenty families diagnosed with glaucoma and two families diagnosed with AMD, 
collected mainly from the Punjab province and the Khyber Pakhtunkhwa (KPK) province 
of Pakistan and were included in the current study. The probands were identified by 
clinicians of different hospitals and were approached for a brief interview about their 
family history, age of onset, and severity of their disease. After drawing the pedigree, 
venous blood was drawn from all family members, and information on their medication, 
diet, occupation, smoking status, and any other disease was documented.  
After a detailed clinical examination the families were classified into different subtypes of 
glaucoma, including POAG, PACG and PCG (Table 2.1). Complete interview and 
ophthalmic examination of the POAG families allowed further classification into JOAG 
and late-onset glaucoma. The potential mode of inheritance was also noted (Table 2.1). 
2.2.2 Sporadic Cases and Controls 
Approximately 500 POAG patients, 200 PACG patients, 300 PEXG patients and 300 AMD 
cases were recruited from different ophthalmological centers in Pakistan, including the Al-
Shifa Eye Trust Hospital in Rawalpindi, the Myo Hospital in Lahore and the Ayub 
Teaching Hospital in Abbottabad. In addition, 300 age- and gender-matched controls with 
no signs of glaucoma or AMD were also sampled from the same centers, as well as from 
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Table 2.1 Overview of collected glaucoma and AMD families  
Family Potential mode 
of inheritance 
Age of 
onset 
Number of sampled individuals 
(Affected/Unaffected) 
Disease 
GLC 1 Dominant Juvenile 10/9 JOAG 
GLC 2 Recessive Congenital  2/5 PCG 
GLC 3 Recessive Juvenile  4/5 JOAG 
GLC 4 Recessive Juvenile 8/11 JOAG 
GLC 5 Dominant Juvenile  7/2 JOAG 
GLC 6 Dominant Late  9/6 POAG 
GLC 7 Dominant Late  8/6 POAG 
GLC 8 Recessive Juvenile 6/8 JOAG 
GLC 9 Dominant Late  11/4 POAG 
GLC 10 Recessive Late  2/3 PACG 
GLC 11 Dominant Late  3/5 POAG 
GLC 12 Dominant Late  10/4 POAG 
GLC 13 Dominant Juvenile 8/9 PACG 
GLC 14 Dominant Juvenile 4/4 PACG 
GLC 15 Dominant Juvenile  5/6 JOAG 
GLC 16 Dominant Congenital  8/16 PCG 
GLC 17 Recessive Congenital  8/12 PCG 
GLC 18 Dominant Late 3/1 POAG 
GLC 19 Dominant Late 10/6 POAG 
GLC 20 Dominant Late 5/7 POAG 
AMD 1 Recessive NA 3/2 AMD 
AMD 2 Recessive NA 2/6 AMD 
NA; Not applicable 
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 the general population. 
2.3 Clinical Diagnostic Criteria  
2.3.1 Diagnosis of Sporadic Cases  
The sporadic cases of POAG, PACG and PEXG were selected on the basis of their clinical 
history, cup–to-disc ratio (CDR), evaluation of the optic disc, visual field determination 
and elevated IOP. They were categorized into open angle (POAG) and closed angle 
(PACG) groups based on gonioscopic findings. In order to determine the presence of 
exfoliative deposits on the pupillary border and the iris of the patients with PEXG, slit lamp 
biomicroscopy was initially performed without dilation of the pupil. Subsequently, after 
pupil dilation, patients were re-examined to detect the presence of white deposits on the 
anterior lens surface. Angles were measured with a gonioscope to differentiate between 
narrow and open angles among PEXG patients. Age-matched controls were recruited in 
the study after complete clinical examination of the fundus. In addition, to rule out any 
ocular anomalies, the controls also underwent applanation tonometery, slit lamp 
examination to exclude exfoliative deposits, CDR measurement and visual field 
assessment. All controls had normal visual fields, IOPs (≤ 20 mmHg) and CDRs (≤0.2).   
AMD patients were recruited on the basis of a diagnosis of severe macular degeneration. 
They were aged ≥ 50 years and recruited on the basis of presence of at least 15 intermediate 
(64-125μm) or at least one large drusen (>125μm). Fundus photography was done as a 
confirmatory test for the presence of drusen and progression of the geographic atrophy (dry 
AMD), whereas fundus fluorescein angiography (FFA) and optical coherence tomography 
(OCT) were performed to distinguish between patients with dry AMD and choroidal 
neovascularisation (wet AMD). Control subjects were aged ≥60 years of age and did not 
have AMD. Fundus examination of the eye was done for all controls before sampling to 
rule out the presence of drusen.  
2.3.2 Diagnosis of Families 
All glaucoma family members underwent complete ophthalmic examination. Tests 
included fundoscopy to observe the optic discs, tonometery to measure the IOP and 
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gonioscopy to distinguish the angle (closed or open). Moreover, FFA was done for all the 
individuals of the family for examination of the retinal nerve fiber layer (RNFL) and to 
determine the thickness of the nerve fiber layer. The diagnosis of PCG was made on the 
basis of an age of onset of less than 3 years; megalocornea or buphthalmos (horizontal 
corneal diameter >13 mm); corneal haze; breaks in Descemet membrane; raised intraocular 
pressure (>21 mmHg); CDR >0.6; and the presence of additional symptoms such as 
blepharospasm and photophobia. 
JOAG was diagnosed on the basis of juvenile appearance of glaucoma symptoms in the 
second decade of life in affected family members. On the other hand, individuals of 
families with a disease onset in the fourth decade of life were diagnosed as late onset 
glaucoma.      
The AMD families went through similar ophthalmic examination as the sporadic cases 
described in 2.3.1.  
2.4 Collection of Blood Samples and Genomic DNA Extraction 
Venous blood was drawn from affected and unaffected family members, sporadic cases 
and controls, and stored at 4oC in acid citrate dextrose (ACD)-containing vacutainers till 
further processing.   
2.4.1 DNA Extraction and Dilution 
The blood samples were first treated with erythrocyte lysis buffer (ELB) to lyse the red 
blood cells and further treatment overnight with reagents (Pronase E, Sodium Dodecyl 
Sulphate, Tris Sodium/Nitrium Chloride EDTA) to digest the proteins, remove cellular 
debris and expose the nucleus. The DNA was then precipitated by the salting-out method 
using 6M NaCl and 99% ethanol. The DNA was then washed in 70% ethanol. The isolated 
and dried DNA was resuspended in 1X TE buffer (pH 8.0) and stored at -20˚C. The 
extracted DNA was separated on 1% agarose gels containing ethidium bromide along with 
a λ-HinD-III DNA ladder for quantification. After electrophoresis, DNA was visualized 
using the Gel Documentation System and Bio Cap MW software V11.01 (Vilber Lourmat, 
Marne-La-Vallee, Cedex1, France). 
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2.5 Screening Glaucoma and AMD Families 
Twenty families with glaucoma were pre-screened for mutations in known glaucoma 
genes. Two families with AMD were analysed for mutations in known AMD genes.   
2.5.1 Exclusion of Known Genes 
The probands of the 20 glaucoma families were first screened for mutations in MYOC, 
OPTN and WDR36 followed by pathogenicity assessment of the variants and segregation 
analysis in the family. Similarly, two families with AMD were screened for mutations in 
CFH.   
2.5.1.1 Primer Design and Polymerase Chain Reaction 
Screening of the genes was done by designing primers for all coding exons and exon-intron 
boundaries (enlisted in Annex 1 and 2) using the Exon Primer tool of the UCSC Genome 
browser (http://genome.ucsc.edu/). Specificity of the primers as well as the primer 
conditions were confirmed by using the online tool Primer 3 version 0.4.0 
(http://frodo.wi.mit.edu/primer3/). The coding regions of all genes were amplified in a 25µl 
reaction volume using a thermal cycler (GeneAMP, PCR System 9700, Applied 
Biosystems) using 1X PCR buffer (100 mM Tris-HCl, (pH 8.3), 500 mM KCl), 0.25mM 
dNTPs, 2.5mM Mg+2, 0.5μM of each primer, 2.5U Taq polymerase (Fermentas Life 
Sciences, Ontario, Canada) and 50ng gDNA. The thermal cycling consisted of initial 
denaturation at 95˚C for 5 min followed by 30 cycles of amplification at 95˚C for 1 min, 
58˚C for 30 sec and 72˚C for 45 sec. A final extension was carried out at 72˚C for 5 min. 
After amplification the samples were separated on 2% agarose gels, visualized under UV 
transillumination and documented using the Gel Documentation System (Vilber Lourmat, 
Marne-La-Vallee, Cedex1, France).  
2.5.1.2 Sanger Sequencing and in Silico Analysis of Variants 
The amplified PCR products of candidate genes were purified using the GeneJET TM PCR 
purification kit (Fermentas, Life Sciences, Ontario, Canada) and sequenced bidirectionally 
with forward and reverse primers using dye-termination chemistry (BigDye Terminator, 
version 3 on a 3730 or 2100 DNA analyzer; Applied Biosystems) at the sequencing facility 
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of the Department of Human Genetics, Radboud University Medical Centre, Nijmegen, 
The Netherlands. Sequence data were analyzed using Vector NTI Advance 11 software 
(Invitrogen, Life Technologies, Carlsbad, CA). Identified variants were analyzed for their 
pathogenicity by in silico analysis using online Alamut Biointeractive software 
(http://www.interactive-biosoftware.com). Conservation scores of the variants 
(http://genetics.bwh.harvard.edu/pph2), defined by the phyloP score and the Grantham 
score (http://www.interactive-biosoftware.com), were calculated for each identified 
variant. Moreover, the damaging effect of the variants was determined online by SIFT 
(sorting intolerant from tolerant) (http://sift.jcvi.org) and Polyphen (polymorphism 
phenotyping v2) (http://genetics.bwh.harvard.edu/pph2/). The Exome Variant Server 
(EVS) (http://evs.gs.washington.edu/EVS/) was used to investigate the population 
frequency of identified variants.  
2.5.1.3 Segregation Analysis of Variants in OPTN, MYOC, WDR36 
Variants in OPTN, MYOC and WDR36 with high pathogenicity scores were analysed in 
the respective families for segregation using Sanger sequencing.   
2.5.1.4 Mutation and Segregation Analysis of Variants in CYP1B1  
Three PCG families were screened for mutations in CYP1B1. Primer designing for the two 
coding exons of CYP1B1 was done as explained in section 2.5.1.1. DNA samples of the 
probands of the three families were first screened for mutations. Segregation analysis was 
performed in all members of PCG family GLC16 by Sanger sequencing.      
2.5.2 Homozygosity Mapping Using Microarray Analysis 
Three families (GLC 2, GLC 4 and GLC 8) with juvenile-onset disease were selected for 
genotyping using 250K SNP arrays (Affymetrix, Santa Clara, CA) to determine 
homozygous regions shared among the affected individuals of the family.  
2.5.2.1 Brief 250K Microarray Protocol 
Briefly, the array analysis consisted of digestion of 250 ng of genomic DNA with 
restriction enzyme NspI. The digested fragments were incubated for 3 hours at 16oC to 
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ligate adaptors, followed by incubation at 70oC for 20 minutes. The ligated DNA fragments 
were then amplified using PCR master mix containing Titanium Taq PCR Buffer, 2.5 mM 
dNTPs, GC-Melt 5M (1µl), 100µM PCR primers and Titanium Taq DNA polymerase. The 
initial denaturation of the thermal cycle was at 94ºC for 3 minutes (1 cycle) followed by 
30 cycles of denaturation at 94 ºC  for 30 sec and annealing at 60ºC  for 45 sec followed 
by extension at 68 ºC for 15 sec. Final extension was done at 78 ºC for 7 min. The amplified 
product was then treated with DNase I and the 3' ends were labeled at 37 ºC for 4 hours. 
The fragmented samples were then hybridized with the probes on the Affymetrix 250K 
array platform, after which the array was scanned using a GeneChip scanner 3000 7G 
(Affymetrix). 
2.5.3 In Silico Analysis of 250K Microarray Data 
The 250K SNP microarray data were initially analyzed using Homozygosity Mapper, an 
online tool (http://www.homozygositymapper.org/), which provides common homozygous 
regions shared between the affected individuals. Homozygous regions larger than 1 Mb 
were further analyzed by CA-repeat marker analysis, and exons of candidate genes in the 
selected regions were sequenced to determine the presence of mutations. All data were 
analysed using the Human Genome Build (hg19) release Feb. 2009. 
2.5.4 CA-repeat Marker Analysis 
Homozygosity mapping with 250K SNP arrays identified three homozygous regions in 
family GLC 2 on chromosomes 3, 7 and 15, three homozygous regions in family GLC 4 
on chromosomes 1, 2 and 10, and four homozygous regions in family GLC 8 on 
chromosomes 3, 4, 6, and 11. CA-repeat marker analysis was performed for family GLC 2 
to determine which of the regions segregated with the disease in the family. CA markers 
were chosen on chromosomes 3, 7 and 15, with heterozygosity greater than 70%. Primer 
sequences to amplify the polymorphic markers, as well as their cytogenetic locations, were 
obtained from the UCSC genome browser (STS marker; https://genome.ucsc.edu), the 
Marshfield Medical Center database (www.marshmed.org.gov/genetics/) and the Human 
Genome Database (www.gdb.org). M13-tailed primers were designed by addition to the 
forward and reverse CA markers the forward M13 sequence 5'-
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TGTAAAACGACGGCCAGT-3' and a reverse M13 sequence (M13 tail) 5'-
CAGGAAACAGCTATGACC- 3' respectively. A list of the CA markers used is provided 
in Tables 2.2 to 2.4. 
A two-step PCR was used, in which the first PCR was a standard PCR amplifying the CA 
markers under standard PCR conditions (Annex 3). In a second PCR, 1 ul of the first PCR 
product was amplified using M13 forward primers fluorescently labeled with FAM (blue), 
NED (yellow) or VIC (green) and an M13 reverse primer. For the second PCR, 2 mM 
MgCl2, 10 mM dNTPs, 20 µM fluorescently labeled M13 forward primer (FAM, VIC or 
NED), 20 µM unlabelled M13 reverse primer, and 1 U Taq polymerase were used in a 
reaction volume of 10µl. The thermal cycling for the second PCR consisted of an initial 
denaturation step of 3 min at 94oC, then 10 cycles of denaturation at 94oC for 30 sec, 
annealing at 55oC for 30 sec and elongation at 72oC for 30 sec, followed by a final extension 
step of 6 min at 72 oC. The products were then visualized on 2% agarose gels to confirm 
amplification. Subsequently, 2µl of the PCR products were mixed with 0.5µl LIZ (internal 
lane standard) and 7.5µl formamide in a final reaction volume of 10µl. The samples were 
then submitted to the Genescan facility of the Department of Human Genetics, Radboud 
University Medical Centre, Nijmegen, The Netherlands, where the fragments were size-
separated using capillary electrophoresis on 3730(XL) DNA analyzer. The results obtained 
were analyzed using Applied Biosystem software Gene Mapper v4.0. The difference in the 
allele sizes of the selected polymorphic markers enabled the construction of haplotypes in 
affected and unaffected family members. The ultimate goal was to use this information to 
determine whether the haplotypes segregated with the disease in the family, and to 
determine the critical linkage interval of the disease locus. 
2.5.5 Plausible Candidate Gene Analysis and Mutation Screening 
Several potential candidate genes resided in the homozygous regions of two families 
(TMCO1 for GLC 4; TMEM74, PITX2, FOXC1 for GLC 8) and were thus screened for 
mutations in the probands of the respective families by Sanger sequencing (sequencing 
primers and product sizes are provided in Annexure 4), followed by segregation analysis 
in all affected and unaffected family members.   
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2.6 Exome Sequencing 
Two unsolved families with JOAG (GLC 1 and GLC 5) and one unsolved family with PCG 
(GLC 2) were sequenced for all exons in the genome by exome sequencing.  This technique 
enables the identification of novel disease genes. In exome sequencing, enrichment of all 
genes of the human genome is performed followed by next-generation sequencing. Three 
affected members of GLC 1, two affected members of GLC 2, and four affected members 
of GLC 5 were selected for exome sequencing.  
The procedure was performed on a 5500xl Genetic Analyzer platform from Life 
Technologies (Carlsbad, CA). The Sure Select XT Human All Exon v.2 Kit (50Mb) from 
Agilent Technologies, Inc. (Santa Clara, CA) was used to capture all coding regions of 
~21,000 genes in the selected family members. This procedure is known as target 
enrichment.   Genomic DNA is digested into smaller fragments of 150-200 bps, blunt ends 
were created followed by phosphorylation of the 5’ end and adenine overhangs were 
produced via Klenow fragments, followed by ligation to the indexing-specific adaptors and 
subsequent PCR amplification. The PCR products were hybridized to the enrichment probe 
library containing biotinylated ribonucleic acid (RNA) probes. Streptavidin-coated 
magnetic beads were used to extract the hybridized fragments and the RNA probes were 
digested, yielding enriched DNA for further use. 
A SOLiD TM sequencer (Life Technologies) was used for next-generation sequencing, 
which uses five universal sequencing primers and a ligation-mediated di-base detection 
system. Initially, the universal primers were annealed to the adapter sequences, followed 
by annealing and ligation of 8 nucleotide probes that was composed of two color-coded 
bases and a fluorescent label at the 3’end. The 3 bases at the 3’ end of the 8 nucleotide 
probes along with the fluorescent label were then cleaved off. All five universal primers 
were then offset by a base followed by probe annealing, ligation, fluorescence detection 
and finally by cleavage of the fluorescent label for the detection of the inserted bases. The 
template DNA sequence was retrieved by decoding the sequences of the colors. The hg19 
reference genome assembly was used to align the variants, using Life Scope software v2.1 
(Life Technologies). Small insertion-deletion changes in the sequences were detected using 
the Small Indel Tool, and variations in single nucleotides were detected using the DiBayes  
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Table 2.2 Primer sequences of CA repeat markers used for the chromosome 3 locus in PCG 
family GLC 2. The Marshfield location (cM), the primer sequence and with product length 
are provided. 
Marker Location 
(cM) 
Primer Sequence 5’ to 3’ Product 
size (bp)  
D3S3678 67.73 F-ACCTGTAGAGTCCAGGGATGC 
R-GGGCTCATTCTCATGCAAAG 
219-265 
D3S3647 67.73 F-GGCTCAGAGCAGGCATAC 
R-CCTAACTAATAAAATGTGTTCCCAG 
190-228 
D3S3597 68.38 F-CACACCCATTAGGATGGAA 
R-GCAAATAGTAGGTGCTCAATAAACA 
261-269 
D3S3624 68.77 F-GGCTCAGAGCAGGCATAC 
R-CCTAACTAATAAAATGTGTTCCCAG 
190-228 
D3S2409 70.61 F-GGTGACAGAGACTCTTGTCTCA 
R-CATTCTGGTTGGGGAACATA 
115-127 
D3S3629 70.81 F-CAAGCAGATGTTGCTGCC 
R-GGAATTACCTGGATTGCCC 
236-25 
D3S3667 70.89 F-TTTAAGAAGCCTTTGTCAGAA 
R-CTATTGATGTTTCATGGTGC 
167-183 
D3S1568 70.89 F-CCATGAACAGAACCTCCCTA 
R-CCGCTGTCCTGCTGTAAG 
276-296 
D3S1621 70.89 F-TTTGAGAAATGCCCCC 
R-GAGCCAAGCCCTGGTT 
97-139 
D3S1573 70.89 F-TTCATTTTTGCTTATTAAGATATGC 
R-CCAGTAAATNACAGGGCTAT 
136-154 
D3S3561 71.22 F-TCCTGGGGACTGTGATG 
R-TCCTGGGGACTGTGATG 
185-229 
D3S1581 71.41 F-CAGAACTGCCAAACCA 
R-GGGTAACAGGAGCGAG 
78-102 
D3S1578 70.61 F-GCCAACACACATTAATCACATA 
R-GGGGCCAAAATCTGCT 
140-166 
D3S1582 72.21 F-CAGCAGGTACTATGAAAGCCTGT 
R-GGAACAGCCCTATGGTTCAC 
154-178 
D3S3660 74.65 F-GCATTTTAAGACTCACAGAATGTT 
R-TGGCAGGAAGTTCTTCATT 
192-202 
D3S1613 75.18 F-TGTGATAAGGACCAAGGC 
R-GAGCAAATTGCAGAATGAG 
225-253 
D3S3721 77.26 F-GAAACCTCCTGACCATCC 
R-CCAGTCTTGCTCTGTCAATC 
203-219 
F, Forward; R, reverse 
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Table 2.3 Primer sequences of CA repeat markers used for the chromosome 7 locus in PCG 
family GLC 2. The Marshfield location (cM), the primer sequence and with product length 
are provided. 
Marker Location 
(cM) 
Primer Sequence 5’ to 3’ Product 
size (bp) 
D7S509 142.55 F-ACTGAACCTGGGGTGG 
R-GTTGCTGGCCCTGTAGTA 
203-225 
D7S495 145.33 F-TGGCATTCATTTACAATAGCC 
R-AGCACCTGGTCCAATTTTCT 
150-168 
D7S2560   145.34 
 
F-AATGACTATTGCAGACTCAAAC 
R-TAATTTCTTAGGATTCTTCAGAGG 
149-195 
D7S684 147.22 
 
F-GCTTGCAGTGAGCCGAC 
R-GATGTTGATGTAAGACTTTCCAGCC 
169-187 
D7S2202 148.73 F-TCTCTTACCCTTTGGGACCT 
R-CTTGCAGATGGCCTAATTGT 
149-169 
D7S2513 150.22 F-GCAGCATTATCCTCAACAGC 
R-CACAAATGGCAGCCTTTC 
157-181 
D7S661 151.16 F-TTGGCTGGCCCAGAAC 
R-TGGAGCATGACCTTGGAA 
252-282 
D7S676 152.14 F-TGANTCTAAGCAGCCACCT 
R-GCAACATGATCCAGAAAACA 
148-166 
D7S2511 154.43 F-CAGAGCAATACCATCAAAAC 
R-GTACCATAAACTGGGTGGC 
225-265 
D7S794 155.1 F-GCCAATTCTCCTAACAAATCC 
R-TATGCCCATGTGTTAGGGTT 
168-208 
D7S2442 159.53 
 
F-TGAGCCAAGATCACAGCACT 
R-TGAGCCAAGATCACAGCACT 
226-236 
D7S688 159.53  
 
F-TGCAGAAATGCCTCCCTAAATATAA 
R-ACAGGAAACGATTGCCATCCTT 
147-161 
D7S2426 160.09 
 
F-GGTGGCTTGCCCAGAG 
R-CCAGTGCATCTGTTTCCC 
105-127 
F, Forward; R, reverse 
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Table 2.4 Primer sequences of CA repeat markers used for the chromosome 15 locus in 
PCG family GLC 2. The Marshfield location (cM), the primer sequence and with product 
length are provided. 
Marker Location 
(cM) 
Primer Sequence 5’ to 3’ Product 
size (bp)  
D15S155 52.33 F-TGGAGTTTCCTGCACCTATC 
R-TGCACCCAGCCTGCTAT 
229-249 
D15S117 56.46 F-GCACCAACAACTTATCCCAA 
R-CCCTAAGGGGTCTCTGAAGA 
132-150 
D15S1026 72.37 
 
F-TGAATTGAACACCTGCCC 
R-AGTCAAGTTGGTTTCCCTGG 
181-215 
D15S1005 75.27 
 
F-GGCTAGAAACAGGATGTCCTC 
R-GCCCAGCCTTAACTGCTT 
102-122 
D15S114 80.3 F-AGAATGAGCAGCACTGTTTG 
R-TTGTCACTGCTTTTCTCTGC 
177-187 
F, Forward; R, reverse 
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algorithm, with high-stringency calling. The data generated were then filtered to identify 
the potential disease-causing mutation.  
2.6.1 Exome Variant Filtering  
Filtering of the genetic variants in the exome data was performed, as initially thousands of 
variants were obtained in each individual. For each family, variants were selected that were 
present in all affected individuals that were analyzed by exome sequencing. The variants 
that were detected in less than 10 reads were removed. Exclusion of synonymous and non-
coding variants resulted in a few hundred remaining variants. Different filtering protocols 
were used for recessive and dominant families. 
2.6.1.1 Variant Filtering in Recessive Families 
In recessive families variants with a population frequency of less than or equal to 0.5% in 
the dbSNP database were retained. Moreover, filtering for homozygous variants was 
conducted by retaining variants that were present in more than 80% of variant calls. For 
filtering of the compound heterozygous variants, 20-80% variant calls were also taken into 
account and only considered 2 (or more) variants that were present in the same gene. To 
confirm the number of the variant calls, validation was done by checking the Binary 
Sequence Alignment/Map format (BAM file) to minimize the chances of automatic 
generation of the number of reads in the output file. Moreover, the variants with a 
Grantham score higher than 80 or a phyloP score of more than 2.0 were retained. All these 
filtering steps enabled to narrow the number of variants from hundreds to just a few 
variants. 
2.6.1.2 Variant Filtering in Dominant Families 
In dominant families, all filtering steps were the same as for recessive families, except that 
variants that were present on 20% - 80% of variant calls were retained, which potentially 
represent heterozygous changes. Moreover, sequences with more than 2 reads were also 
considered.  
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2.6.2 Variant Screening and Validation 
Variant filtering in PCG family GLC 2 resulted in the identification of a single 
heterozygous 18-bp deletion in SH3PXD2B (previously implicated in Frank-Ter Haar 
syndrome, an autosomal recessive disorder involving glaucoma (Iqbal et al., 2010)) and 9 
homozygous variants. These variants were screened for segregation in all family members 
by Sanger sequencing. To determine whether a second heterozygous variant in SH3PXD2B 
was missed by exome sequencing, all coding exons of SH3PXD2B were screened in family 
GLC 2 by Sanger sequencing (primer sequences are given in Appendix 5).  The exome 
data for the dominant families GLC 1 and 5 were filtered using the above mentioned 
criteria. First, variants in genes in the known glaucoma loci were filtered, and sequenced 
to evaluate their segregation in the families (Table 2.5). Next, heterozygous variants and 
compound heterozygous variants with high phyloP or Grantham scores were then analysed 
for segregation (Table 2.5). Finally, variants in genes related to pathways of known 
glaucoma genes were screened for segregation in family GLC 5 (Table 2.5). 
After variant filtering, less than 40 potentially pathogenic variants remained for families 
GLC 1 and GLC 5, which were all validated and analysed for segregation in the families 
by Sanger sequencing. The sequencing primers for the variants were designed by the online 
software Primer3 (http://frodo.wi.mit.edu/).  The primer sequences and product sizes that 
were used to amplify all analysed variants in GLC 1, GLC 2 and GLC 5 are provided in 
Tables 2.5-2.7. The amplified PCR products were sequenced as described above in section 
2.5.1.2.  
2.7 Screening of Sporadic Cases 
Approximately 500 cases with POAG, 200 cases with PACG, 300 cases with PEXG 
patients, 300 AMD patients and 300 age- and gender-matched controls were genotyped for 
various glaucoma and AMD associated SNPs. The SNPs were selected on the basis of their 
previously reported associations with the disease. In addition, for the glaucoma cohorts two 
variants (p.Thr377Arg in MYOC and p.Met98Lys in OPTN) were selected that were 
recurrently detected in affected individuals of glaucoma families by exome sequencing and 
were predicted to be potentially pathogenic by different pathogenicity predicting softwares. 
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Moreover, the Exome Variant Server (EVS) (http://evs.gs.washington.edu/EVS/) and 1000 
Genomes were used to determine the frequency of the variants. Selected SNPs were 
genotyped in the respective cohorts using various techniques as described in the following 
sections (2.7.1 to 2.7.4). 
2.7.1 SNPs Genotyped by Taqman® / Kaspar’s (KASP) Assay 
Three intronic SNPs, rs11720822 in PDIA5, rs2754511 in BIRC6, rs10906308 in OPTN, 
and the exonic variant rs2234926 in MYOC were screened in sporadic glaucoma cases and 
matched controls, whereas rs1061170 in CFH, rs10490924 in ARMS2, rs429608 near CFB, 
rs2230199 near C3, rs5749482 near TIMP3 and rs442063 near APOE were genotyped in 
AMD samples and matched controls using the Taqman®/KASP allelic discrimination 
assays performed by Real-time PCR (Applied Biosystems 7900HT Fast System and 
Sequence Detection Systems Software v2.3, Foster City, CA). PCR amplification was 
performed according to the protocol of the manufacturer using 10ng of DNA in a reaction 
mixture of 4l, using fluorescently labeled primers containing VIC and FAM. After an 
initial denaturation step of 12 min at 95oC, 50 cycles of amplification were performed for 
15 sec at 92oC and termination for 90 sec at 60oC. The results of the Taqman® and KASPar 
allelic discrimination assays were then analyzed with the software SDS1.4/SDS2.0.6 on 
the 7500 Fast Real-time PCR system or SDS2.3/SDS2.4 on the 7900HT Fast Real-time 
PCR system.  
2.7. 2 PCR-Restriction Fragment Length Polymorphism (RFLP) Analysis 
Glaucoma and matched control samples were genotyped by PCR-RFLP, for the following 
SNPs: exonic SNPs rs11258194 in OPTN, rs1801270 in p21, rs2567206 in CYP1B1, 
rs1042522 in p53, rs1043618 in HSP70, rs11024102 in PLEKHA7, rs3753841 in 
COL11A1, and rs1015213 in PCMTD1. The AMD samples and matched controls were 
genotyped by PCR-RFLP for the following SNPs: rs3732379 and rs3732378 in CCRX1, 
rs243866 in MMP2, rs17576 in MMP9, rs1800629 in TNF and rs16944 in IL1B. PCR 
primers used for amplifying the genomic intervals containing these SNPs, the product 
length of the PCR product, and the annealing temperature for the PCR are provided in  
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Table 2.5 Exome variants and their primer sequences screened in JOAG family GLC 5 
F, Forward; R, reverse 
 
Gene 
name 
Variant PhyloP Grantham SNP/ Novel 
variant 
Primer Sequence 5’ to 3’ Product 
size bp) 
SH3RF2 1105G>C;  
p.Ala369Pro 
3.22 0.00 
rs145544864 
F-CCACAAACCACAGAGAGGAC 356 
R-TGTCTCTGGATGGGATGTTT 
ERAP1 1939C>T; 
p.Val647Ile 
5.71 29 rs111363347 F-ATGATCGGGCGAGTCTCATT 246 
R-TCCTTCCTTCAAGTGCCTTAGT 
GPR151 694G>A; 
p.Arg232* 
0.05 1000 Novel F-GAGACAGTGCCAAATGTTCC 376 
R-TGGTTTAACATGGCCAGAAT 
TSSK1B 28G>A;  
p.Arg10* 
1.01 1000 Novel F-CAGCCAGCAACACTTCCTTG 230 
R-GGAGATGAGCATGTGGAGGA 
ITGA8 405C>G; 
p.Trp135Cys 
6.089 215 Novel F-TTTGGAGGAGTTTGACAAGG 288 
R-GCTTGAAAACATTCCAGTGC 
ICMT 211A>T;  
p.Cys71Arg 
2.82 112 Novel F-TCAGCAAATCGGCTCTATCT 292 
R-GATGAGACAGGGATGAGGAA 
CASD 1046G>A; 
p.Ser349Asn 
2.48 81 Novel F-TGAGCTAAGACCCCCACAG 388 
R-CCACAGAGAGACCGAGAGAA 
MYCBP2 7295A>C; 
p.Ile2432Thr 
142 99 Novel F-TAGGATTGCCAGGAGGTATG 447 
R-AGTCATGAGGGCTACAGTGC 
SLC7A7 1103A>G; 
p.Met368Thr 
3.5 81 Novel F-AAACCAGAAGAGGACCAGGA 326 
R-ACAACTCCAGCTGTTTCAGG 
HEATR5A 911T>C;  
p.Glu304Gly 
4.92 94 rs191067821 F-CGCAGAGTATCTTTGGAGGA 290 
R-AATGTTTTGGCCTTACCATTTA 
DLGAP4 733G>A;  
p.Ala245Thr 
5.30 58 rs146757517 F-AGTCCAGCGGCTTTTCTT 439 
R-AATGTTTTGGCCTTACCATTTA 
DNAH17 11588G>T; 
p.Ser3863Phe 
5.75 144 Novel F-GCTGAAGAAAGTCCACCAAA 364 
R-TGAAGTGGTGTCTCATGTGC 
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Table 2.5 cont. 
F, Forward; R, reverse 
 
Gene 
name 
Variant PhyloP Grantham SNP/ Novel 
variant 
Primer Sequence 5’ to 3’ Product 
size bp) 
UQCRB 200A>T; p.Leu67Pro 4.65 113 rs139283183 F-AGGGTTAATGCGAGATGATACA 204 
R-TGAGCAACACTGTCAGGTAGA 
OPLAH 1750C>A; p.Gly584Ser 2.31 159 rs10107332 F-AGAAGCAGAACAGGTGTCCT 246 
R-AGTCAGGAAGCCACGTACC 
RMI1 980del; 
p.Gln327_Thr333delinsPro 
4.11 1000 rs146219782 F-CAGAACGATGTTTCACCACA 389 
R-AACAGATGGACAACCAAATGA 
GPR148 266C>T; p.Pro89Leu 1.48 98 Novel F-CAGCCAGCAACACTTCCTTG 230 
R-GGAGATGAGCATGTGGAGGA 
GPR148 205C>G; p.Leu69Leu 2.39 32 Novel F-CAGCCAGCAACACTTCCTTG 230 
R-GGAGATGAGCATGTGGAGGA 
MASTL 928A>G; p.Ile310Val 1.69 29 Novel F-GGAATGCCTGTGAAGTGTCT 157 
R-TCCCTCAAACCTGGCAATCT 
MASTL 2128C>T; p.Thr710Ala 5.33 74 Novel F-ACGCCTAGTAGCCTATGAGC 228 
R-TCAGGTGCAAGGTAGTCTGG 
NUP210 4063C>A;  p.Ala1355Thr 1.78 99 Novel F-TTTTGTTTTCCAAAGGGATG 292 
R-CGTTCACCTTCCAGCTAAGA 
EBLN1 644T>C; p.Glu215Gly 0.46 98 Novel F-CGATATGCACCAACAGCCTC 247 
R-ATCATCTGTGCTTTGCTGGC 
MMP14 1016G>A; p.Arg339His 2.91 29 rs140740223 F-GACAACAGTGTGAGACTCCATC 351 
R-GAGTGCCTGGTTACCTTTGA 
IFT80 1229G>A; p.Pro410Leu 2.8 98 rs148396265 F-TTTTCCCAAGGATAAACTATTCTG 397 
R-TTTGAAAACAAAATAGAAAGCTCA 
GBA2 587C>T; p.Arg196Gln 4.53 43 Novel F-TGATGGTGCAGTGGTAACAG 322 
R-AAGATGGGTGTGATCTGACG 
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   Table 2.5 cont. 
Gene 
name 
 
Variant PhyloP Grantham SNP/ Novel 
variant 
Primer Sequence 5’ to 3’ Product 
size bp) 
APLO3 104C>A 0.84 109 rs148885226 F-CTGGGAAGCATCCTGTTTT 176 
R-AACAGCTGGATCTTGCTCAC 
SKIV2L2 1A>T; p.Met1? 3.11 11 Novel F-ATCGTGGGTAGGAGGGAGAT 182 
R-TCCTTACCCTGCCTTGTCTG 
EYS 6982C>T; 
p.Gly2328Arg 
0.30 125 Novel F-GCCATATTCCTGCAAATGTT 300 
R-GACTTGTCATTTTCGTCTCTCA 
SPHK1 957G>C; 
p.Pro319Pro 
2.23 22 Novel F-TGAGAAGTATCGGCGTCTGG 236 
R-CTAGCACAAAGTCCTCGTCG 
MYCBP2 7295A>C; 
p.Ile2432Thr 
3.30 142 Novel F-CCAGTGAGAATATGCTGATCCG 210 
R-GTCTAGTGCAAGTTAATGGGCA 
BDKRB1 844C>G;  
p.Arg282* 
0.17 125 rs145322761 F- CGCAAGGATAGCAAGACCAC 194 
R- AGGGAGCTGTTAGTGAAGGC 
ATM 2932T>C; 
p.Ser978Pro 
3.98 74 rs139552233 F-GAAGAGTACCCCTTGCCAAT 374 
R-CTTGCATTCGTATCCACAGA 
DCBLD1 568G>A; 
p.Val190Ile 
2.36 29 Novel F- CCCCTTGCCAATGGAAGATG 249 
R- GTCCATATTGCTTTGACCTAGGT 
COL22A1 3754C>T; 
p.Gly1252Ser 
2.73 56 Novel F-TGAAACTGCCTTCGTCTTTC 288 
R-TGGGGACAGCAGTGTTTACT 
     F, Forward; R, reverse 
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Table 2.6 Variants detected by exome sequencing and analysed for segregation analysis in JOAG family GLC 1   
Gene 
name 
Variant PhyloP Grantham SNP/ Novel 
Variant 
Primer Sequence 5’ to 3’ Product size 
(bp) 
VPS13D 
 
3272G>A; 
p.Cys1091Tyr 
6 
 
194 Novel F-TTTGATATTCCAACGGGAAG 380 
R-CCTTGTTCTCTGAAGCTTCTTT 
AASS 
 
2152G>A; 
p.His718Tyr 
5.86 
 
83 Novel F-GTGTGCCTTCTCAATGTTCC 399 
R-CTGTCCCCAACTCCTAATGA 
KIF19 
 
664G>A; 
p.Ala222Thr 
5.82 
 
58 rs34016821 F-TTTCCCAACTGCTCAGACAT 469 
R-TCCAACTCCTACGAAGCTGA 
GCDH 
 
886G>A; 
p.Gly296Ser 
5.57 
 
56 Novel F-TGTGATGTGAACCACAACCT 299 
R-AGAGAGTGAAACCCAAGCTG 
ENOX1 
 
171C>T; 
p.Met57Ile 
5.41 
 
10 Novel F-AACAAACACCCTTGCCTATG 294 
R-AAAGACTGTGTCCAACACTCG 
PLIN2 
 
269A>G; 
p.Ile90Thr 
4.58 
 
89 Novel F-AGCCCATTATTGCCATTTTT 224 
R-CCAGGTTGGGAAAACAAGTA 
COL9A2 
 
1061G>A; 
p.Pro354Leu 
4.48 
 
98 Novel F-AATCAGGAGCCAAGAGGATT 146 
R-AGGAGAAAGAGCTTCCCTGA 
MYO18A 
 
2071G>A; 
p.Arg691Cys 
4.42 
 
180 Novel F-TCCTTTAGGACCTGCTCATTC 491 
R-CAGAGCATCTGTTCACTCCA 
NFIB 
 
274G>A; 
p.Phe92Leu 
4.34 
 
74 rs140030018 F-CATTCATCGAGGCACTTCTT 285 
R-CGGGATTGGATAAGACACAG 
TMPRSS7 
 
311T>G; 
p.Leu104Ser 
3.79 
 
61 Novel F-ATTGGCCTTACCTTGAATCC 382 
R-TCCCACATTGTAATGCTTCA 
R3HDM1 
 
2492T>C; 
p.Val831Ala 
3.76 
 
64 Novel F-GGCTTCAACCTGGTTTTCTT 369 
R-CGGGATTTCAAATTCAAGC 
CNTRL 
 
1136A>G; 
p.Asp379Gly 
3.49 
 
94 Novel F-TCCAAACTTTCACTCTTCTGTG 388 
R-GTTGTTCATCTGGCTCCATC 
F, Forward; R, reverse 
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Table 2.6 continued 
Gene name Variant PhyloP Grantham SNP/ Novel 
variant 
Primer Sequence 5’ to 3’ Product size 
(bp) 
SUSD4 
 
190C>T; 
p.Glu64Lys 
3.11 
 
56 Novel F-TAAAATGTCCTTGGCTTTGG 362 
R-TTCCGTGGAGAAGTAAGCAC 
ADPRH 
 
977C>A; 
p.Ser326Phe 
3.07 
 
144 Novel F-TCTTTCGGTGTGAAGGAGAG 397 
R-AATCCATCAGAAGTGAACATCA 
C4orf21 
 
163C>T 2.62 
 
21 rs148197910 F-CGCCTAGCTCTAATATGTGTTGT 273 
R-TCGGCCAGAGGATATAAATG 
CNGB3 
 
1208C>T; 
p.Arg403Gln 
2.39 
 
43 rs147876778 F-CCTCCTTGGGCTTGTTTCAT 390 
R-GTTTGTGGTTCTGGAAGGCC 
ARHGAP44 
 
2371C>T; 
p.Arg791Cys 
2.21 
 
180 Novel F-ATCGACTGTGCAACACAATG 298 
R-AGAACACTTGGCAAGCTCAT 
C9orf128 
 
133A>C 0.89 
 
99 rs151344607 F-TGAAGCCTGTACCCTGTTCT 370 
R-ATAGGTAGGGGTCTCTGAAGGA 
WBSCR28 
 
373G>A; 
p.Ala125Thr 
0.71 
 
58 Novel F-TGCTCCTCAAGATCAACCTC 146 
R-AAGCAGTGGGACTTCTGACA 
BDKRB1 
 
721G>A; 
p.Gly241Arg 
0.62 
 
125 rs45528332 F-TCCCAGATCTGAACATCACC 497 
R-GCTTGCACCTGGAATAAGAA 
DKK3 
 
1018C>A; 
p.Ala340Thr 
0.53 
 
99 Novel F-GATGTTGACGGGAAGTGAAG 491 
R-GGGGAAACTTACTGGGAAGA 
WBSCR28 
 
550C>T; 
p.Arg184Cys 
0.009 
 
180 Novel F-TGTCAGAAGTCCCACTGCTT 295 
R-TCTGGGAGTTTCTTGCTCTG 
CGN 
 
725A>G; 
p.Asp242Gly 
0.79 
 
94 Novel F-TCACTCATCAACAAGTTTGACAG 270 
R-CAAAACTCTGAAGGACCCAGT 
NCOA7 
 
724C>T; 
p.Val242Met 
0.26 
 
83 Novel F-ACCTGGCTTCAGAAAAGGAT 298 
R-CAAATGCAGAAGAAGTGTCG 
F, Forward; R, reverse 
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Table 2.6 continued 
Gene name Variant PhyloP Grantham SNP/ Novel 
variant 
Primer Sequence 5’ to 3’ Product size 
(bp) 
ZP4 
 
1226G>A; 
p.Pro409Leu 
0.62 
 
98 Novel F-CCATCCTGGTAAAGGGGTAA 390 
R-TTGTAAGTTGGGGAGGTTCA 
ASB10 
 
545G>A; 
p.Lys182Arg 
2.39 
 
64 rs151344607 F-CTGTGTTCATGTGCTGCTGG 154 
R-GCCTCTTTGCTTCCCTTCAG 
NEBL 
 
1108G>T; 
p.Gln370* 
3.16 
 
53 rs146198369 F-ATATGCTTTTCTTTTTCCAATGA 296 
R-TAGACAAGATCCCAGGCAGT 
F, Forward; R, reverse 
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Table 2.7 Homozygous variants detected by exome sequencing and analysed for segregation analysis in PCG family GLC 2  
Gene name 
 
Variant PhyloP  Grantham SNP/ Novel 
Variant Primer Sequence 5’ to 3’ 
Product 
size(bp) 
SH3PXD2B 
 
2629del; 
p.Phe876Lysfs*16 
4.35 
 
1000 
Novel 
F-CTCTTTGTATGTGGCCGTGG 
202 R-TCTAGGCAGAAAGGGAGTCG 
CACNA1D 
 
2474T>C; 
p.Ile825Thr 
4.27 
 
89 
rs147933585 
F-TTCAGCCTTCTTCTCACCTG 
452 R-GTGACACATTCTGCCTGTGA 
CILP 
 
217G>A; 
p.Arg73Trp 
3.80 
 
101 
Novel 
F-AGGGAAAGGAGAACTGGAGC 
162 R-ACGGTCCCCATAGTAGAAGC 
ANKDD1A 
 
1096C>T; 
p.Arg366Cys 
2.5 
 
180 
rs144426862 
F-ACCTTTCTGCTCTCAGCGTA 
349 R-ATCACCTGCTTGGAGACTGA 
LRRC8E 
 
580G>C; 
p.Gly194Arg 
2.33 
 
125 
Novel 
F-TCGTGGTCATTCACACACTC 
492 R-CCACCAGGAAACTGATCTTC 
CSPG4 
 
4813G>A; 
p.Leu1605Phe 
2.22 
 
24 
Novel 
F-GTGCTGATCATGGGCATT 
505 R-TTCTGGGAACATGAACTTGC 
CLRN3 
 
532C>T; 
p.Gly178Arg 
1.89 
 
125 
Novel 
F-CATGCCATGCATGAAACTC 
300 R-ATAAAATTCCGTCCCTTGGA 
ALS2CL 
 
2843T>G; 
p.His948Arg 
0.46 
 
77 
Novel 
F-CTATTGAGCCCTAGATCCTGTG 
299 R-AGCATCTTCCTGTGCAAAAC 
TRAIP 
 
898C>T; 
p.Glu300Lys 
2.83 
 
56 
rs143310707 
F-AGGTCATCTCTGCCTTCAGC 
112 R-GGGGGAGTATCCACATCAAA 
F, Forward; R, reverse; del, deletion  
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Table 2.8. After PCR amplification, PCR products were subjected to RFLP analysis for all 
above mentioned SNPs. The amplified products were digested overnight at 37°C with 
respective restriction enzymes (Fermentas, Waltham, MA) (Table 2.8). The digested 
products were then electrophoretically separated on agarose gels ranging from 2-4%, 
resulting in the separation of the homozygous ancestral allele from heterozygous and 
homozygous variant alleles. 
2.7.3 Variable Number of Tandem Repeat (VNTR) Genotyping 
A 27-bp insertional VNTR in intron 4 of NOS3 was genotyped by PCR amplification in 
the glaucoma and AMD cohorts, and matched controls. The VNTR region was amplified 
using the Gene amp® PCR system 2700 (ABI, Foster City, CA). Briefly, the protocol 
consisted of 35 cycles of DNA denaturation at 95°C for 1 min, primer annealing at 60°C 
for 45 sec and extension at 72°C for 1 min, followed by a final extension step at 72°C for 
5 min. The constituents of the reaction consisted of: 1.2 pM of each primer, 10 mM dNTPs, 
2 mM MgCl2, 1 U Taq polymerase and 1× PCR buffer, along with 40–50 ng of DNA. The 
PCR products were electrophoretically separated on 4% agarose gels and visualized under 
ultraviolet light. Two alleles were obtained when this region was amplified: “NOS34a,” 
which was 393 bp long and consisted of four 27-bp repeat units, and “NOS34b,” which 
was 420 bp long and consisted of five 27-bp repeat units.  
2.7.4 Variant Analysis by Sanger Sequencing 
150 AMD samples and 150 matched controls were sequenced for eight SNPs in the 
promoter region of VEGF using a single primer set with forward primer 5’-
GCAGCGTCTTCGAGAGTGAG-3’ and reverse primer 5’-
CCGCTACCAGCCGACTTT-3’. The promoter region variants were selected because 
these variants may be important for regulating the gene expression. The SNPs that were 
analyzed in this 0.5kb region were rs833061 (-460C>T); rs833062 (-417T>C); rs13207351 
(-152G>A); rs59260042 (-1210C>A); rs79469752 (-1203C>T); (-160C>T); rs28357093 (-
141A>C); and rs1570360 (-116G>A). The sequences were analyzed using Vector NTI 
Advance 11 software (Invitrogen Life Technologies, Carlsbad, CA).  
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Table 2.8 Primers sequences and restriction enzymes used for RFLP analysis 
Gene Variant Primer Sequence 5’ to 3’ Annealing 
Temp. 
Enzyme 
OPTN rs11258194 F-TCCACTTTCCTGGTGTGTGA 
R-TTTTCCAAGCTCTTCCTTCAA 
58oC Stu1 
P21 rs1801270 F-GTCAGAACCGGCTGGGGATG 
R-CTCCTCCCAACTCATCCCGG 
57oC Esp1 
CYP1B1 rs2567206 F-GGTTGTGAGCGTGGTTC 
R-TCTCACAACTGGAGTCGCAG 
55oC Taq1 
P53 rs1042522 F-TTGCCGTCCCAAGCAATGGATGA 
R-TCTGGGAAGGGACAGAAGATGAC 
60oC Bsh12361 
HSP70 rs1043618 F- CGCCATGGAGACCAACACCC 
R- GCGGTTCCCTGCTCTCTGTC 
60oC Brsb1 
PLEKHA7 rs11024102 F-GTAGCACCTACTATATGATCT 
R-TTCGCCTAGCTGGCTTCT 
58 oC AseI 
COL11A1 rs3753841 F-TCATTCTAGGGTCCTGTTGGT 
R-TCCTGCATTTGCAATTACTTT 
58oC  NlaIV 
PCMTD1 rs1015213 F-CTGATGCTGAGGCTGTACCTC 
R-GAGGCTGACCTACCTCTGGTG 
58oC HpyCH4III 
TNF rs1800629 F-AGGCAATAGGTTTTGAGGGCCAT 
R- GTAGTGGGCCCTGCACCTTCT 
60oC  NcoI 
IL1B rs16944 F- TGGCATTGATCTGGTTCATC 
R- GTTTAGGAATCTTCCCACTT 
60oC  Ava1 
CX3CR1 rs3732379 F-CTCCCCAGCAAATGCATAG 
R- GAATGCCTTGGTGACTACCC 
60 oC AcI1 
CX3CR1 rs3732378 F-GCAATGCATCTCCATCACTC 
R-AACCACAAGAAAGCCAAAGC 
60 oC HpyCH4III 
MMP2 rs243866 F-ACTGACTCTGGAAAGTCAGAGCA 
R-GGCACAGGGTGAGGGATGG 
63oC Tsp45I 
MMP9 rs17576 F-GAGAGATGGGATGAACTG 
R-GTGGTGGAAATGTGGTGT 
63oC MspI 
F, Forward; R, reverse; Temp, temperature 
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2.8 Statistical Analysis 
Allele frequencies between the unaffected controls and the patient groups were compared 
with the Pearson χ2 test using online software (http://statpages.org/ctab2x2.html). The 
genotype frequencies were calculated by logistic regression analysis keeping age and 
gender as covariates. The data were statistically analyzed using R software (R Core Team 
(2012). (R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, 
URL http://www.R-project.org/). In addition, Bonferoni correction was applied to the 
individual p-values generated from logistic regression analysis.
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3 Results 
In the current study, twenty families with glaucoma and 2 families with AMD were 
analysed. In addition, in the glaucoma association studies 350 healthy controls, 500 POAG, 
200 PACG and 300 PEXG patients were analyzed for different SNPs, while for the AMD 
association studies 300 healthy controls and 300 AMD patients were analysed for different 
SNPs. 
3.1 Results of Glaucoma Families 
Initial screening of glaucoma families for mutations in known glaucoma associated genes, 
resulted in linking one family with PCG to CYP1B1. In the rest of the families, two affected 
members of the GLC 2 family (PCG), one member of GLC 4 (JOAG) and four affected 
members of GLC 8 (JOAG) were selected for 250K SNP array analysis.   
Of the unsolved glaucoma families, two affected members of GLC 1 with early onset of 
symptoms of the disease, two affected members of GLC 2, and four affected members of 
GLC 5 were selected for exome sequencing. 
3.2 Exclusion of known genes 
3.2.1 MYOC, OPTN, WDR36 and CYP1B1 Screening 
Probands of the 20 families with glaucoma were screened for mutations in known 
glaucoma-associated genes: MYOC, OPTN, WDR36 and CYP1B1. 
3.2.1.1 MYOC, OPTN and WDR36 analysis 
Several known and novel variants in MYOC, OPTN and WDR36 were found in the 
probands of the 20 families, but these variants did not segregate with the disease in these 
families (Table 3.1). However, a non-synonymous SNP in MYOC (rs2234926 c.227G>A, 
p.(Arg76Lys)) was found in 50% of the probands, and an intronic SNP (rs2032555, 
c.730+35G>A) was found in 13 % of the probands. In OPTN three variants were identified 
in the families. Of these, the synonymous SNP rs2234968 (c.102G>A, p.(=)), c.293T>A,  
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Table 3.1 Recurrent SNPs and de novo variations in glaucoma and AMD associated genes identified by sequencing 
NC; Not checked because the SNPS were not pathogenic 
Gene 
Families 
Screened 
Coding 
Exons 
Recurrent 
Variants (SNPs) 
Segregation of 
SNPs in Family 
Novel 
Variants 
Segregation of Novel 
Variants in Family 
MYOC 
20 Glaucoma 
families 
3 
rs2234926 NC c.648G>A 
Not Segregating 
rs2032555 NC c.1438A>C 
OPTN 
20 Glaucoma 
families 
16 
rs2234968 NC 
p.Glu95Gln Not segregating 
rs11258194 Not Segregating 
WDR36 
20 Glaucoma 
families 
23 -- -- c.1628G>A Not Segregating 
                                                       
CYP1B1 
20 Glaucoma
families 
1 -- -- c.1169G>A Segregating 
PXDN GLC 2 23 
rs17841813 NC p.Thr237Asn Not segregating  
rs1863135 NC p.Val1284Leu Heterozygous 
TMEM74 GLC 8 2 --  --  
CFH 
2 AMD 
families 
23 
rs800292 NC 
p.Glu850Lys Not Segregating rs1061147 Not Segregating 
rs368670743 NC 
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p.(Met98Lys) Fig. 3.1) was identified in 6.3% probands. In addition a novel variant (M2: 
c.283G>C, p.(Glu95Gln)) in exon 5 of OPTN was found in one proband, however, none of 
these variants segregated with the disease in the families (segregation is shown in Fig. 3.1 
A,B,C & D, chromatograms are shown in Fig. 3.2 A & B).  
Analysis of the variants Arg76Lys in MYOC and Met98Lys in OPTN were further extended 
by screening the association of these variants with unrelated sporadic cases of POAG, 
PACG and PEXG and compared with unaffected controls. The MYOC variant was not 
associated with any subtype of glaucoma, but the OPTN variant was associated with 
increased risk of POAG (section 3.5.1.2). 
In WDR36 a novel variant, c.1628G>A (p.Arg543Lys), was identified in exon 14 of a 
single proband, but further segregation analysis in the family revealed that the variant did 
not segregate with the disease in the family.  
3.2.1.2 Identification of a Homozygous CYP1B1 Mutation in a PCG family 
Affected individuals of a family (GLC 16) were diagnosed with PCG, with the symptoms 
appearing in the first decade of life. The affected individuals shared the same phenotype 
and had raised IOP (>40 mmHg) and visual field damage. They had large bulging eyes 
(buphthalmus) with varying opacity in the affected individuals. Due to the corneal 
opacification, the optic nerve could not be examined. The elder affected members of the 
family in their third and fourth decade, were completely blind. All symptoms were absent 
in normal individuals of the family. The proband V:1 had bilateral juvenile open angle 
glaucoma, 360o iris processors and increased CDR (right eye=0.6, left eye=0.9). 
Pachymetry revealed thin corneas (right=0.44, left=0.43). Bilateral trabeculectomy had 
been done and in the left eye, and a glaucoma Ahmed valve was inserted to control the 
IOP. 
Sequence analysis of the coding exons of CYP1B1 revealed a homozygous missense 
mutation (c.868dup; p.Arg290Profs*37) segregating with the disease in PCG family 
GLC16 (Fig.3.3). The variant was not found in 140 unaffected control individuals.  
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Figure 3.1 Segregation analysis and sequencing chromatogram of identified variants in 
OPTN in POAG families A, B & C. Pedigrees with segregation analysis of rs11258194 
(M1: c.293T>A, p.[Met98Lys]) and of a novel variant (M2: c.283G>C p.[Glu95Gln] D). 
Generation numbers in the pedigrees are indicated by roman numerals. Filled squares and 
circles are affected males and females, respectively, while the unfilled symbols are 
unaffected individuals. Probands are indicated by an arrow, and all individuals that 
underwent molecular genetic analysis are indicated by their mutation pattern, ‘+’ indicatest 
the ancestral allele, ‘M’ indicates the derived allele. Individuals indicated with +|+ carry 
the homozygous ancestral genotype, those indicated by +|M are heterozygotes carrying one 
ancestral and the derived allele, and individuals with M|M carry the derived allele 
homozygously.  
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Figure 3.2 A) Sequence chromatogram of rs11258194 c.293T>A p.Met98Lys in OPTN 
showing the homozygous ancestral genotype (upper panel), the heterozygous genotype 
(middle panel), and the derived homozygous genotype (lower panel). B) Sequence 
chromatogram of c.283G>C showing the ancestral homozygous genotype (upper panel), 
the heterozygous genotype (middle panel), and the derived homozygous genotype (lower 
panel). 
A B 
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Figure 3.3 Pedigree of a large consanguineous Pakistani family with PCG (GLC 16). The c.868dup; p.Arg290Profs*37 mutation in 
CYP1B1 is indicated with an M, and the ancestral allele with a +. All affected individuals carry the mutation homozygously, while the 
unaffected individuals are heterozygous or do not carry the mutation. The mutation segregates with the disease in the family through a 
recessive mode of inheritance.
GLC16 (c.868dup; p.Arg290Profs*37) 
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3.3 SNP Microarray Analysis Results 
3.3.1 Identification of a Possible Novel Locus of Primary Congenital Glaucoma 
A recessive PCG family (GLC 2) was sampled from a village in Multan located in southern 
Punjab, consisting of two affected and five unaffected individuals. Both affected 
individuals suffered from raised IOP and nystagmus bilaterally. They had completely 
opaque and bulging avascularised corneas, which were highly sensitive to touch and hence 
normal ophthalmic tests were not possible for the affected individuals (Fig. 3.4). The IOP 
measurement was conducted carefully with air puff tonometery and the IOP was found to 
be >40 mmHg in both individuals. The patients’ fundus and the optic nerve could not be 
visualized due to the opacity of the cornea. The patients also had Haab’s striae, which are 
horizontal breaks in the Descemet's membrane. The signs of the disease started appearing 
in the first year of their life, which was progressive and resulted in complete blindness. 
Trabeculectomy had also been done for one individual to lower the IOP and pain in the 
eyes. All the other unaffected siblings had no signs of glaucoma.   
Affymetrix 250K SNP microarray analysis was conducted for both affected members of 
the family, followed by analysis of the data by Homozygosity Mapper. This revealed five 
homozygous regions: one on chromosome 3, one on chromosome 7 and three regions on 
chromosome 15 (Fig. 3.5). Microsatellite marker analysis confirmed the homozygous 
region on chromosome 7 and excluded the regions on chromosome 3 and 15 (Fig. 3.6). The 
region was further refined by using microsatellite markers and a 2 Mb region was marked 
as a common homozygous region in the affected individuals, while it was not homozygous 
among any of the unaffected individuals, thus suggesting a possible novel locus for PCG. 
No plausible candidate gene was present in the locus, and therefore the family was further 
analyzed by exome sequencing. No potentially pathogenic variants were found within this 
homozygous region on chromosome 7. In addition, all filtered homozygous variants with 
high pathogenicity scores observed in the exome data were screened in the family (Table 
2.7), but none of the variants segregated with the disease. 
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Figure 3.4 Clinical analyses of the two affected members in the PCG family GLC 2. i) 
Shows an opaque cornea and bulging of the eyes due to an elevated IOP in individual II:3. 
ii) Shows an opaque cornea of individual II:4, which also bulges out. Both individuals were 
completely blind, iii) showing the B-scans done for II:4. The B-scan of the right eye shows 
an integral haze with a total freely mobile fibrotic posterior vitreous detachment. The optic 
nerve head shows a markedly deep excavated cup indicated with an arrow. The B-scan of 
the left eye also shows a deep excavated cup (indicated with an arrow), but the patient had 
normal tomographs. 
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Figure 3.5 Homozygosity Mapper plot of the congenital glaucoma family (GLC 2) (details of regions are given in Appendix 6) 
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Figure 3.6 Homozygous region linked to PCG in two affected individuals (II: 3 and II: 4) of family GLC 2. Both SNP array and 
Exome sequencing were performed for both affected individuals. 
GLC 2 (Chr.7:139,681,371-141,507,822) 
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3.3.2 Identification of a Homozygous Region in Juvenile Open Angle Glaucoma 
Family (GLC 4)    
A family with JOAG (GLC 4) with a dominant pattern of inheritance was sampled from 
the suburbs of southern Punjab, Pakistan. Six affected individuals and seven unaffected 
individuals were sampled from this family for analysis. Among the six affected individuals 
four (indicated by * in Fig. 3.8) were not aware of having developed the disease and were 
clinically suspected to be suffering from glaucoma based on persistent headaches and 
blurred of vision. All family members (affected, glaucoma suspects and unaffected) 
underwent diagnostic tests. Gonioscopic findings revealed a CDR> 0.5 in the affected and 
individuals suspected of having glaucoma and all of them had visual field defects and a 
raised IOP (>30 mmHg). Fundus fluorescein angiography (FFA) was conducted for the 7 
normal individuals and 2 affected and 4 glaucoma suspects. The affected individuals as 
well as glaucoma suspects had thinning of the nerve fibre layer. All normal individuals also 
underwent diagnostic tests such as visual field analysis, IOP measurement, CDR analysis 
and RNFL thickness estimation, which were within normal limits in all cases. Individual 
V:2 was seven years of age and was most severely affected in the family. The diagnostic 
tests helped in confirmation of the affected status of the glaucoma suspects as they all had 
damaged optic disc, impaired visual field and thinned nerve fiber layer, all of these 
symptoms were similar as in the established affected members of the family (III:3 and V:2).  
Known glaucoma genes were excluded in the family and one individual (V:2) was selected 
from the family for 250K SNP microarray analysis. The data were analysed by 
Homozygosity Mapper, which revealed three homozygous regions in the family located on 
chromosomes 1, 3 and 10 (Fig. 3.7, Annexure 6). OPTN, TMCO1, and COL11A1 were 
positional candidate genes in these regions and were screened for the presence of 
mutations. OPTN screening revealed no novel variant in the family, but SNP rs11258194 
(Met98Lys) was found, which had previously been shown to be associated with glaucoma. 
However, the Met98Lys variant did not segregate with the disease in the family (Fig. 3.8). 
Analysis of the other two genes, TMCO1 and COL11A1, did not reveal any mutation in 
this family. Therefore, the family was included in the panel of unsolved families (A; 
Annexure 7). 
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 Figure 3.7 Homozygosity Mapper plot of homozygous regions in a juvenile open angle glaucoma family GLC 8 (details of regions are 
given in Annexure 6) 
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Figure 3.8 Pedigree of a recessive consanguineous Pakistani family with juvenile open angle glaucoma (GLC 4). The polymorphism 
Met98Lys in OPTN is indicated with an M, and the ancestral allele with a ‘+’. All affected individuals carry the mutation homozygously 
or heterozygously, while some of the unaffected individuals were also heterozygous, demonstrating that the variation did not segregate 
with the disease in the family. 
 
GLC 4 (c.293T>A; p.Met98Lys) 
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3.3.3 Identification of Homozygous Region in Juvenile Open Angle Glaucoma 
Family GLC 8 
A JOAG family with a recessive pattern of inheritance was sampled from KPK province 
of Pakistan. Six affected and eight normal individuals were sampled for further analysis 
(Fig. 3.9). The proband of the family (V:5) suffered from a raised IOP and blurred vision. 
Due to the raised IOP, the individual was suspected to have glaucoma and underwent 
additional diagnostic tests. Visual field analysis revealed arcuate defects in vision, 
tonometery revealed a raised IOP (>30 mmHg), and gonioscopic findings also supported 
the other two tests revealing an increased cup-to-disc ratio (CDR=0.7). The individual had 
a family history of the disease and hence all the approachable family members were 
screened clinically for glaucoma. There were six individuals in the family who had an 
increased CDR (>0.6), an elevated IOP (>30 mmHg) and visual field defects. The normal 
individuals had no visual field defects or alterations in the CDR and their IOP was in the 
normal range. The symptoms of the disease started appearing at the end of the second 
decade of life in all affected individuals. In addition, individual IV:3 (the father of proband) 
suffered from diabetic retinopathy. Four affected individuals from the fifth generation (V:1, 
V:3, V:5 and V:7) were selected for 250K SNP microarray analysis. Homozygosity 
Mapper was used to analyse the data obtained from the array, which revealed 4 
homozygous regions on chromosomes 3, 4, 6 and 11 (Fig. 3.10 Annexure 6). The family 
(GLC 8, Fig. 3.9) was screened for mutations in known glaucoma genes (MYOC, OPTN, 
WDR36 and CYP1B1), and no causative mutation was found in any of these genes. Using 
the online UCSC genome browser, two genes known to be involved in anterior segment 
defects (PITX2 and FOXC1) and four candidate genes (IFT80, COL25A1, ATXN1, 
PLEKHA7) were selected from the homozygous regions, and were screened in the family 
for disease-causing variants. No mutation was found in any of these genes. Therefore, this 
family was also added to the panel of unsolved families (Annexure 7).  
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Figure 3.9 Pedigree of a consanguineous Pakistani family with juvenile open angle glaucoma (GLC 8), exhibiting an autosomal 
recessive inheritance pattern. The sampled family members are indicated by *, and the proband by an arrow.             
GLC 8 (Juvenile Open Angle Glaucoma Family) 
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Figure 3.10 Homozygosity Mapper plot of homozygous regions in juvenile open angle glaucoma family GLC 8 (details of regions are 
given in Annexure 6) 
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3.4 Next Generation Sequencing Analysis 
3.4.1 Identification of Three Variants MYO18A, ENOX1 and COL9A2 in JOAG 
Family GLC 1 
A large glaucoma family (GLC1) with a dominant mode of inheritance was sampled, but 
due to a difference in the age of disease onset in the two loops of the family they were 
analysed separately as independent families. GLC 1a had a juvenile onset (mean age 25 
years). While GLC 1b had a late onset (mean age 50 years, Fig. 3.11). GLC 1a consisted 
of ten sampled members (seven affected and three unaffected). There were two non-
consanguineous loops in GLC 1a, one of which had an early onset of the disease with a girl 
(V: 5) being affected in the first decade of life. In the other affected individuals of loop 
GLC1a the onset of signs and symptoms was in the mid to late half of the second decade 
of life or at the beginning of the third decade. The patients suffered from a raised IOP and 
pain in the eyes and forehead region. Ophthalmic examination revealed a raised CDR (0.7- 
0.9), and visual field analysis showed loss in the field of vision. In addition, FFA was 
conducted, which revealed RNFL thinning in the affected (individual IV:10, Fig. 3.12) and 
also in two members of the family (IV:2, IV:4) who were unaware of the onset of 
glaucomatic changes and were subsequently categorized as affected members (Fig. 3.11).  
Two members of the family from the GLC1a branch (IV:10 and V:5) were selected for 
exome sequencing. After filtering of the exome data, only 38 overlapping variants were 
left among the two affected individuals. All variants were checked for segregation among 
the GLC 1a and GLC 1b loops, and three heterozygous variants 2071G>A; Arg691Cys in 
MYO18A, 171C>T; Met57Ile in ENOX1 and 1061C>T; Pro354Leu (rs201772619) in 
COL9A2 segregated with the disease in the affected family members of loop GLC 1a. 
Hence, all the affected members carry three variants in three genes, which were not present 
in any of the normal members in any of the two branches. These three variants were not 
present in 200 normal healthy unrelated control individuals. Two of the variants (in 
MYO18A and ENOX1) were also present in a normal individual in loop GLC 1b (IV:1) but 
of the third variant in COL9A2 was absent in this individual.  
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Figure 3.11 Pedigree of a consanguineous Pakistani family with JOAG (GLC 1a) as well as late onset POAG (GLC 1b) inherited 
dominantly. Exome sequencing was performed for individuals IV:10 and V:5. Variants in three genes, MYO18A c. 2071G>A (black), 
ENOX1 c.171C>T (blue), and COL9A2 c.1061C>T (red), were found to segregate with the disease in loop GLC1a. The variant allele is 
indicated with an M, and the ancestral allele with a ‘+’. All affected individuals in loop GLC 1a carry the mutations heterozygously (IV: 
10 carries MYO18A variant homozygously). The proband is indicated by arrow. 
GLC 1 (MYO18A c. 2071G>A; p.Arg691Cys, ENOX1 c.171C>T; p.Met57Ile, COL9A2 c.1061C>T; p.Pro354Leu) 
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Figure 3.12 RNFL thickness for the patient IV:10 of JOAG family GLC1a.  The figure 
shows RNFL thinning in all four quadrants (nasal, temporal, superior and inferior), which 
along with measurement of IOP, CDR clearly indicates that the individual is glaucomatic.   
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Exome sequencing revealed only one variant (724C>T; p.Val242Met) in the NCOA7 gene 
segregated with the disease in the GLC 1b loop of the family (Fig. 3.13). The variant was 
present in heterozygous form among the two affected members (IV:2 and IV:4) of the 
family in the fourth generation; all unaffected individuals in this generation had the 
homozygous ancestral allele. Of the three sampled individuals in the fifth generation, two 
unaffected individuals (V:2 and V:3) carried the variant allele in a heterozygous state. 
These two individuals at the time of sampling were in their first decade of life. As the 
disease has a late onset in this branch of the family, the symptoms of the disease might not 
have surfaced yet in these unaffected individuals. In loop GLC 1a, the variant in NCOA7 
was present heterozygously in all affected members, except for one affected individual 
(IV:12), while all normal individuals carried the ancestral allele (segregation not shown in 
the pedigree). The variant was not identified in 200 unrelated normal unaffected controls.  
3.4.2 Identification of a Variant in PHKG1 in JOAG Family GLC 5 
Family GLC 5 (Fig. 3.14) was a consanguineous family with a dominantly inherited form 
of glaucoma, sampled from the suburbs of southern Multan. This family had early onset of 
the disease in two individuals (V:2, V:6) with appearance of symptoms in the middle of 
the second decade of life, whereas among all other individuals the symptoms appeared in 
the later half of the third decade. Individual V: 6 presented with a raised IOP (>30 mmHg) 
as well as increased CDR, which was higher for the vertical diameter than the horizontal 
diameter, creating a notch in the neuroretinal rim superiorly. Treatment of the patient with 
beta-blockers helped in lowering the IOP to the normal range (18-20 mmHg). The other 
affected members of the family (III:1, IV:4, IV:6, IV:7, IV:8) had a late onset of the disease 
with the symptoms appearing in the later half of the third decade. Six affected members 
and two normal individuals of the family were sampled. All sampled individuals underwent 
ophthalmic examination. The visual field test confirmed abnormalities among the affected 
members of the family only. They also had a raised IOP (>30 mmHg) and increased CDR 
(0.8). All normal individuals of the family had an IOP in the normal range (<20 mmHg) 
and normal CDR (0.1-0.3).  
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Figure 3.13 Pedigree of a consanguineous Pakistani family with late onset glaucoma (GLC 1b) inherited dominantly. Segregation of 
variant c.724C>T; p.Val242Met in NCOA7 is shown in the figure. The derived allele is indicated with an M, and the ancestral allele 
with a ‘+’. All elderly affected individuals in the third generation of loop GLC 1b carry the variant heterozygously, while in the fourth 
generation, V: 2 and V:3 carry the varaint heterozygously. 
GLC 1b (NCOA7: c.724C>T; p. p.Val242Met) 
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Figure 3.14 Pedigree of a consanguineous Pakistani family with juvenile onset open angle glaucoma inherited dominantly. Exome 
sequencing was performed for individuals IV:4, IV:6, IV:7 and V:6. Segregation of a variant (c.125C>T) in the PHKG1 gene is shown 
in the figure. The derived allele is indicated with an M, and the ancestral allele with a ‘+’. All affected members of the family are 
heterozygous for the variant, and V: 6 was homozygous for the variant. The proband is indicated by an arrow.   
GLC 5 (PHKG1: c.125 C>T; p.Thr42Met) 
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No novel or recurrent variants were found in the known glaucoma genes in this family, and 
thus the family was further analysed by exome sequencing. Exome data filtering resulted 
in forty variants, which were subsequently screened in the family for segregation. Out of 
all variants, only one variant, 125C>T (p.Thr42Met) in PHKG1, segregated with the 
disease in the family (Fig. 3.14). The variant was present in a heterozygous state in affected 
individuals who had an onset of disease in the fourth decade of life, as well as in one normal 
individual (V:7) of age below 10 years, and in homozygous form in one affected individual 
(V: 6) who had juvenile onset of the disease and a severe phenotype with much raised IOP 
and CDR as compared to other affected members of the family as well as severely reduced 
visual fields. 
3.5 Case-Control Association Studies  
3.5.1 Case-Control Association Studies for Glaucoma  
Patients and controls included in the case-control association studies for glaucoma were 
age- and gender-matched (Table 3.2). The mean age (± standard deviation) of the controls 
was 48.1±13.2 years, of patients with POAG 48.3±16.5 years, of patient with PACG 
45.5±16.5 years and of patients with PEXG 50.09±14.1 years (Table 3.2). In total 350 
healthy subjects (52% males and 48% females), 500 patients with POAG (51% males and 
49% females), 200 patients with PACG (49.5% males and 50.5% females) and 300 patients 
with PEXG (48% males and 52% females) were enrolled in the study. The majority of the 
patients were under treatment by β-blockers, or had undergone surgery (trabeculectomy) 
to lower their IOP. 
3.5.1.1 Screening BIRC6 and PDIA5 Polymorphisms in Glaucoma Cohort 
The allele and genotype frequencies of rs11720822 in PDIA5 were not significantly 
different between POAG, PACG and PEXG as compared to the control individuals (Table 
3.3). The T allele of rs2754511 in BIRC6 was found in 35% of control alleles, while it was 
found in 32% of POAG alleles, 35% of PACG alleles, and 28% of PEXG alleles. The 
frequency of the T allele was found to be significantly lower in PEXG  
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Table 3.2 Demographic and clinical features of the control, POAG, PACG and PEXG cohorts 
 
 Controls POAG 
p-
value 
PACG 
p-
value 
PEXG 
p-
value 
Age 48.1±13.2 48.3±16.5 >0.05 45.5.±16.5 >0.05 50.09±14.1 >0.05 
Gender   
>0.05 
 
>0.05 
 
>0.05 Males 52% 51% 49.5% 48% 
Females 48% 49% 50.5% 52% 
IOP 16.4±2.3 30.5±11.6 <0.05 26.4±10.2 <0.05 28.4±10.5 <0.05 
CDR 0.39±0.18 0.85±.63 <0.05 0.67±.27 <0.05 0.76±.23 <0.05 
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Table 3.3 Results of logistic regression analysis for genotype and allele frequencies of SNPs rs11720822 in PDIA5 and rs2754511 in BIRC6 in POAG, 
PACG and PEXG patients and control individuals 
PDIA5 
rs11720822 
POAG 
 Est. 
Z 
value 
OR (95%CI) P-value/pb 
PACG 
Est. 
Z 
value 
OR (95%CI) p-value/pb 
PEXG 
Est. 
Z 
value 
OR (95%CI) p-value/pb 
CC 
0.07 
17.90 
0.16  
0.02 
0.9 (0.37-2.26) a 
5.95(0.00-Inf) a 
0.86/1.00b 
0.98/1.00b 
0.22  
12.89 
-0.45 
0.01 
0.79 (0.29-2.13)a  
3.69 (0.00-Inf)a 
0.64/1.00b 
0.98/1.00b 
0.60 
15.55 
1.30  
0.01 
1.82(0.74-4.48)a  
5.68(0.00-Inf)a 
0.18/1.00b  
0.98/1.00b 
CT 
TT 
Allele Frequency 
C - - 
0.74 (0.41-1.34)c 0.28/1.00b 
- - 
1.00 (0.51-1.96)c 0.99/1.00b 
- - 
1.15 (0.60-2.19)c 0.66/1.00b 
T - - - - - - 
BIRC6 
rs2754511 
     
AA 
0.39  
0.18 
-2.53 
0.81 
0.67 (0.49-0.91)a  
0.83 (0.52-1.30)a 
0.01/0.06b 
0.41/1.00b 
0.05 
 0.18 
-0.28 
0.59 
0.94 (0.62-1.41)a  
1.20 (0.65-2.22)a 
0.77/1.00 
0.54/1.00b 
0.35  
0.84 
-1.87  
2.58 
0.70 (0.48-1.01)a  
0.42 (0.22-0.81)a 
0.06/0.36b  
0.009/0.05b 
AT 
TT 
Allele Frequency 
A - - 
0.85 (0.68-1.06)c 0.15/0.90b 
- - 
0.95(0.72-1.26)c 0.28/1.00b 
- - 
0.72 (0.55-0.94)c 0.01/0.06b 
T - - - - - - 
a Age- and gender-adjusted OR and (95%CI) from multivariate logistic regression analysis; pb Bonferroni-corrected p values; c OR and (95%CI) 
from univariate logistic regression analysis; Est., estimates 
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patients as compared to the controls (p=0.01; OR 0.72 [95% CI 0.55-0.94]) (Table 3.3), 
however this association did not remain significant when Bonferroni correction was 
applied to the data (p=0.06). Logistic regression analysis was conducted adjusting for age 
and gender, which showed that the homozygous TT genotype of the studied BIRC6 
polymorphism is protective in the case of PEXG (p=0.009), which remained significant 
even after Bonferroni correction was applied (p=0.05).  
3.5.1.2 Screening OPTN and MYOC Polymorphisms in Glaucoma Cohort 
The genotype and allele frequencies of the SNP rs11258194 in OPTN were not 
significantly associated with increased risk of POAG after correction of p values for 
multiple testing, (p=0.07, OR=2.85 [95% CI=1.15-7.06]; p=0.06, OR=2.68 [95% CI=1.07-
7.12]; Table3.4). The AA genotype was present in low percentage (0% in controls, and 1% 
in cases; data not shown) therefore it was merged into the TA genotype for logistic 
regression analysis. Similarly, no significant associations were observed for PACG or 
PEXG (PACG; p=0.25, OR=2.05 [95% CI=0.05-7.14]; p=0.22, OR=1.96 [95% CI=0.58-
6.68], PEXG; p=0.33, OR=1.76 [95% CI=0.56-5.51]; p=0.17, OR=1.96 [95% CI=0.67-
6.11]; Table3.4). In addition, rs10906308 in OPTN and rs2234926 in MYOC were not 
found to be significantly associated with POAG, PACG, or PEXG (Table 3.4). Moreover, 
the mean IOP of POAG patients carrying the variant allele rs11258194 (23.6±9.2 mmHg) 
was not significantly different from the mean IOP in POAG patients who had the ancestral 
allele (25.2±10.1 mmHg; p>0.05). Haplotype analysis of the two SNPs in OPTN was also 
conducted, which showed that the haplotype A-G (rs11258194-rs10906308) was 
significantly associated with increased risk of POAG (p=0.019, OR=2.96 [95% CI=1.20-
7.31]; Table 3.5).  
3.5.1.3 Screening Oxidative Stress and Apoptotic Pathway Gene Polymorphisms in 
Glaucoma Cohort 
Polymorphisms in three genes (P21, P53, P450) of the apoptotic pathway were selected 
for screening in the glaucoma cohorts. In addition, polymorphisms in the oxidative stress 
genes NOS3 and HSP70 were screened in these cohorts. Logistic regression analysis 
revealed that the P21 polymorphism rs1801270 is not associated with any type of 
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Table 3.4 Logistic regression analysis for rs11258194 and rs10906308 in OPTN and rs2234926 in MYOC in Pakistani glaucoma 
cohorts and controls 
Genotype 
rs11258194 
Estimate 
POAG 
Z 
value 
OR (95%CI) 
p value/ 
*p-value 
Estimate 
PACG 
Z 
value 
OR (95%CI) 
p value/ 
*p-value 
Estimate 
PEXG 
Z 
value 
OR (95%CI) 
p value/ 
*p-value 
TT -- -- 
2.85 (1.15-7.06)a 0.02/0.07 
-- -- 
2.05(0.05-7.14)a 0.25/0.60 
-- -- 1.76 (0.56-
5.51)a 
0.33/0.72 
TA+AA 1.05 2.27 0.71 1.13 0.56 0.97 
Allele Frequency 
T -- -- 
2.68(1.07-7.12)b 0.02/0.06 
-- -- 
1.96(0.58-6.68)b 0.22/0.66 
-- -- 1.96(0.67-
6.11)b 
0.17/0.51 
A -- -- -- -- -- -- 
Genotype rs10906308 
GG -- --  
0.96(0.35-2.62)a 
1.16(0.68-1.98)a 
 
0.45/0.92 
0.92/0.99 
-- --  
0.99(0.58-1.68)a 
1.04(0.41-2.66)a 
 
0.98/1.00 
0.91/0.99 
-- --  
0.87(0.25-2.99)a 
0.99(0.51-1.93)a 
 
0.98/1.00 
0.78/0.99 
GA 0.15 0.73 -0.003 -0.01 -0.006 -0.02 
AA -0.03 -0.08 0.04 0.10 -0.13 -0.27 
Allele Frequency 
G -- -- 
1.10(0.86-1.63)b 0.54/1.00 
-- -- 
1.10(0.75-1.61)b 0.92/1.00 
-- -- 1.00(0.68-
1.47)b 
0.71/1.00 
A -- -- -- -- -- -- 
Genotype rs2234926 
GG -- --  
0.91(0.60-1.38)a 
0.75(0.36-1.55)a 
 
0.69/0.99 
0.44/0.91 
-- --  
0.74(0.43-1.26)a 
0.88(0.37-2.12)a 
 
0.27/0.72 
0.79/0.99 
-- --  
0.71(0.35-1.43)a 
1.23(0.42-3.54)a 
 
0.22/0.64 
0.61/0.98 
GA -0.08 -0.39 -0.29 -1.09 -0.33 -1.21 
AA -0.28 -0.76 -0.11 -0.26 0.20 0.49 
Allele Frequency 
G -- -- 
0.87(0.60-1.26)b 0.49/1.00 
-- -- 
0.87(0.60-1.26)b 0.47/1.00 
-- -- 1.00(0.69-
1.45)b 
1.00/1.00 
C -- -- -- -- -- -- 
aAge- and gender-adjusted OR and (95% CI) from multivariate logistic regression analysis, bOR and (95%CI) from univariate logistic regression 
analysis, *p Bonferroni corrected p-values,  
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Table 3.5 Haplotype analysis of OPTN SNPs rs11258194 and rs10906308 in Pakistani 
POAG cohorts 
  rs11258194  rs10906308 Freq OR (95%CI) P-value 
1 T G 0.6733 1.00 --- 
2 T A 0.2789 1.10 (0.80-1.51) 0.55 
3 A G 0.0398 2.96 (1.20-7.31) 0.019 
Global haplotype association p-value:0.0082 
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glaucoma. The P450 polymorphism c.-2805T>C was found to possibly have a protective role 
in patients with PEXG (estimate=-0.81, z value=-3.68, OR=0.44, [95% CI=0.25-0.77], p=8.8e-
04) in the presence of the heterozygous genotype. However, the P450 c.-2805T>C 
polymorphism was not found to be associated with POAG or PACG (Table 3.6).  
The P53 polymorphism rs1042522 was also not found to be associated with any type of 
glaucoma (Table 3.6). When univariate logistic regression analysis was applied to the allele 
frequencies (Table 3.7), it was seen that the minor allele ‘C’ of this polymorphism was not 
associated with either POAG, PACG or PEXG (POAG: OR=1.01, [95% CI=0.83-1.23], 
p=1.00), (PACG: OR=1.25 [95% CI=1.00-1.58], p=0.2),  (PEXG: OR=1.26 [95% CI=1.02-
1.57], p=0.15) (Table 3.7).  
The HSP70 rs1043618 polymorphism was found to be significantly associated with POAG, 
both for the heterozygous genotype (GC) (estimate=0.98, z value= 6.19, OR=2.68 [95% 
CI=1.79-4.01], p=2.22e-09) as well as for the homozygous variant genotype (CC) 
(estimate=0.60, z value= 3.06, OR=1.83 [95% CI=1.11-3.04], p=0.009) (Table 3.6). It was also 
found to be significantly associated with PACG, both in heterozygous (GC) form 
(estimate=0.65, z value= 2.87, OR=1.91 [95% CI=1.08-3.39], p=0.01) as well as in 
homozygous (CC) form (estimate=0.65, z value= 3.41, OR=1.91 [95% CI=1.18-3.10], 
p=0.002). In PEXG only the homozygous variant genotype (CC) of the polymorphism was 
significantly associated with the disease (estimate=1.05, z value= 0.19, OR=2.87 [95% 
CI=1.75-4.71], p=2.5e-07). Univariate logistic regression analysis showed that the risk allele C 
of the HSP70 rs1043618 polymorphism is significantly associated with all three types of 
glaucoma; POAG (OR=1.69 [95% CI=1.37-2.09], p=<0.001), PACG (OR=1.60 [95% 
CI=1.25-2.05], p=<0.001), and PEXG (OR=2.02 [95% CI=1.61-2.54], p=<0.001) (Table 3.7). 
The heterozygous genotype of in 27bp intron 4 VNTR polymorphism in NOS3 was found to 
be significantly associated with POAG and PEXG (estimate=0.55, z value= 3.06, OR=1.74, 
[95% CI=1.10-2.75], p=0.01) and (estimate=0.51, z value= 2.38, OR=1.68, [95% CI=1.01-
2.74], p=0.04), respectively. However, PACG was found to be significantly associated with 
both heterozygous (estimate=0.73, z value= 3.5, OR=2.09, [95% CI=1.23-3.55], p=0.001) as 
well as homozygous genotypes (estimate=0.87, z value= 2.46, OR=2.38, [95% CI=1.00-
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Table 3.6 Logistic regression analysis of genotype frequency distribution of P21 (rs1801270), P450 (c.-2805T>C), P53 (rs1042522), 
HSP70 (rs1043618) and NOS3 (27bp intron 4) polymorphisms in Pakistani glaucoma cohorts and controls 
Categories 
POAG 
Estimate 
Z 
 
value 
OR (95%CI) p value/ 
*p-value 
PACG 
Estimat
e 
Z 
 
Value 
OR (95%CI) p value/ 
*p-value 
PEXG 
Estimat
e 
Z  
value 
OR (95%CI) p value/ 
*p-value 
P21 (rs1801270) polymorphism 
CC -- -- -- 
0.76 (0.26-2.23)/0.02/0.95 
1.55 (0.93-2.57)/0.53/0.12 
-- -- -- 
1.10 (0.58-2.06)/0.68/0.99 
0.11 (0.007-1.59)0.03/0.15 
-- -- -- 
0.98 (0.62-1.566)/0.95 
1.08 (0.47-2.50)/0.84 
CA -0.26 -0.62 0.09 0.40 -0.01 -0.05 
AA 0.44 2.18 -2.1 -2.07 0.08 0.19 
 P450 (rs2567206) polymorphism 
CC -- -- 
-- 
0.61(0.36-1.03)/0.01/0.07 
0.80 (0.47-1.36)/0.031/0.74 
-- -- 
-- 
0.73 (0.39-1.37)/0.21/0.59 
1.03 (0.54-1.94)/0.89/0.99 
-- -- -- 
0.44 (0.25-0.77)/0.0002/8.8 e-
04 
0.63 (0.36-1.11)/0.04/0.15 
CT -0.49 -2.35 -0.31 -1.25 -0.81 -3.68 
TT -0.21 -1.03 0.03 0.12 -0.45 -2.04 
 P53 (rs1042522) polymorphism 
GG -- -- -- 
1.29 (0.83-1.99)/0.13/0.43 
1.05 (0.64-1.70)/0.78/0.99 
-- -- -- 
1.2 (0.74-2.15)/0.26/0.69 
1.4 (0.85-2.63)/0.07/0.25 
-- -- -- 
1.23 (0.75-2.01)/0.27/0.71 
1.51 (0.89-2.55)/0.04/0.17 
GC 0.25 1.50 0.23 1.11 0.21 1.09 
CC 0.05 0.26 0.40 1.80 0.41 1.99 
HSP70 (rs1043618) polymorphism 
GG -- -- -- 
2.68 (1.79-4.01)/0.000/2.22 e-09 
1.83 (1.11-3.04)/0.002/0.009 
-- -- -- 
1.91 (1.08-3.39)/0.0006/0.01 
1.91 (1.18-3.10)/0.004/0.002 
-- -- -- 
1.04 (0.64-1.68)/0.81/0.99 
2.87 (1.75-4.71)0.000/2.5 e-07 
GC 0.98 6.19 0.65 2.87 0.04 0.23 
CC 0.60 3.06 0.65 3.41 1.05 0.19 
NOS3 (27 bp intron 4 VNTR polymorphism) 
 Bb -- -- -- 
1.74 (1.10-2.75)/0.002/0.01 
1.34 (0.57-3.13)/0.37/0.86 
-- -- -- 
2.09 (1.23-3.55)/0.0004/0.001 
2.38 (1.00-5.82)/0.01/0.05 
-- -- -- 
1.68 (1.01-2.7)/0.009/0.04 
1.56 (0.64-3.78)/0.20/0.61 
 Ba 0.55 3.06 0.73 3.5 0.51 2.38 
 Aa 0.29 0.88 0.87 2.46 0.44 1.27 
 *p p-values corrected by simultaneous inference.  
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Table 3.7 Allele frequency distribution of P21 (rs1801270), P450 (c.-2805T>C), P53 (rs1042522), HSP70 (+190G>C), and NOS3 
(27bp intron 4) polymorphisms in Pakistani glaucoma cohorts and controls 
P21 
(rs1801270) 
Controls 
N=350 
POAG 
N=518 
OR (95%CI) p value/ 
*p-value 
PACG 
N=274 
OR (95%CI) p value/ 
*p-value 
PEXG 
N=348 
OR (95%CI) p value/ 
*p-value 
C 636 (91%) 922 (89%) 
1.23 (0.88-1.72) 
0.20/1.00 
510 (93%) 
0.74 (0.48-1.15) 
0.15/0.75 
631 (91%) 
1.02 (0.70-1.49) 
0.89/1.00 
A 64 (9%) 114 (11%)  38 (7%)  65 (9%)  
P450 (rs2567206) 
C 440 (63%) 643 (62%) 1.03 (0.84-1.27) 
0.73/1.00 
351 (64%) 0.95 (0.75-1.21) 
0.66/1.00 
414 (60%) 1.15 (0.92-1.44) 
0.19/0.95 T 260 (37%) 393 (38%) 197 (36%) 282 (40%) 
P53 (rs1042522 ) 
G 342 (49%) 503 (49%) 1.01 (0.83-1.23) 
0.90/1.00 
236 (43%) 1.25 (1.00-1.58)  
0.04/0.2 
300 (43%) 1.26 (1.02-1.57) 
0.03/0.15 C 358 (51%) 533 (51%) 312 (57%) 396 (57%) 
HSP70 (rs1043618) 
G 500 (71%) 618 (60%) 1.69 (1.37-2.09) 
<0.001/<0.001 
334 (61%) 1.60 (1.25-2.05) 
<0.001/<0.001 
385 (55%) 2.02  (1.61-2.54) 
<0.001/<0.001 C 200 (29%) 418 (40%) 214 (39%) 311 (45%) 
NOS3 (27bp intron 4) 
B 616 (88%) 861 (83%) 1.49 (1.12-1.99) 
0.005/0.02 
432 (79%) 1.97 (1.43-2.71) 
<0.001/<0.001 
575 (83%) 1.54 (1.13-2.11) 
0.004/0.02 A 84 (12%) 175 (17%) 116 (21%) 121 (17%) 
*p Bonferroni corrected p-values.  
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5.82], p=0.05). The risk allele of the NOS3 gene polymorphism was also significantly 
associated with POAG (OR=1.49, [95% CI=1.12-1.99], p=0.005), PACG cohort 
(OR=1.97, [95% CI=1.43-2.71], p=<0.001), as well as the PEXG cohort (OR=1.54, [95% 
CI=1.13-2.11], p=0.004) (Table 3.7). 
3.5.1.4 Screening PLEKHA7, COL11A1, and PCMTD1 polymorphisms in the 
PACG Cohort 
PACG-associated SNPs rs11024102 in PLEKHA7, rs3753841 in COL11A1 and rs1015213 
in PCMTD1 were screened in 200 PACG patients and 200 age- and gender-matched 
unaffected controls. The genotype and allele frequencies of the SNP rs3753841 in 
COL11A1 were significantly associated with PACG (homozygous derived genotype; 
p=0.05, OR=0.44 [95% CI=0.19-1.00]; derived allele; p<0.001, OR=0.56 [95% CI=0.41-
0.75]; Table3.8), respectively, suggesting a protective role. As opposed to this, no 
significant association was observed in the PACG cohort with SNP rs1015213 in 
PCMTD1, where the minor genotype (TT) was present at a low percentage, and therefore 
it was merged with the CT genotype for logistic regression analysis [genotype; (p=0.15, 
OR=0.59 [95% CI=0.31-1.1]; allele frequency; p=1.00, OR=1.00 [95% CI=0.7-1.45]; 
Table3.8). Moreover, genotype and allele frequencies of the rs11024102 polymorphism in 
PLEKHA7 were not found to be significantly associated with PACG (CT: p=0.89, 
OR=0.79 [95% CI=0.36-1.7]; CC: p=0.89, OR=0.74 [95% CI=0.33-1.6]; allele frequency; 
p=0.19, OR=0.82 [95% CI=0.61-1.1], Table 3.8). 
3.6 Results of AMD Families 
Two families with AMD were recruited in the current study. Family AMD 1 was sampled 
from the federal capital of Pakistan with three affected individuals, but at the time of 
sampling only two affected members were alive and hence sampled (Fig. 3.15 A). Family 
AMD 2 (Fig. 3.15 B) was a small family consisting of two affected members belonging to 
DG Khan in Pakistan. The probands of both families had wet AMD and were treated with 
Avastin injections to control neovascularisation. As there were only two affected 
individuals from each family available, only analysis of known genes was conducted for 
the families. All exons of the CFH gene were screened in the probands of both families,  
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Table 3.8 Logistic regression analysis of genotype and allele frequency distribution of COL11A1 (rs3753841), PCMTD1 (rs1015213), 
and PLEKHA7 (rs11024102) polymorphisms in Pakistani PACG cohort and controls 
Genotype 
 
COL11A1 (rs3753841) 
OR (95% CI) 
p value/ 
*p-value 
PCMTD 1 
(rs1015213) OR (95% 
CI) 
p value/ 
*p-value 
PLEKHA7 
(rs11024102) OR (95% CI) 
p value/ 
*p-value 
Est. Z value Est. Z value Est. Z value 
Ancestral allele 
genotype 
-- -- 
 
 
0.65 (0.30- 1.4) 
 
0.44 (0.19-1.0) 
 
 
0.16/0.49 
 
0.01/0.05 
-- -- 
0.59 (0.31- 
1.1) 
0.03/0.15 
-- -- 
 
 
0.79 (0.36- 1.7) 
 
0.74 (0.33- 1.6) 
 
 
0.44/ 0.89 
 
0.36/0.82 
Heterozygous -0.42 -1.38 0.51** -2.07** -0.23 -0.75 
Derived allele 
Genotype  
-0.80 -2.48   -0.29 -0.90 
Allele 
Frequency 
Con. PACG  Con. 
Patient
s 
  Con. Patients  
Ancestral allele 126 (32%) 180 (45%) 
0.56 (0.41-0.75) 
<0.001 
<0.001 
318 
(80%) 
317 
(79%) 1.0 (0.7-
1.45) 
1.00/1.00 
152 
(38%) 
171 
(43%) 
0.82 (0.61-1.1) 0.19/0.57 
Derived allele 274 (69%) 220 (55%) 
82 
(20%) 
83 
(21%) 
248 
(62%) 
229 
(57%) 
*p values of genotype frequency corrected by simultaneous inference and p values of allele frequency corrected by Bonferroni method  
** Multivariate logistic regression done by merging Heterozygous CT and Homozygous TT genotypes together, Est.; Estimate. 
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Figure 3.15 Pedigrees of non-consanguineous Pakistani families with AMD. A) Segregation of variant c.1204C>T; p.His402Tyr in CFH 
is shown in family AMD 1. Derived allele is indicated with an M and the ancestral allele with a ‘+’. B) Segregation of variant 
c.2548G>A; p.Glu850Lys in CFH is shown in family AMD 2. The variant allele is indicated with an M2, and the ancestral allele with 
a ‘+’.  
AMD 2 (CFH: c.2548G>A) AMD 1 (CFH: c.1204C>T) 
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which identified non-synonymous SNPs rs800292 in exon 2, rs1061170 in exon 9 and 
rs368670743 in exon 14. Among these SNPs rs1061170 was previously shown to be 
associated with AMD and thus its segregation was checked in the respective family 
(Fig.3.15).  Another variant, c.2548G>A (p.Glu850Lys), was found in the proband of 
family AMD 2, which upon segregation analysis showed no linkage with the disease (Fig.3. 
15 B). 
3.7 Case-Control Studies in AMD 
Patients and controls included in the current study were age- and gender-matched. The 
mean age (± standard deviation) of the controls was 64.6±10.92 years and of AMD cases 
65.9±10.92 years. 300 healthy subjects (52% males and 48% females) and 300 patients 
with AMD (51% males and 49% females) were enrolled in the case-control association 
studies. The AMD patients were further bifurcated into two categories i.e. wet AMD and 
dry AMD. Moreover, the individuals who had stopped smoking at least 3 years ago were 
categorised as former smokers and those individuals who had been smoking for the past 5 
years were categorized as current smokers. Multivariate logistic regression analysis was 
applied to the data keeping age and gender as covariates. The p-values were corrected by 
simultaneous inference (test of hypothesis) for multiple testing. Univariate logistic 
regression analysis was applied to the allele frequencies to determine the effect of the 
variant allele on the disease. The data analysis showed that the current smokers were at a 
higher risk of developing AMD as compared to the non-smokers [OR=2.42(95%CI=2.42-
5.01) p=0.004]. Moreover, the former smokers were at higher risk of development of the 
disease as compared to the non-smokers [OR=5.34 (95%CI=2.55-11.17) p<0.0001]. The 
former smokers with dry and wet AMD were more at risk of development of advanced 
stages of AMD [OR=5.42 (95%CI=1.95-15.01) p<0.0001] as compared to the current 
smokers with dry or wet AMD [OR=2.76 (95%CI=1.16-6.57) p=0.008]. 
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3.7.1 Screening Polymorphisms in Known AMD Gene  
3.7.1.1 CFH and ARMS2 
Multivariate logistic regression analysis showed that rs1061170 in CFH was not associated 
with AMD overall or with wet AMD. The ‘CC’ as well as the ‘TC’ genotype of the 
polymorphism rs1061170 was not associated with the risk of having AMD or any subtype 
of AMD (Table 3.9) (AMD overall; TC: p=0.77, OR=0.94 [95% CI=0.64-1.38], CC: 
p=0.02, OR=2.14 [95% CI=1.08-4.25]; Wet AMD (TC: p=0.53, OR=0.85 [95% CI=0.52-
1.39], CC: p=0.03, OR=2.37 [95% CI=1.06-5.32];  Dry AMD (TC: p=0.80, OR=1.05 [95% 
CI=0.68-1.62], CC: p=0.06, OR=2.05 [95% CI=0.96-4.37; Table 3.9]).  
Univariate logistic regression analysis showed that the risk allele C was also not associated 
with the disease in the combined data (p=0.13, OR=1.24 [95% CI=0.93-1.64]) nor with the 
subtypes of the disease (Wet AMD; p=0.22, OR=1.23 [95% CI=0.87-1.76], Dry AMD; 
p=0.15, OR=1.24 [95% CI=0.90-1.71]; Table 3.9).  
Multivariate logistic regression analysis showed that the derived genotype ‘TT’ of 
rs10490924 in ARMS2 was significantly associated with AMD in the overall data as well 
as with wet AMD. The ‘GT’ genotype of the polymorphism rs10490924 was not associated 
with the risk of developing AMD (AMD overall; GT: p=0.92, OR=1.15 [95% CI=0.69-
1.91], TT: p=0.003, OR=2.61 [95% CI=1.28-5.32] nor with wet AMD (GT: p=0.94, 
OR=1.19 [95% CI=0.61-2.32], TT: p=0.0006, OR=3.57 [95% CI=1.52-8.37]). None of the 
genotypes were associated with dry AMD (GT: p=0.97, OR=1.12 [95% CI=0.63-1.99], 
TT: p=0.06, OR=2.14 [95% CI=0.97-4.37]). Univariate logistic regression analysis showed 
that the risk allele T was significantly associated with the disease in the overall data 
(p<0.001, OR=1.61 [95% CI=1.22-2.11]) as well as with the subtypes of the disease (wet 
AMD; p<0.001, OR=1.89 [95% CI=1.34-2.65], dry AMD; p=0.04, OR=1.43 [95% 
CI=1.05-1.95]; Table 3.9). 
3.7.1.2 C2/CFB 
An AMD-associated SNP (rs429608) near C2 and CFB genes on chromosome 6p21.3 was 
screened in AMD cases and controls (Table 3.10). Multivariate logistic regression analysis 
adjusted for age, gender and smoking status showed that the genotype and allele frequency 
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Table 3.9 Logistic regression analysis of genotype and allele frequency distribution of polymorphisms rs1061170 in CFH and 
rs10490924 in ARMS2 in AMD patients and controls  
Genotype 
CFH 
(rs1061170) 
Overall OR (95%CI) 
p/*p 
value 
Wet AMD OR (95%CI) 
p/*p 
value 
 
Dry AMD OR (95%CI) 
p/*p 
value 
Est. Z value   Est. 
Z  
value 
  Est. Z value  
 
 
TT -- -- - 
0.94 (0.64-1.38) 
2.14 (1.08-4.25) 
- 
0.77/0.99 
0.02/0.11 
- - - 
0.85 (0.52-1.39) 
2.37 (1.06-5.32) 
- 
0.53/0.95 
0.03/0.13 
- - - 
1.05 (0.68-1.62) 
2.05 (0.96-4.37) 
- 
**0.80 
**0.06 
TC -0.05 -0.28 -0.15 -0.62 0.05 0.24 
CC 0.76 2.18 0.86 2.10 0.71 1.85 
Allele  
Frequency 
Controls Overall  
Allele 
Frequency 
 
Allele 
Frequency 
 
T 281 (70%) 393 (66%) 
1.24 (0.93-1.64) 0.13/0.26 
164 (66%) 
1.23 (0.87-1.76) 0.22/0.4 
229 (65%) 
1.24 (0.90-1.71) 
**0.15/
0.3 C 119 (30%) 207 (34%) 86 (34%) 121 (35%) 
ARMS2 (rs10490924) 
GG - - 
- 
1.15 (0.69-1.91) 
2.61 (1.28-5.32) 
- 
0.47/0.92 
0.0006/ 
0.003 
- - 
- 
1.19 (0.61-2.32) 
3.57 (1.52-8.37) 
- 
0.50/0.94 
0.0001/ 
0.0006 
- - 
- 
1.12 (0.63-1.99) 
2.14 (0.97-4.37) 
- 
0.60/0.9
7 
0.01/0.0
6 
GT 0.14 0.71 0.17 0.66 0.11 0.51 
TT 0.96 3.39 1.27 3.76 0.76 2.42 
Allele  
Frequency 
Controls Overall  
Allele 
Frequency 
 
Allele 
Frequency 
 
G 273 (68%) 343 (57%) 
1.61 (1.22-2.11) 
<0.001/<
0.001 
133 (53%) 
1.89 (1.34-2.65) 
<0.001/<0
.001 
210 (60%) 
1.43 (1.05-1.95) 
0.02/0.0
4 T 127 (32%) 257 (43%) 117 (47%) 140 (40%) 
*p values corrected by simultaneous inference, **p value not corrected 
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Table 3.10 Logistic regression analysis of genotype and allele frequency distribution of rs429608 polymorphism near C2/CFB in AMD 
patients and controls 
Genotype 
C2/CFB 
(rs429608) 
Overall 
OR (95% CI) 
P 
value 
Wet AMD 
OR (95% CI) 
P 
value 
Dry AMD 
OR (95% CI) 
P 
value Est. Z value Est. 
Z 
value 
Est. 
Z 
value 
GG             
GA 
-0.03* -0.15* 0.96 (0.63- 1.47) 0.8* 
-0.44 -1.50 0.63 (0.35- 1.14) 0.13 0.23 0.93 1.26 (0.77- 2.06) 0.35 
AA -0.22 -0.37 0.79 (0.23- 2.65) 0.70 -0.40 -0.61 0.66 (0.18- 2.43) 0.54 
Allele  
Frequency 
Controls AMD  
Allele 
Frequency 
 
Allele 
Frequency 
 
A 310 (79%) 400 (79%) 
0.97 (0.69-1.36) 0.89 
167 (81%) 
0.86 (0.55-1.34) 0.52 
233 (78%) 
0.98 (0.66-1.44) 1.00 
G 84 (21%) 106 (21%) 39 (19%) 62 (22%) 
Est.; Estimate, 
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of rs4420638 was not associated with AMD. The homozygous genotype AA was present 
in a small number of cases. Therefore, the heterozygous and homozygous genotype groups 
were merged together in the combined AMD data to conduct multivariate logistic 
regression analysis (AMD overall; p=0.8, OR=0.96 [95% CI=0.63-1.47], wet AMD; GA: 
p=0.13, OR=0.63 [95% CI=0.35-1.14], AA: p=0.70, OR=0.79 [95% CI=0.23-2.65]; Table 
3.10, dry AMD; GA: p=0.35, OR=1.26 [95% CI=0.77-2.06], AA: p=0.54, OR=0.66 [95% 
CI=0.18-2.43]; Table 3.10). Univariate logistic regression analysis showed that the risk 
allele A was also not associated with the disease in the combined data (p=0.89, OR=0.97 
[95% CI=0.69-1.36]) nor with the subtypes of the disease (wet AMD; p=0.52, OR=0.86 
[95% CI=0.55-1.34], dry AMD; p=1.00, OR=0.98 [95% CI=0.66-1.44]; Table 3.10). 
3.7.1.3 C3 
An AMD-associated SNP (rs2230199) in C3 was screened in AMD cases and controls. 
Multivariate logistic regression analysis adjusted for age, gender and smoking status 
showed that the genotype and allele frequencies of the polymorphism rs2230199 were not 
associated with AMD  (AMD overall; GC: p=0.17, OR=0.31 [95% CI=0.05-1.70], CC: 
p=0.31, OR=0.42 [95% CI=0.08-2.24], wet AMD; GC p=0.32, OR=0.35 [95% CI=0.04-
2.78], CC: p=0.28, OR=0.33 [95% CI=0.04-2.52], dry AMD; GA: p=0.13, OR=0.24 [95% 
CI=0.03-1.53], AA: p=0.36, OR=0.44 [95% CI=0.07-2.61]; Table 3.11). Univariate 
logistic regression analysis showed that the risk allele C was also not associated with the 
disease in the overall data (p=0.62, OR=1.10 [95% CI=0.7-1.64]) nor with the subtypes of 
the disease (wet AMD; p=0.5, OR=0.86 [95% CI=0.53-1.3], dry AMD; p=0.18, OR=1.36 
[95% CI=0.84-2.19]; Table 3.11). 
3.7.2 Screening Polymorphisms in Lipid Metabolism Associated Gene   
3.7.2.1 APOE 
A previously reported AMD-associated SNP (rs4420638) 14 kb upstream of the APOE 
gene was screened in AMD cases and controls. Multivariate logistic regression analysis 
adjusted for age-, gender and smoking status showed that the genotype and allele 
frequencies of polymorphism rs4420638 were not associated with AMD (Table 3.12). The  
102 
 
 
 
 
 
 
Table 3.11 Logistic regression analysis of genotype and allele frequencies of the rs2230199 polymorphism near C3 in AMD patients 
and controls 
Genotype 
C3 
(rs2230199) 
Overall 
OR (95% CI) 
P 
value 
Wet AMD 
OR (95% CI) 
P 
value 
Dry AMD 
OR (95% CI) 
P 
value Estimate Z value Est. 
Z 
value 
Est. 
Z 
value 
GG             
GC -1.16 -1.34 0.31 (0.05- 1.70) 0.17  -1.04 -0.99 0.35 (0.04- 2.78) 0.32 -1.41 -1.50 0.24 (0.03- 1.53) 0.13 
CC -0.84 -1.0 0.42 (0.08- 2.24) 0.31 -1.10 -1.06 0.33 (0.04- 2.52) 0.28 -0.81 -0.90 0.44 (0.07- 2.61) 0.36 
Allele  
Frequency 
Controls Overall  
Allele 
Frequency 
 
Allele 
Frequency 
 
G 56 (14%) 69 (13%) 
1.10 (0.7-1.64) 0.62 
35 (16%) 
0.86 (0.53-1.3) 0.5 
34 (11%) 
1.36 (0.84-2.19) 0.18 
C 344 (%) 469 (87%) 185 (84%) 284 (89%) 
Est.; Estimate, Con.; Controls 
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Table 3.12 Logistic regression analysis of genotype and allele frequencies of the rs4420638 polymorphism near APOE in AMD 
patients and controls 
Genotype 
APOE 
(rs4420638) 
Overall 
OR (95% CI) 
p 
value 
Wet AMD 
OR (95% CI) 
p 
value 
Dry AMD 
OR (95% CI) p value 
Est. Z value Est. 
Z 
value 
Est. 
Z 
value 
GG   1.34 (0.79- 
2.28) 
0.27 
  
0.99 (0.50- 1.99) 0.99 
  
1.55 (0.86- 2.80) 0.14 
GA+AA 0.29 1.08 -0.001 -0.003 0.44 1.46 
Allele  
Frequency 
Controls AMD  
Allele 
Frequency 
 
Allele 
Frequency 
 
G 373 (91%) 454 (90%) 1.15 (0.72-
1.84) 
0.57 
185 (92%) 
0.92 (0.48-1.75) 0.88 
269 (88%) 
1.31 (0.78-2.19) 0.31 
A 37 (9%) 52 (10%) 17 (8%) 35 (12%) 
, Est.; Estimate, 
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homozygous genotype AA was not present in the patients and only one control individual 
was homozygous for the risk allele. Therefore, the heterozygous and homozygous genotype 
groups were merged together to conduct the multivariate logistic regression analysis (AMD 
overall; p=0.27, OR=1.34 [95% CI=0.79- 2.28], wet AMD; p=0.99, OR=0.99 [95% 
CI=0.50-1.99], dry AMD; p=0.14, OR=1.55 [95% CI=0.86-2.80]; Table 3.12). Univariate 
logistic regression analysis showed that the risk allele A was also not associated with the 
disease in the combined data (p=0.57, OR=1.15 [95% CI=0.72-1.84]) nor with the subtypes 
of the disease (wet AMD; p=0.88, OR=0.92 [95% CI=0.48-1.75], dry AMD; p=0.31, 
OR=1.31 [95% CI=0.78-2.19]; Table 3.12).    
3.7.3 Screening Polymorphisms in Immune System Pathway Genes  
3.7.3.1 CX3CR1 
Two SNPs, rs3732378 (c.839C>T) and rs3732379 (c.745G>A), in CX3CR1 were 
genotyped in the AMD cohort and controls. Multivariate logistic regression analysis 
showed that the genotype distribution of rs3732378 was not associated with AMD (AG; 
p=0.5, OR=2.04 [95% CI=0.57-7.31]; GG; p=0.6, OR=1.77 [95% CI=0.55-5.69]; Table 
3.13), nor with any of the sub-types of AMD (Table 3.13). Univariate logistic regression 
analysis showed that the risk allele ‘G’ was also not associated with AMD (p=0.28, 
OR=0.76 [95% CI=0.52-1.10]; Table3.13), nor with wet AMD (p=0.60, OR=0.76 [95% 
CI=0.46-1.24]; Table 3.13), but was significantly associated with dry AMD (p=0.00, 
OR=0.30 [95% CI=0.16-0.55]; Table 3.13) suggesting a protective role in dry AMD. 
Multivariate logistic regression analysis showed that the heterozygous genotype ‘CT’ of 
rs3732379 in CX3CR1 was significantly associated with AMD (CT; p=0.005, OR=0.26 
[95% CI=0.08-0.77], TT; p=0.9, OR=1.59 [95% CI=0.37-6.69]; Table 3.13), and also with 
dry AMD (CT; p=0.0008, OR=0.19 [95% CI=0.06-0.60], TT; p=0.9,OR=1.41 [95% 
CI=0.30-6.48]; Table 3.13) but not with wet AMD (CT; p=0.5, OR=0.41 [95% CI=0.09-
1.85], TT; p=0.7, OR=2.25 [95% CI=0.35-14.1]; Table 3.13). Univariate logistic 
regression analysis showed that the risk allele ‘T’ was not associated with AMD overall 
(p=0.64, OR=1.12 [95% CI=0.88-1.44]; Table 3.13), nor with wet AMD (p=0.36, OR=1.23  
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Table 3.13 Logistic regression analysis of genotype and allele frequencies of rs3732378 and rs3732379 polymorphisms in CX3CR1 in 
AMD patients and controls  
CX3CR1 
(rs3732378) 
Overall 
OR (95%CI) 
p value/ 
*p-value 
Wet AMD 
OR (95%CI) 
p value/ 
*p-value 
Dry AMD 
OR (95%CI) 
p value/ 
*p-value Est. Z value Est. 
Z 
value 
Est. 
Z 
valu
e 
AA -- --   -- --   -- --   
AG 0.71 1.47 2.04 (0.57- 7.31) 0.13/0.5 0.30 0.50 1.35 (0.27- 6.57) 0.61/0.9 1.08 1.71 2.95 (0.56- 15.6) 0.08/0.3 
GG 0.57 1.30 1.77 (0.55- 5.69) 0.19/0.6 0.28 0.53 1.33 (0.32- 5.54) 0.59/0.9 0.79 1.33 2.21 (0.46- 10.4) 0.18/0.6 
Allele  
Frequency 
Con. AMD  
Allele 
Frequency 
 Allele Frequency  
A 429 (86%) 533 (89%) 
0.76 (0.52-1.10) 0.14/0.28 
222 (89%) 
0.76 (0.46-1.24) 0.30/0.60 
314 (95%) 
0.30 (0.16-0.55) 
<0.0001 
<0.001 G 71 (14%) 67 (11%) 28 (11%) 16 (5%) 
CX3CR1 (rs3732379) 
CC -- --       -- --   
CT -1.34 -3.28 0.26 (0.08- 0.77) 
0.001/ 
0.005 
-0.89 -1.56 0.41 (0.09- 1.85) 0.11/0.5 -1.64 
-
3.80 
0.19 (0.06- 0.60) 
0.0001/ 
0.0008 
TT 0.46 0.85 1.59 (0.37- 6.69) 0.39/0.9 0.81 1.17 2.25 (0.35- 14.1) 0.24/0.7 0.34 0.60 1.41 (0.30- 6.48) 0.54/0.9 
Allele  
Frequency 
Con. AMD  
Allele 
Frequency 
 Allele Frequency  
C 250 (50%) 282 (47%) 
1.12 (0.88-1.44) 0.32/0.64 
112 (45%) 
1.23 (0.89-1.69) 0.18/0.36 
170 (48%) 
1.05 (0.79-1.40) 0.72/1.00 
T 250 (50%) 318 (53%) 138 (55) 180 (52%) 
*p values corrected by simultaneous inference, 
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[95% CI=0.89-1.69], and neither with dry AMD (p=1.00, OR=1.05 [95% CI=0.79-1.40]; 
Table 3.13). 
3.7.4 Screening Vascular System Related Gene Polymorphisms 
3.7.4.1 VEGF 
Three promoter region polymorphisms of VEGF were screened in 150 AMD samples (50% 
wet AMD and 50% dry AMD) and 150 age-matched controls. Multivariate logistic 
regression analysis was conducted and the results showed that rs8333061 was not 
associated with AMD overall, nor with wet AMD or dry AMD (AMD overall; CT: p=0.80, 
OR=1.05 [95% CI=0.68-1.62], TT: p=0.44, OR=2.05 [95% CI=0.96-4.37], wet AMD; CT: 
p=0.44, OR=1.34 [95% CI=0.62-2.86], TT: p=0.10, OR=1.89 [95% CI=0.86-4.15), Dry 
AMD; CT: p=0.68, OR=0.86 [95% CI=0.43-1.72], TT: p=0.65, OR=0.84 [95% CI=0.39-
1.79]; Table 3.14). 
In addition, rs13207351 was also not associated with AMD or any subtype of AMD in the 
current cohort (AMD overall; AG: p=0.93, OR=0.97 [95% CI=0.53-1.76], GG: p=0.72, 
OR=1.12 [95% CI=0.58-2.17], Wet AMD; AG: p=0.28, OR=1.55 [95% CI=0.69-3.48], 
GG: p=0.12, OR=1.96 [95% CI=0.82-4.66), Dry AMD; AG: p=0.28, OR=0.68 [95% 
CI=0.34-1.36], GG: p=0.32, OR=0.67 [95% CI=0.30-1.48]; Table 3.14). 
Also rs1570360 was not associated with AMD or any subtype of AMD in the current cohort 
(AMD overall; GA: p=0.20, OR=1.37 [95% CI=0.87-2.25], AA: p=0.45, OR=1.31 [95% 
CI= 0.65-2.64], wet AMD; GA: p=0.30, OR=1.35 [95% CI=0.75-2.45], AA: p=0.46, 
OR=0.68 [95% CI=0.25-1.86], dry AMD; GA: p=0.23, OR=1.45 [95% CI=0.78-2.70], 
AA: p=0.07, OR=2.08 [95% CI=0.93-4.65]; Table 3.14). Univariate logistic regression 
analysis showed that the risk allele C of rs8333061, the risk allele G  of rs13207351 as well 
as risk allele A of rs1570360 were not associated with AMD [(rs8333061; AMD overall; 
T: p=0.41, OR=1.59  [95% CI=0.83-1.62], wet AMD: p=0.08, OR=1.42 [95% CI=0.93-
2.16], dry AMD; p=0.84, OR=0.94 [95% CI=0.62-1.43], rs13207351; AMD overall; 
p=1.00, OR=1.01 [95% CI=0.72-1.41], wet AMD: p=0.23, OR=1.27 [95% CI=0.84-1.93], 
dry AMD; p=0.31, OR=0.80 [95% CI=0.53-1.21]), (rs1570360; AMD overall; p=0.25, 
OR=1.23 [95% CI=0.86-1.76], wet AMD: p=1.00, OR=0.98 [95% CI=0.62-1.54]) but the  
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Table 3.14 Logistic regression analysis of genotype and allele frequencies of VEGF polymorphisms in AMD patients and controls 
Genotype 
VEGF 
rs8333061 
Overall OR (95%CI) 
p 
value 
Wet AMD OR (95%CI) 
*p 
value 
Dry AMD OR (95%CI) 
*P 
value 
Est. Z value   Est. 
Z  
value 
  Est. 
Z 
value 
  
CC - -  
1.05 (0.68- 1.62) 
2.05 (0.96- 4.37) 
- 
0.86 
0.44 
- - - 
1.34 (0.62- 2.86) 
1.89 (0.86-4.15) 
- 
0.44 
0.10 
- - - 
0.86(0.43- 1.72) 
0.84(0.39-1.79) 
- 
0.68 
0.65 
CT 0.05 0.24 0.29 0.75 -0.14 -0.40 
TT 0.71 1.85 0.64 1.60 -0.17 -0.44 
Allele 
Frequency 
Controls AMD   
Allele 
frequency 
  
Allele 
frequency 
  
C 142 (47%) 131 (44%) 
1.59 (0.83-1.62)  0.41 
58 (39%) 
1.42 (0.93-2.16)  0.08 
73 (49%) 
0.94 (0.62-1.43)  0.84 
T 158 (53%) 169 (56%) 92 (61%) 77 (51%) 
rs13207351 
AA - -  
0.97 (0.53- 1.76) 
1.12 (0.58-2.17) 
- 
0.93 
0.72 
- - - 
1.55 (0.69-3.48) 
1.96 (0.82- 4.66) 
- 
0.28 
0.12 
- - - 
0.68(0.34- 1.36) 
0.67(0.30- 1.48) 
- 
0.28 
0.32 
AG -0.02 -0.08 0.43 1.06 -0.38 -1.07 
GG 0.11 0.34 0.67 1.52 -0.39 -0.97 
Allele 
Frequency 
Controls AMD   
Allele 
frequency 
  
Allele 
frequency 
  
A 140 (47%) 135 (45%) 
1.01 (0.72-1.41)  1.00 
59 (39%) 
1.27 (0.84-1.93)  0.23 
76 (51%) 
0.80 (0.53-1.21)  0.31 
G 169 (53%) 165 (55%) 91 (61%) 74 (49%) 
rs1570360 
GG - -  
1.37 (0.84- 2.25) 
1.31 (0.649- 2.64) 
- 
0.20 
0.45 
- - - 
1.35 (0.75-2.45) 
0.68 (0.25- 1.86) 
- 
0.30 
0.46 
- - - 
1.45(0.78-2.70) 
2.08(0.93- 4.65) 
- 
0.23 
0.07 
GA 0.32 1.27 0.30 1.01 0.37 1.19 
AA 0.27 0.75 -0.37 -0.73 0.73 1.79 
Allele 
Frequency 
Controls AMD   
Allele 
frequency 
  
Allele 
frequency 
  
G 209 (70%) 195 (65%) 
1.23 (0.86-1.76)  0.25 
105 (70%) 
0.98 (0.62-1.54)  1.00 
90 (60%) 
1.53 (0.99-2.35)  
0.04/0
.12 A 91 (30%) 105 (35%) 45 (30%) 60 (40%) 
*p values corrected by simultaneous inference, Est.; Estimate 
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risk allele ‘A’ of the SNP  rs1570360 was found to be associated with dry AMD; p=0.04, 
OR=1.53 [95% CI=0.99-2.35]; Table 3.14) but the association did not remain significant 
after the p-values were corrected. 
3.7.4.2 Intron 4, 27bp VNTR in NOS3 
Multivariate logistic regression analysis of the intron 4, 27 bp VNTR in NOS3 showed that 
the genotype frequencies were not associated with AMD (ba; p=0.22, OR=1.59 [95% 
CI=0.87-2.90], aa; p=0.07, OR=1.91 [95% CI=0.47-7.66]; Table 3.15), nor with wet AMD 
(ba; p=0.1, OR=1.80 [95% CI=0.86-3.73], aa; p=0.8, OR=1.88 [95% CI=0.36-9.56]; Table 
3.15) or with dry AMD (ba; p=0.7, OR=1.41 [95% CI=0.69-2.87], aa; p=0.9, OR=1.55 
[95% CI=0.31-7.66]; Table 3.15). Univariate logistic regression analysis showed that the 
risk allele ‘a’ was associated with AMD in the overall cohort (p=0.01, OR=1.57 [95% 
CI=1.00-2.28]; Table 3.15), as well as with wet AMD (p=0.008, OR=1.81 [95% CI=1.15-
2.84], but not with dry AMD (p=0.11, OR=1.40 [95% CI=0.91-2.16]; Table 3.15).  
3.7.5 Screening Polymorphisms in Genes Implicated in Oxidative Stress 
3.7.5.1 MMPs 
Two SNPs, rs17576 and rs243866, in MMP9 and MMP2, respectively, were genotyped in 
the AMD cohort and controls. Multivariate logistic regression analysis showed that 
rs17576 in MMP9 was significantly associated with AMD (AG; p=0.005, OR=8.47 [95% 
CI=1.57-45.5]; GG; p=0.05, OR=5.34 [95% CI=0.97-29.25]; Table 3.16)), but not with 
any of the sub-types of AMD (Table 3.16). Univariate logistic analysis showed that the risk 
allele ‘G’ was not associated with AMD (p=1.00, OR=1.06 [95% CI=0.8 2-1.38]; Table 
3.16), nor any subtype of AMD (Wet AMD; p=1.00, OR=0.97 [95% CI=0.68-1.33]; Dry 
AMD; p=0.60, OR=1.15 [95% CI=0.85-1.56]; Table3.16).  
For the rs243866 SNP in MMP2, multivariate logistic regression analysis showed that the 
homozygous risk genotype ‘AA’ was significantly associated with AMD (AA; p=0.01, 
OR=4.98 [95% CI=1.25-19.88]; Table 3.16), and also with dry AMD (AA; p=0.01, 
OR=5.55 [95% CI=1.22-25.1]; Table 3.16), but not with wet AMD (AA; p=0.06, OR=4.76 
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Table 3.15 Logistic regression analysis of genotype and allele frequencies of the 27-bp VNTR polymorphism in NOS3 in AMD 
patients and controls  
Genotype 
NOS3 
Overall 
OR (95% CI) 
*P 
value 
Wet AMD 
OR (95% CI) 
*P 
value 
Dry AMD 
OR (95% CI) 
*P 
value Est. Z value Est. 
Z 
value 
Est. 
Z 
value 
Bb -- --   -- --   -- --   
Ba 0.46 2.04 1.59 (0.87- 2.90) 
0.04/0.
22 
0.58 2.13 1.80 (0.86- 3.73) 
0.03/
0.1 
0.34 0.26 1.41 (0.69- 2.87) 
0.19/0
.7 
Aa 0.64 1.23 1.91 (0.47- 7.66) 
0.21/0.
76 
0.63 1.02 1.88 (0.36- 9.56) 
0.30/
0.8 
0.44 0.73 1.55 (0.31- 7.66) 
0.46/0
.9 
Allele 
Frequency 
Con AMD  
Allele 
Frequency 
 
Allele 
Frequency 
 
B 446 (89%) 504 (84%) 
1.57 (1.0-2.28) 0.01 
205(85%) 
1.81 (1.15-2.84) 0.008 
299 (85%) 
1.40 (0.91-2.16) 0.11 
A 54 (11%) 96 (16%) 45 (18%) 51 (15%) 
*p values corrected by simultaneous inference, Est.; Estimate, Con.; controls 
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Table 3.16 Logistic regression analysis of genotype and allele frequencies of MMP9 (rs17576) and MMP2 (rs243866) polymorphisms 
in AMD patients and controls 
Genotype 
MMP9 
(rs17576) 
Overall 
OR (95%CI) 
p value/ 
*p-value 
Wet AMD 
OR (95%CI) 
p value/ 
*p-value 
Dry AMD 
OR (95%CI) 
p value/ 
*p-value Est. Z value Est. Z value Est. 
Z 
value 
AA -- --   -- --       
AG 2.13 3.33 8.47 (1.57- 45.5) 
00008/ 
0.005 
2.55 2.45 12.92 (0.85- 19.6) 
0.01/ 
0.07 
1.90 2.46 6.7 (0.88- 50.4) 
0.01/ 
0.07 
GG 1.67 2.58 5.34 (0.97-29.25) 
0.009/ 
0.05 
1.78 1.69 5.93 (0.37- 92.5) 
0.09/ 
0.3 
1.56 2.00 4.78 (0.62- 36.7) 
0.04/ 
0.22 
Allele  
Frequency 
Con. AMD  Allele Frequency  Allele Frequency  
A 175 (35%) 201 (66.5%) 
1.06 (0.82-1.38) 0.61/1.00 
90(36%) 
0.97 (0.68-1.33) 0.8/1.00 
111(32%) 
1.15 (0.85-1.56) 0.33/0.60 
G 325 (65%) 399 (33.5%) 160(64%) 239(68%) 
MMP2(rs243866) 
GG -- --   -- --   -- --   
GA -0.01 -0.05 0.98 (0.57-1.69) 
0.95/ 
1.00  
-0.22 -0.85 0.79 (0.39-1.61) 
0.39/ 
0.9 
0.09 0.39 1.09 (0.58- 2.04) 0.69/0.9 
AA 1.60 3.07 4.98 (1.25-19.88) 
0.002/ 
0.01 
1.56 2.54 4.76 (0.94-24.1) 
0.01/ 
0.06 
1.71 3.00 5.55 (1.22- 25.1) 0.002/0.01 
Allele 
Frequency 
Con. AMD  Allele Frequency  Allele Frequency  
G 421 (84%) 469 (78%) 
1.48 (1.08-2.05) 0.01/0.02 
202 (81%) 
1.26 (0.83-1.91) 0.25/0.5 
267 (76%) 
1.60 (1.12-2.29) 0.008/0.01 
A 79 (16%) 131 (22%) 48 (19%) 83 (24%) 
*p values of genotype frequency corrected by simultaneous inference and p values of allele frequency corrected by Bonferroni method, 
Est.; Estimate, Con,; Controls,  
111 
 
[95% CI=0.94-24.1]; Table 3.16). Similarly, univariate logistic regression analysis showed 
that the risk allele ‘G’ was associated with AMD (p=0.02, OR=1.48 [95% CI=1.08-2.05]; 
Table3.9), as well as with dry AMD (p=0.01, OR=1.65 [95% CI=1.15-2.37]), but not with 
wet AMD (p=0.5, OR=1.26 [95% CI=0.83-1.91]; Table 3.16). 
3.7.5.2 TIMP3 
A previously reported AMD-associated SNP (rs5749482) 100 kb upstream of TIMP3 was 
screened in AMD cases and controls. The multivariate logistic regression analysis adjusted 
for age, gender and smoking status showed that the genotype and allele frequencies of the 
polymorphism rs4420638 were not associated with AMD. As the homozygous genotype 
AA was present in in only a few cases, the heterozygous and homozygous genotype groups 
were added together in the combined AMD multivariate logistic regression analysis (AMD 
overall; p=0.60, OR=1.13 [95% CI=0.70-1.81], wet AMD; p=0.73, OR=1.10 [95% 
CI=0.60-2.02], dry AMD; p=0.48, OR=1.21 [95% CI=0.70-2.06]; Table 3.17). Univariate 
logistic regression analysis showed that the risk allele C was also not associated with the 
disease in the overall data (p=0.69, OR=1.08 [95% CI=0.72-1.63]) nor with the subtypes 
of the disease (wet AMD; p=0.80, OR=1.06 [95% CI=0.63-1.78], dry AMD; p=0.65, 
OR=1.10 [95% CI=0.69-1.74]; Table 3.17). 
3.7.5.3 TNF and ILβ  
The SNP rs1800629 in TNF and SNP rs16944 in ILβ were genotyped in the AMD cohort 
and controls. Multivariate logistic regression analysis showed that there was no genotype 
association between the TNF rs1800629 SNP and the AMD cohort nor with any subtype of 
AMD (Table 3.18). For rs16944 in ILβ, multivariate logistic regression analysis showed 
that the  heterozygous genotype ‘CT’ as well as homozygous risk allele ‘TT’ were 
significantly associated with AMD (CT; p=0.01, OR=1.87 [95% CI=1.10-3.18]) TT; 
p=0.02, OR=2.38 [95% CI=1.06-5.38]; Table 3.18), and also with wet AMD (CT; p=0.05, 
OR=2.01 [95% CI=1.0-4.12], TT; p=0.009, OR=3.23 [95% CI=1.21-8.62]; Table 3.18) as 
well as with dry AMD but only with the CT genotype (CT; p=0.006, OR=2.17 [95% 
CI=1.16-4.06], TT; p=0.15, OR=2.29 [95% CI=0.85-6.21]; Table 3.18). Univariate logistic 
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Table 3.17 Logistic regression analysis of genotype and allele frequencies of the rs5749482 polymorphism near TIMP3 in AMD patients 
and controls 
Genotype 
TIMP3 
(rs5749482) 
Overall 
OR (95% CI) 
P 
value 
Wet AMD 
OR (95% CI) 
P 
value 
Dry AMD 
OR (95% CI) 
P 
value Estimate Z value Est. 
Z 
value 
Est. 
Z 
value 
GG - - 
1.13 (0.70- 1.81) 0.60 
- - 
1.10 (0.60- 2.02) 0.73 
- - 
1.21 (0.70- 2.06) 0.48 
GC+CC 0.124 0.51 0.10 0.33 0.19 0.69 
Allele  
Frequency 
Controls Overall  
Allele 
Frequency 
 
Allele 
Frequency 
 
G 340 (87%) 450 (86%) 
1.08 (0.72-1.63) 0.69 
185 (86%) 
1.06 (0.63-1.78) 0.80 
265 (86%) 
1.10 (0.69-1.74) 0.65 
C 50 (13%) 72 (14%) 29 (14%) 43 (14%) 
Est.; Estimate, Con.; Controls 
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Table 3.18 Logistic regression analysis of genotype and allele frequencies of rs1800629 in TNF and rs16944 in ILβ in AMD patients 
and controls  
Genotype 
TNF 
rs1800629 
Overall 
OR (95%CI) 
*p 
value 
Wet AMD 
OR (95%CI) 
*p 
value 
Dry AMD 
OR (95%CI) 
*P 
value Estimate  Z value Est. Z  Est. 
Z 
value 
GG -- --   -- --   -- --   
GA 0.15 0.62 1.16 (0.60- 2.27) 0.5/0.9 0.33 1.08 1.40 (0.61- 3.18) 0.27/0.8 0.08 0.27 1.08 (0.49- 2.38) 0.78/0.9 
AA 0.19 0.20 1.21 (0.09- 15.38) 0.8/0.9 1.21 1.13 3.37 (0.19- 57.9) 0.25/0.8 -0.53 -0.41 0.58 (0.01- 17.4) 0.67/0.9 
Allele  
Frequency 
Controls AMD  
Allele 
Frequency 
 
Allele 
Frequency 
 
G 461 (92%) 545 (91%) 
1.19 (0.76-1.87) 
0.44/0.
88 
224 (90%) 
1.37 (0.78-2.38) 
0.27/0.5
4 
321 (92%) 
1.06 (0.62-1.81) 0.79/1.00 
A 39 (8%) 55 (9%) 26 (10%) 29 (8%) 
ILβ rs16944 
TT -- --   -- --   -- --   
TC 0.62 3.14 1.87 (1.10- 3.18) 
0.001/0
.01 
0.70 2.5 2.01 (1.00- 4.12) 
0.009/0.
05 
0.77 3.27 2.17 (1.16- 4.06) 
0.001/0.00
6 
CC 0.87 2.83 2.38 (1.06- 5.38) 
0.004/0
.02 
1.17 3.16 3.23 (1.21- 8.62) 
0.001/0.
009 
0.83 2.21 2.29 (0.85- 6.21) 0.02/0.15 
Allele  
Frequency 
Controls AMD  
Allele 
Frequency 
 
Allele 
Frequency 
 
T 348 (70%) 371 (62%) 
1.41 (1.09-1.83) 
0.008/0
.01 
148 (59%) 
1.57 (1.13-2.19) 
0.005/0.
01 
223(64%) 
1.30 (0.96-1.76) 0.07/0.14 
C 152 (30%) 229 (38%) 102 (40%) 127 (36%) 
*p values corrected by simultaneous inference, 
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regression analysis showed that the risk allele ‘T’ was associated with [95% CI=1.09-1.83]; 
Table3.18), and with wet AMD [p=0.01, OR=1.57 [95% CI=1.13-2.19], but not with dry 
AMD (p=0.14, OR=1.30 [95% CI=0.96-1.76]; Table 3.18).  
3.8 Summary 
The Summarised results of the multivariate logistic regression (OR and 95% CI) are 
presented in the forest plots (Fig. 3.16; POAG, Fig. 3.17; PACG and Fig. 3.18; 
PEXG, Fig. 3.19; wet AMD and Fig. 3.20; dry AMD). 
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Fig 3.16 Forest plot of the SNPs screened for POAG. Diamond shape represents OR, horizontal lines represent 95% CI, HG; 
heterozygous genotype, VG; variant allele genotype, AF; Allele frequency, * the p values were significant before correction for 
multiple testing. The vertical line at unit 1 represents the central value of OR. All the horizontal lines that cross this line represent non-
significant association of the SNPs. Those left of this central line are protective (OR<1), and those right of the line are risk-conferring 
SNPs (OR>1).     
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Fig 3.17 Forest plot of the SNPs screened for POAG. Diamond shape represents OR, horizontal lines represent 95% CI, HG; 
heterozygous genotype, VG; variant allele genotype, AF; Allele frequency. The vertical line at unit 1 represents the central value of 
OR. All the horizontal lines that cross this line represent non-significant association of the SNPs. Those left of this central line are 
protective (OR<1), and those right of the line are risk-conferring SNPs (OR>1).   
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Fig 3.18 Forest plot of the SNPs screened for POAG. Diamond shape represents OR, horizontal lines represent 95% CI, HG; 
heterozygous genotype, VG; variant allele genotype, AF; Allele frequency, * the p values were significant before correction for 
multiple testing. The vertical line at unit 1 represents the central value of OR. All the horizontal lines that cross this line represent non-
significant association of the SNPs. Those left of this central line are protective (OR<1), and those right of the line are risk-conferring 
SNPs (OR>1).   
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Fig 3.19 Forest plot of the SNPs screened for POAG. Diamond shape represents OR, horizontal lines represent 95% CI, HG; 
heterozygous genotype, VG; variant allele genotype, AF; Allele frequency, * the p values were significant before correction for 
multiple testing. The vertical line at unit 1 represents the central value of OR. All the horizontal lines that cross this line represent non-
significant association of the SNPs. Those left of this central line are protective (OR<1), and those right of the line are risk-conferring 
SNPs (OR>1).   
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Fig 3.20 Forest plot of the SNPs screened for POAG. Diamond shape represents OR, horizontal lines represent 95% CI, HG; 
heterozygous genotype, VG; variant allele genotype, AF; Allele frequency. The vertical line at unit 1 represents the central value of 
OR. All the horizontal lines that cross this line represent non-significant association of the SNPs. Those left of this central line are 
protective (OR<1), and those right of the line are risk-conferring SNPs (OR>1).  
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4 Discussion 
Glaucoma and AMD are multifactorial diseases, caused by a combination of genetic and 
environmental factors. Some of the features reflecting the complex nature of the diseases 
are their heterogeneous nature (different genes causing the same phenotype) and polygenic 
involvement (more than one gene interacts to cause the disease). In addition, environmental 
factors also influence disease progression (phenocopies), and sometimes the mutation 
carriers do not have disease symptoms due to the presence of modifier elements. In 
addition, such diseases may also not necessarily follow Mendelian rules of inheritance 
(Faucher et al., 2002; Baird et al., 2003; Pang et al., 2002; Lander and Schork 1994). For 
such complex diseases, although it is difficult but is very important to ascertain the 
pathogenic nature of the variant, penetrance of the disease and age of disease onset. 
Moreover another indicator of the pathogenicity of a certain variant is indicated by its 
higher presence in affected individuals as compared to an unaffected control population 
(Alward et al., 1998). 
In an attempt to identify the underlying genetic factors in Pakistani patients implicated in 
multifactorial disorders including glaucoma and AMD, genetic screening was carried out 
for 20 families with glaucoma and 2 families with AMD. In the glaucoma families, possible 
novel disease genes were identified, including a possible novel locus for PCG. The 
previously associated glaucoma genes MYOC, OPTN and WDR36 were found not to be 
involved in the pathogenesis of glaucoma in the studied Pakistani families. However, a 
mutation in CYP1B1 was found to be involved in the pathogenicity of PCG in a Pakistani 
family. Of the 20 families studied, in 4 (20%) families of glaucoma a possible genetic cause 
was identified in the current study. Along with the screening of the familial cases, case-
control association analysis for both glaucoma and AMD was carried out where 12 SNPs 
in 1000 cases with glaucoma (500 POAG, 200 PACG and 300 PEXG) and 300 controls, 
and 16 SNPs in 300 cases with AMD and ~300 controls were studied. In the Pakistani 
population a few SNPs were found to have a protective role while others had a pathogenic 
role and yet others had no role in the pathogenicity of the diseases. The difference in the 
association of the SNPs in Pakistani populations as compared to the populations in which 
the SNPs are associated with the respective diseases (glaucoma and AMD) might be due 
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to variations in the distribution of the alleles of a particular SNP in various populations of 
the world.  
4.1 Glaucoma Families 
All the glaucoma families were pre-screened for candidate glaucoma genes MYOC OPTN, 
WDR36 and CYP1B1. Though MYOC is known to be involved in disease progression in 
2.6% to 4.4% of POAG cases (Fingert et al., 1999), no pathogenic variant in the gene was 
found in the current cohort with the exception of a non-synonymous SNP (rs2234926). 
This variant was identified in 16 probands, and was therefore screened in a panel of 
unrelated POAG, PACG and PEXG patients. However, no significant association was 
found for rs2234926 with the different types of glaucoma. This polymorphism is a 
recurrent SNP among MYOC variations and being the most common SNP it is reported to 
be disease-associated in various populations (Lam et al., 2000; Pang et al., 2002). In 
addition, mutations in MYOC occur in various populations of the world with varying 
frequency; 8% of Italian glaucoma patients carry MYOC variants, whereas in the Finnish 
population no MYOC variants were identified (Lam et al., 2000; Pang et al., 2002; Fingert 
et al., 1999). In the Indian population, mutations in the gene are reported to be responsible 
for 2% of POAG cases (Sripriya et al., 2004). Although no disease-causing mutation was 
found in the current cohort, recently the c.1130C>T, p.(Thr377Arg) variant in MYOC has 
been reported to be a disease-causing mutation in a Pakistani family (Waryah et al., 2013). 
This indicates the possibility that the gene might be involved in the pathogenesis of 
glaucoma in the Pakistani population, but is probably a rare cause of the disease. Similarly, 
in the current cohort only a known pathogenic SNP, Met98Lys, was found in OPTN in 
three probands. The result is not surprising as the association of the SNPs and mutations in 
OPTN varies among various populations of the world (Leung et al., 2003; Ayala-Lugo et 
al., 2007). The original study that highlighted OPTN as a candidate gene for glaucoma 
described the Met98Lys, was found in OPTN in three probands. The result is not surprising 
as the variant to be associated with NTG (Rezaie et al., 2002). Although subsequent studies 
showed conflicting results about the involvement of the variant in glaucoma, meta-analysis 
did indicate association of the Met98Lys, was found in OPTN in three probands. The result 
is not surprising as the variant with glaucoma but only a weak association was found in 
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various Asian populations (Ayala-Lugo et al., 2007; Alward et al., 2003; Fuse et al., 2004; 
Sripriya et al., 2006). Keeping in view the diversity of the association of this SNP with 
different populations, Ayala-Luogo et al (2007) proposed that the involvement of 
rs11258194 might be evaluated in glaucoma families as well as in sporadic cases. Thus in 
the current study the segregation of rs11258194 was checked in the families of the 3 
probands (in whom it was initially identified), as well as its association with sporadic 
POAG, PACG and PEXG cohorts. Although the SNP did not segregate in the 3 POAG 
families, an interesting pattern of segregation was seen when the overall frequency 
distribution of the alleles was calculated in the affected as well as unaffected family 
members. In this analysis it was observed that of the total individuals 2 (11%) had the 
ancestral TT genotype, 14 (78%) were heterozygous (TA) and 2 (11%) had the 
homozygous variant allele (AA). This pattern was not seen in unaffected controls 
(TT=96.4%, TA=3.6%, AA=0%), or sporadic cases of POAG (TT=90.8%, TA=9%, 
AA=0.2%). Although this variant did not segregate in the families, the preponderance of 
the TA genotype in the families suggests a possible role in the progression of the disease. 
This genotype may interact with some other unknown gene and thus increase the risk of 
glaucoma in the families carrying this variant. In order to preclude the possibility that the 
high prevalence in the affected families was by chance, we also analyzed two other POAG 
families in which this variant was not found in the probands, but none of the members of 
these families were found to carry the variant A allele. This further strengthens our 
conjecture that when present, this variant might play a role in the initiation or progression 
of the disease in the affected families. In addition, this SNP has previously been reported 
to be associated with low IOP, and thus has a modifying effect on the glaucoma phenotype. 
OPTN increases the sensitivity of glial neuronal cells to risk factors of glaucoma, even at 
normal IOP (Melki et al., 2003). In the current study no difference was detected between 
the IOP in patients with and without this variant, which is in agreement with the previous 
work of Ayala-Luogo et al. (2007) who also did not find an IOP lowering effect of the 
variant allele of this SNP. However, its role in an increased risk due to sensitivity of glial 
cells at normal IOP cannot be ruled out, thus studies of NTG patients are required to further 
validate this.  
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When WDR36 was screened in the familial cases no mutation was found in any of the cases. 
Previously Monemi et al (2005) have shown that WDR36 was associated with Glaucoma, 
where they found 4 mutations in this gene present in 11 patients. However, in subsequent 
studies of the same gene no association of WDR36 was observed with glaucoma (Fingert 
et al., 2007; Footz et al., 2009) thus making it one of the rare genes causing glaucoma in a 
select ethnic group.  
In the current cohort, there were three families of PCG, and in one family (GLC 2) among 
thethem a possible novel locus on chromosome 7 was found to be linked with the disease, 
and in another family (GLC 16) a mutation (Arg290Profs*37) in CYP1B1 segregated with 
the disease. One family however, remained unsolved. The incidence of PCG worldwide is 
1:10,000, which is much higher among populations where the rate of consanguineous 
marriages is higher (Papadopoulos et al., 2007). To date the highest incidence of PCG has 
been found in Gypsies (1:1,250) (Gencik 1989) and Saudis (1:2500) (Gencik et al., 1982) 
whereas in India 1:3300 children suffer from PCG (Dandona et al., 1998). In the Pakistani 
population the ratio of consanguineous marriages is much higher (Afzal et al., 1994; 
Hussain and Bittles 1998), hence the rate of PCG is expected to be high but due to a lack 
of epidemiological studies the exact rate is not known. To date 4 loci (GLC3A to GLC3D) 
have been reported to be associated with PCG (Sarfarazi et al., 1995; Akarsu et al., 1996).  
Two genes in two of these loci have been found to be involved in the pathogenicity of PCG, 
one of which is well established; CYP1B1 in GLC3A (Stoilov et al., 1997) and LTBP2 in 
GLC3D. The later still needs to be functionally validated for its involvement in PCG 
(Moren et al., 1994). It has been more than a decade that CYP1B1 has been shown to be 
causative in PCG patients (Sarfarazi et al., 1995), and screening of POAG and PCG for 
CYP1B1 in different populations of the world has revealed various mutations involved in 
the pathogenesis of the disease. Mostly these mutations have been identified in 
homozygous form in PCG patients owing to the recessive pattern of inheritance of the 
disease (Stoilov et al., 1998). Nearly 150 mutations are known in CYP1B1, causing PCG 
in various populations while a few of them have been identified to be disease-associated in 
the Pakistani population, which include p.Leu177Pro, p.Ile87Val, p.Asp374Asn (Beier and 
Fahimi 1985), p.Ala288Pro, p.Asp242Ala (Micheal et al., 2014). This higher prevalence 
of mutations in a particular gene resulting in the same phenotype in a population is 
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indicative of its pathogenicity and screening of this gene could be effectively used as a 
diagnostic tool for pre-screening of PCG patients before whole genome analysis. 
Another interesting result of the current work was the identification of possible trigenic 
inheritance in a JOAG family (GLC 1). Novel variants in MYO18A, ENOX1 and COL9A2 
segregated with the disease in one loop (GLC1a) of the family, while in the other loop 
(GLC1b) a variant in NCOA7 segregated with the disease in the family. The difference in 
both loops was the age at which the symptoms of the disease started to appear. In the loop 
where the three variants were present the mean age of onset was 25 years, whereas in the 
loop where this possible trigenic pattern was absent, the mean age of onset of the disease 
was 50 years. The interaction of different genes resulting in variation in the age at which 
the symptoms of a particular phenotype appear within the same family has also been 
reported previously in glaucoma, where a single mutation in MYOC (Gly399Val) resulted 
in disease development among the affected individuals at a mean age of 57 years, and when 
this mutation was present in tandem with a mutation in another gene, CYP1B1 
(Arg368His), it resulted in a lower mean age of disease onset to 27 years (Vincent et al., 
2002).  
Among the three variants, the variant in MYO18A (c.2071C>T; p.Arg691Cys) lies in a 
highly conserved region in 12 species (phyloP 4.40) where it is present in the motor head 
domain of the protein, resulting in the change of a basic amino acid (Arg) to a hydrophobic 
amino acid (Cys), which gave a higher physicochemical difference among the two amino 
acids (Grantham distance=180). SIFT analysis revealed the variant as deleterious and 
Mutation Taster categorises the variant as disease-causing. The gene MYO18A encodes a 
P21 activated kinase (PAK) involved in Golgi localization, cytoskeleton maintenance and 
acts as an immunological cell surface protein (Hsu et al., 2010). Moreover, it also plays an 
important role in the migration ability of epithelial cells (Taft et al., 2013). The motor 
domain of MYO18A has a binding site for ATP and F-actin, and it is localized near the 
cell periphery in the lamellar actomyosin bundles (Taft et al., 2013). There is no previous 
report of the involvement of the gene in pathogenicity of glaucoma, but in a study 
conducted by Thomas et al (2011) on the differential expression of protein phosphorylating 
genes in response to increased pressure on the glial cells (astrocytes), the authors found 
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that MYO18A was one of the few genes highly expressed in the region as a result of 
increased hydrostatic pressure. Inhibition of the protein kinases can result in the disruption 
of the actin filaments, present in the eyes, which can  change the TM and as a consequence 
alter the ECM matrix composition and aqueous humor outflow (Thomas et al., 2011), 
which can result in raising the IOP. High expression of the gene is seen in the mouse eye 
(genome.ucsc.edu). All members of the family in the current study carrying the variant had 
elevated IOP, which was reduced to the normal range by the use of medicine.   
The second variant (c.171G>A, p.Met57Ile) in the family (GLC1) was found in the Ecto 
NADH Oxidase (ENOX1) disulphide exchanger 1 gene. This variant also lies in a highly 
conserved region of the gene in 12 species (phyloP 5.37), resulting in the change of 
methionine (Met) to isoleucine (Ile). As both amino acids are hydrophobic, the 
physicochemical difference is low (Grantham distance=10) and the pathogenicity 
predicting programme SIFT grades the variant as tolerated, whereas Mutation Taster 
identifies it as a disease-causing variant. The ENOX1 exhibits oxidoreductase activity as 
well as N disulphide thiol interchange activity (Jiang et al., 2008). It also plays an essential 
role in the plasma membrane electron transport pathway, which in turn is involved in 
cellular defence, intracellular redox homeostasis and control of cell growth and survival 
(Venkateswaran et al., 2014). It has been observed that there are strong interactions 
between the plasma membrane and cytosolic redox homeostasis imbalance and oxidative 
stress. Once the ratio is imbalanced the induction of Bcl-2 occurs resulting in apoptotic cell 
death (Morré and Morré, 2012).    
The third variant (c.1061C>T, p.Pro345Leu) segregating with the disease in the family was 
located in the collagen, type IX, alpha 2 (COL9A2) gene, present in a highly conserved 
region in 11 species (PhyloP 4.48). This change results in incorporation of the amino acid 
leucine instead of the normally translated amino acid proline. As both amino acids are 
hydrophobic, there is very little physciochemical difference between them (Grantham score 
21). The pathogenicity predictor SIFT predicts the variant to be deleterious and the 
Mutation Taster grades it as disease-causing. This is a rare variant and has been assigned a 
reference SNP number rs201772619. The collagens play an important role in strengthening 
and structurally supporting connective tissues (Bruce et al., 2007) such as tendons and 
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ligments. The type 9 collagens are the most flexible collagens among all. Mutations in the 
genes coding the protein are known to cause dominant multiple epiphyseal dysplasia 
(Villemain et al., 1990), intervertebral disc disease (Higashino et al., 2007) and Stickler’s 
syndrome (Baker et al., 2011). The features of Stickler syndrome are distinctive facial 
appearance, eye abnormalities, hearing loss and joint problems. The eye abnormalities can 
be severe myopia (mostly), increased IOP and glaucoma, retinal detachment as well as 
cataract (Nikopoulos et al., 2011; Pagon et al., 2012). Mutations in the gene have 
previously been reported to cause severe myopia in Han Chinese (Chen et al., 2014a).  
Glaucoma in the above mentioned family may possibly be due to a result of the combined 
effect of all the three variants. The combination of these variants may also result in 
lowering the age of onset of the disease, as in the patients (GLC1b) where the variant was 
not present the age of onset of the disease was much higher. Moreover it was observed that 
an individual who had both variants in MYO18A and ENOX1 had no symptoms of the 
disease. Therefore, it is hypothesized that the presence of the third variant in COL9A2 
interacts with the other two variants and results in the appearance of the phenotype at an 
early age. Another possibility is that only one variant among the three is responsible for 
the disease pathogenicity and COL9A2 variant is deemed to be the most likely disease 
causative variant in this family. However, there is still a need of conducting functional 
studies to validate the involvement as well as the interaction of these variants with each 
other in the manifestation of disease. As opposed to this, the variant (c.724G>A, 
p.Val242Met) in exon 11 of NCOA7 (nuclear receptor coactivator 7) segregated with the 
disease in the loop with higher age of onset of the disease. The variant lies in a highly 
conserved region (PhyloP 6.18) resulting in a change of valine to methionine in the 
peptidoglycan-binding lysin domain. As both amino acids are hydrophobic, there is a small 
physiochemical difference between them (Grantham distance=21). The pathogenicity 
predicting software SIFT scores the variation deleterious, Mutation Taster categorises it as 
disease-causing, and PolyPhen considers the variant as probably damaging. NCOA7 
encodes a protein involved in nuclear hormone receptor binding and ligand-dependent 
nuclear receptor transcription coactivator activity. It is involved in the enhancement of the 
transcriptional activities of several nuclear receptors and coactivation of different nuclear 
receptors, such as estrogen receptor 1, thyroid hormone receptor, beta, peroxisome 
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proliferator-activated receptor gamma and retinoic acid receptor, alpha. The gene has been 
implicated in reducing oxidative stress, thus lowering its damaging effects (Durand et al., 
2007), in diseases such as neurological diseases. These are regulated by interferons, 
moreover the exons 11, 12 and 15 are expressed excessively as compared to other exons in 
the neurological disorders (Yu et al., 2014). The variant c.724G>A also lies in the Exon 11 
of the gene and thus functional studies are required for the elucidation of disruption in the 
function of the gene as a consequence of this change. 
Another family with dominant glaucoma (GLC 5) was screened by exome sequencing; the 
family had two individuals with early appearance of glaucoma symptoms. Only one variant 
(c.125C>T, p.Thr42Met) in PHKG1 segregated with the phenotype in the family in a 
heterozygous form, with the exception of the individuals with early appearance of 
symptoms in which it was present homozygously. The variant lies in four overlapping 
domains; the protein kinase catalytic domain, serine-threonine/tyrosine-protein kinase 
catalytic domain, serine/threonine/dual specificity protein kinase catalytic domain and 
tyrosine-protein kinase catalytic domain. This variant lies in a highly conserved region in 
ten different species (phyloP 5.94), and results in an amino acid change from threonine to 
methionine, thus changing a polar uncharged amino acid to a hydrophobic amino acid 
(Grantham score= 81). SIFT scores the variation deleterious, Mutation Taster categorises 
it as disease-causing, and PolyPhen considers the variant to be probably damaging.  
4.2 Case Control Association Analysis: Glaucoma 
Previously reported SNPs associated with POAG in various studies including GWAS, were 
screened in the current glaucoma cohort. Since recent studies have suggested that common 
genetic factors might contribute to various forms of glaucoma, the current study was 
extended to PACG and PEXG. A summary of the SNPs genotyped for glaucoma in the 
Pakistani cohort and their pathways is given in Figure 4.1. Results indicated association of 
SNPs in HSP70 and NOS3 with all three types of glaucoma, whereas an association of 
BIRC6 and P450 polymorphisms was observed only with PEXG. No association was 
observed for SNPs in PDIA5, P21 and P53 with any type of glaucoma in the current cohort. 
Besides these SNPs, three SNPs in genes PLEKHA7, COL11A1 and PCMTD1 were 
recently reported to be associated with PACG in the Asian population, therefore the SNPs 
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Figure 4.1 Summary of the SNPs genotyped for glaucoma. ‘*’ represents the SNPs that were genotyped for PACG only, ER; 
Endoplasmic Reticulum, TM; Trabecular Meshwork. 
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were studied in the current cohort which identified only the COL11A1 SNP to be associated 
with PACG. 
Stress and apoptosis induced RGC degeneration is accentuated by the involvement of 
multiple factors such as raised intraocular pressure (IOP), vascular abnormalities and 
oxidative stress. These genes play an important role in oxidative stress and apoptosis and 
one of the mechanisms via which the modification of cells as a result of oxidative stress 
are dealt with, is controlled expression and regulation of various genes. NOS3 and HSP70 
are two such genes, which are expressed in the cells in response to stress-inducing factors 
such as heat, toxic metabolites, high intensity light and free radicals (Fletcher et al., 2008). 
These genes have been shown to elicit enhanced transcription levels of the respective 
mRNA when the body is under stress (Ishii et al., 2003; Liu and Neufeld 2003). NOS3 is 
involved in different processes, such as neurotransmission, the regulation of vascular tone, 
vasodilatation and apoptosis. In addition, it also regulates blood flow to the ocular tissues 
and has been implicated in the pathogenesis of different neurodegenerative disorders, such 
as diabetic retinopathy (Awata et al., 2004), glaucoma (Toda and Nakanishi-Toda 2007) 
and migraines (Gruber et al., 2010). Plasma NO levels are regulated by NOS3, thus any 
environmental or genetic risk factor that enhances NOS3 expression would contribute to 
NO mediated toxicity. It has been previously reported that the VNTR in intron 4 
of NOS3 significantly influences the plasma NO levels. Functional studies have shown that 
the variant ‘a’ allele (with four 27-bp repeats) in homozygous form is strongly correlated 
with increased plasma NO levels, which were found to be twice as high as the level found 
in the ‘b/b’ genotype (with five 27-bp repeats), indicating the NOS3 underlying potential 
for NO-related pathogenicity (Malek et al., 1999).  
The NOS3 expression is regulated at the transcriptional level by microRNAs (Balligand et 
al., 2009) that repress NOS3 expression by interfering with the gene transcription 
efficiency. Moreover the microRNAs act as an endogenous sequence-specific feedback 
regulatory molecule that reversibly inhibited this process and thus enabled the rapid 
turnover of NOS3 molecules to minimize the damage associated with stress and hypoxia. 
Zang et al. (2005) postulated that the amount of microRNA would vary from individual to 
individual. In contrast to the ‘b’ allele with five 27-bp repeats, the variant ‘a’ allele with 4 
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repeats produced fewer microRNAs and hence, reduced transcriptional repression would 
occur, correlating with the increased plasma NO. 
The current results are in line with the above observations, as in the current study 
significant association of the NOS34 a/b genotype was found with all forms of glaucoma 
in the Pakistani cohort, which is probably a result of high plasma NO levels that are toxic 
to the optic nerve and ultimately cause its degeneration, which is a classic hallmark of 
glaucoma. Earlier studies conducted to establish a possible association between glaucoma 
and altered NOS expression focused mainly on POAG patients (Galassi et al., 2004; 
Karantzoulis-Fegaras et al., 1999) and were able to show a positive correlation between 
this polymorphism and the disease, which is in agreement with the current results. 
In the current work, the involvement of the intron 4 VNTR polymorphism of NOS3 was 
also studied in PACG, as impairment in the NO production might lead to closure of the 
angle (Awadalla et al., 2013), which can be partially associated with 
altered NOS3 expression and the resultant NO-mediated neurotoxicity. The current results 
indicate that there is indeed a correlation between PACG and the polymorphism in NOS3, 
as a significantly higher frequency of the variant NOS3 a allele was found in PACG patients 
as compared to the unaffected controls. Previously also the 27bp variant allele of the NOS3 
intron 4 VNTR polymorphism has been shown to be significantly associated with PACG 
in Australians (Awadalla et al., 2013). In the current cohort an association of ‘ba’ and ‘aa’ 
genotypes of the NOS3 gene polymorphism was also found with PACG. As opposed to this 
in the POAG and PEXG cohorts, the heterozygous ‘ba’ genotype was found to be 
associated with the disease. The mechanism behind the PACG pathogenicity might be that 
NO production in the anterior chamber results in the relaxation of the ciliary muscle and 
thus increases the depth of the anterior chamber of the eye (Shi et al., 2014). The site for 
the formation of NOS3 lies in excess in the ciliary muscle, and the outflow passageway of 
the aqueous humor and thus has been proposed to be involved in the regulation of IOP 
(Nathanson and Mckee 1995). The anatomical change induced by NO in PACG is 
postulated to be due to its effect on the activity of MMP9, which when down regulated, 
might result in the narrowing of the anterior chamber and refractive errors by affecting the 
ECM remodelling (Shi et al., 2014). In the presence of the ‘ba’ or ‘aa’ genotype the 
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narrowing of the chamber occurs, which is a characteristic feature of PACG (Shi et al., 
2014). In POAG and PEXG there are other mechanisms such as the accumulation of debris 
in the TM for disease pathogenicity as opposed to the narrowing/closing of the angle, which 
in the later case remains open.  
In glaucoma patients, raised IOP causes stress mediated neuron injury and to overcome 
this stress heat shock proteins (HSPs) are recruited. Besides its protective effects one of 
the side effects of the HSPs is the stimulation of the immune system and engagement of 
the antigen presenting cells. Thus the HSPs not only act as neuroprotective molecules in 
the cell but they can also contribute to the progression of the disease by over-activating the 
auto-stimulatory immune responses leading to optic nerve neuropathy (Tezel et al., 2004; 
Ishii et al., 2003). In glaucoma patients, it has been observed that as a result of activation 
of the immune system, there are increased titers of anti-HSP antibodies, which aid in the 
progression of the disease by minimising the protective abilities of the native HSPs (Tezel 
et al., 2000). 
The regulation of HSPs’ expression pattern determines the fate of the cell, the 
underexpression leads to an inefficient stress response and overexpression drives 
immunodestruction, with the outcome in both cases being damage driven by the oxidative 
free radicals in one case and by cytokines in the other. This is supported by the data of 
Tezel et al. (2000), who have previously shown HSPs to be significant enhancers of both 
the cytoprotective and neurodegenerative functions of the immune system in RGCs and 
glial cells, and clearly demonstrated that these proteins were critical in facilitating the 
glaucomatous changes resulting in optic nerve damage and neurodegeneration. 
The rs1043618 polymorphism in HSP70 screened in the current cohort has previously been 
shown to be associated with reduced HSP70 expression, which could result in an inability 
of the cell to cope with stress and to perform cytoprotective functions. Functional analyses 
of the rs1043618 polymorphism, which maps to the 5′ UTR region of HSP70, has revealed 
that compared with the G allele, the variant C allele causes reduced promoter activity and 
lower HSP70 protein levels (He et al., 2009). Tosaka et al. (2007) had previously reported 
a significant association between the -110A>C polymorphism in HSP70 and POAG 
(p=0.026) in the Japanese population. This polymorphism is known to increase HSP70 
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expression, thus supporting the hypothesis that neuropathy is associated with 
autoimmunity as a result of the elevated HSP70 levels. However, Tosaka et al. (2007) did 
not find any association between glaucoma and the rs1043618 polymorphism. The same 
mechanism might be involved in the onset of PEXG seen in the current study, as the raised 
IOP-induced stress on the RGCs might recruit the HSPs to overcome the stress. Moreover, 
Fung et al. (2005) have reported that lower levels of HSP70 are not able to provide 
protection against neurodegeneration in Alzheimer’s disease. On the basis of a higher 
frequency of the risk allele “C” in PEXG, POAG and PACG patients it is hypothesized that 
this polymorphism might be associated with pathogenesis of all three types of glaucoma.   
In both the primary forms of glaucoma the association of the heterozygous ‘GC’ as well as 
homozygous ‘CC’ genotype was observed with the disease but in the secondary form i.e. 
PEXG, only the homozygous ‘CC’ genotype was found to be associated with the disease. 
In different studies different risk factors of POAG and PACG have been established 
whereas, there is still limited understanding of the factors responsible for PEXG 
predisposition. Raised IOP is the major contributor of OAG in patients with PEXG, but the 
contribution of the risk factors such as the dandruff-like flakes that accumulate in all the 
aqueous bathed surfaces of the eye in PEXG cannot be ignored (Eagle 2012). Differential 
expression of the stress response genes is seen in eyes with PEXG, as seen in the case of 
clustrin gene, an efficient extracellular chaperone, which is down regulated in the case of 
PEXG, resulting in the aggregate formation and accumulation of PEX material in the TM, 
hence clogging it and elevating the IOP (Zenkel et al., 2006). This mechanism might 
indicate that the changes in the PEXG patients carrying the ‘CC’ genotype of the HSP70 
polymorphism is more severe as compared to those carrying the ‘GC’ genotype.     
The current study identified a moderate protective association of the BIRC6 rs2754511 
polymorphism with PEXG in the Pakistani population (p=0.05). In agreement with the 
previous findings in the Salt Lake City and San Diego populations, which demonstrated a 
protective effect of the T allele of rs2754511 on the development of POAG (Carbone et 
al., 2011), this allele in the homozygous form (TT) was also found to be protective in 
PEXG in the current study. BIRC6 is ubiquitin carrier protein involved in the protection of 
the cell against apoptosis and also reduces cellular stress (Carbone et al., 2011; Lamers et 
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al., 2012). Increased intraocular pressure, ROS and free radicals create a stressful 
environment in the eye (Sacca et al., 2007; Izzotti et al., 2011). In the ER, stress can be 
accompanied by the aggregation of misfolded proteins, which can activate a cytoprotective 
signal response known as unfolded protein response (UPR) that triggers the activator 
functions such as adaptation, alarm and apoptosis (Xu et al., 2005). When stress is 
prolonged and adaptation and alarm fail to pull the cell back towards normal conditions, 
the UPR results in activation of apoptosis (Kim et al., 2008) and also elicits an 
inflammatory response in order to restore the normal environment of the cell. This 
mechanism has been found to be involved in the pathogenesis of many neurodegenerative 
disorders such as Alzheimer’s, Parkinson’s and cerebral ischemic insults (Wang and 
Kaufman 2012). Apoptosis might be one of the various mechanisms that is involved in the 
degeneration of RGCs in PEXG. BIRC6 is an anti-apoptotic protein, which promotes cell 
survival by inhibiting caspases (Ren et al., 2005). Association of downregulation of BIRC6 
with various polymorphisms and mutations leads to upregulation of P53, resulting in 
mitochondrial-mediated apoptotic cell death (Ren et al., 2005).  
Another polymorphism in CYP1B1, rs2567206, iwas also screened, which indicated a 
strong association of the polymorphism with PEXG only and not with POAG or PACG. 
CYP1B1 belongs to the family of cytochrome P450 (Zhao et al., 2013) and is involved in 
regulating the metabolic pathways by acting as an intermediate catalyst. This protein also 
plays an important role in the proper development and functioning of the iridocorneal angle 
of the eye (Sarfarazi 1997). Vasiliou and Gonzalez (2008) observed that CYP1B1 deficient 
mice had an abnormal drainage structure, including abnormalities in the trabecular 
meshwork; the same phenomenon has been observed in human PACG patients. Mutations 
in this gene associated with PACG have been reported in Pakistani (Firasat et al., 2008), 
Indian (Kumar et al., 2007) and European families (Reddy et al., 2003; Kakiuchi-
Matsumoto et al., 2001). Polymorphisms in different region of the gene have been reported 
to be associated with modified activity of the CYP1B1 enzyme, which has been shown to 
cause certain types of cancers and POAG in different populations. The SNP rs2567206 has 
previously been found to be associated with PCG but not with primary open angle or angle 
closure glaucoma. It has been hypothesized that the variant results in lowering the activity 
of the promoter in the TM cells, and regulates the gene in vivo (Chakrabarti et al., 2010). 
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It has also been observed that the polymorphism rs2567206 covers the site of the promoter 
region, which contains the binding site of transcription factors and could thus interfere with 
this process (Kim et al., 2002; Price et al., 1992).  
The association of both BIRC6 and CYP1B1 SNP only with PEXG might be due to the 
more aggressive nature of PEXG i.e severe degenerative changes occurring in PEXG as 
compared to POAG or PACG. Moreover, in patients with PEXG the damage to the ONH 
is more severe than in POAG or PEXG in the current cohort as depicted by  the CDRs, 
(mean CDR values; PEXG=0.79±0.26, POAG=0.62±0.23, & PACG=0.61±0.27). The 
extracellular matrix of the trabecular meshwork is disrupted as a consequence of damage 
to the mitochondria, a characteristic mechanism involved in the pathogenicity of POAG 
and PEXG (Izzotti et al., 2011). Konstas et al. (1997) have observed excessive 
mitochondrial alterations in PEXG. The highest level of mitochondrial damage and 
mitochondrial loss per cell was seen in PEXG as compared to POAG, which indicates its 
more aggressive nature. Zenkel et al (2005) have reported differential expression of ECM 
proteins and stress response genes in the eyes of PEXG patients compared to eyes of normal 
healthy controls. The expression of ECM genes is upregulated, resulting in aggregation of 
ECM proteins. Glutathione S-transferase 1, which is involved in protection from oxidative 
stress, has been reported to be downregulated in these patients. In addition, clusterin, an 
efficient extracellular chaperone, is downregulated in PEXG eyes, resulting in aggregation 
of pathologic ECM proteins. Consequently, abnormal proteins accumulate, resulting in the 
formation of pseudoexfoliative material (Zenkel et al., 2006). In the anterior chamber this 
hinders the outflow of aqueous humor by clogging the trabecular meshwork, which results 
in elevation of the IOP (Streeten et al., 1992; Streeten et al., 1990). All these stresses result 
in severe degenerative changes in PEXG.  
The SNP rs1801270 was also screened in the current glaucoma cohort but no association 
was found. The SNP is located in a highly conserved region, which encodes the DNA-
binding zinc-finger domain of the protein and results in incorporation of Arg at position 31 
instead of Ser (Ressiniotis et al., 2005). Incorporation of Arg results in failure to protect 
the RGCs from degeneration in glaucomatous neuropathy. RGC death via apoptosis has 
been extensively explored (Nickells 1999) and the major transcription factor in this 
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apoptotic cascade is P53, which is also known as guardian of the genome (Rosenbaum et 
al., 1998) and is involved in the transcription of the kinase inhibitor P21 (Ressiniotis et al., 
2005). Damage to the DNA causes the activation of the P21 enzyme, which then causes 
cell cycle arrest by inhibiting the cyclin dependent kinases, thus blocking the entry of the 
cell cycle from the G1 to S phase and from the S to G2 phase, finally leading the cell 
towards apoptosis. In normal ocular tissue a higher expression of P53 is usually observed 
(Acharya et al., 2002), therefore it has been speculated that any alteration in its expression 
might stimulate P53-induced apoptosis. Tsai et al (2004) concluded that the post-
transcriptional product of rs1801270 was important in the development of POAG. 
However, studies conducted on Caucasian (Ressiniotis et al., 2005) and Turkish (Saglar et 
al., 2009) populations showed non-significant association of rs1801270 with glaucoma. 
The current results are in agreement with the above mentioned studies as there was no 
association between the P21 SNP and all the three different types of glaucoma in the 
Pakistani population. The distribution of the minor allele of the SNP is highly variable 
among populations; according to NCBI, it is 0.02 among Europeans and reaches 0.41 
among Asians, while Africans and Hispanics had a frequency distribution in between these 
values (Gravina et al., 2009).  
Different studies of Chinese (Lin et al., 2002) and Caucasians (Daugherty et al., 2009) 
have demonstrated significant association of P53 polymorphism (rs1042522) with POAG. 
However, Acharya et al (2002), Saglar et al (2009) and Mabuchi et al (2009) studied P53 
polymorphism in Indians, Turks and Japanese, respectively, and found no association 
between the P53 alleles and POAG. Another interesting aspect of the polymorphism is that 
the presence of Arg is associated with POAG in the Chinese population (Lin et al., 2002) 
whereas the presence of the variant amino acid Pro is associated with POAG in Caucasians 
(Daugherty et al., 2009). The aim of the current work was to study the role of this SNP in 
the Pakistani population and the results of the current study were found to be in agreement 
with Dimasi et al (2005) who also did not find any association of this SNP with POAG. 
One possible explanation of not finding association in the current cohort could be that P53 
might be contributing towards the development of glaucoma as a non-IOP genetic factor 
(Mabuchi et al., 2009; Nickells 1999), increasing the susceptibility of NTG patients toward 
glaucoma as compared to the patients with high tension glaucoma. Since in the current 
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cohort patients were studied with predominantly higher IOP, no association was observed, 
while taking the NTG association under consideration, Dimasi et al (2005) screened their 
patients with NTG for the polymorphism but found no association of the SNP with the 
disease, which might be due to a smaller cohort of patients (62) of NTG in their study.  
In addition a previously associated SNP, rs11720822 in the protein disulphide isomerase 
family A member 5 (PDIA5) gene was also screened, but no association was found with 
the disease in the Pakistani population. The gene is upregulated in response to endoplasmic 
reticulum stress (Hayano and Kikuchi 1995), and the SNP has been shown to be associated 
with POAG in San Diego in a GWAS study (Carbone et al., 2011). According to the dbSNP 
database, occurrence of the T allele of rs11720822 in PDIA5 is very rare in various 
populations of the world including the Asian and African populations 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=rs11720822), which supports 
the current finding, as in the current study high occurrence of the allele was not observed.  
Among the three genes found to be implicated in the pathogenicity of PACG (Vithana et 
al., 2012), the polymorphism rs3753841 in COL11A1 was the only one found to be 
associated with PACG in the Pakistani population. This polymorphism results in a change 
from proline at position 1323 to leucine. The collagen type 11 has two α chains and the 
gene COL11A1 transcribes one of them. Mutations in the gene have already been known 
to cause Marshall syndrome and Stickler syndrome, both of which have glaucoma as one 
of the features, in addition to features such as face flattening, auditory and skeletal 
dysfunctioning. Due to aberrations in this gene, abnormality in the fibrillar collagen matrix 
in the sclera occurs causing ocular deformities. The gene is also expressed in TM cells and 
might be associated with the regulation of aqueous humor drainage, which when aberrant 
might predispose the person to ocular anomaly. Vithana et al (2012) propose that common 
variants in the gene affect the normal ocular architecture and might result in PACG. The 
other two polymorphisms, one in PLEKHA7 (rs11024102) and the other in PCMTD1 
(rs1015213), were not found to be associated with PACG in the current Pakistani cohort. 
PLEKHA7 is involved in stabilizing the cellular junctions (adherens junctions), which are 
essential in the iris, cillary body and aqueous humor outflow and the choroid. The SNP 
rs1015213 resides 120 kb upstream of the gene and is in linkage disequilibrium (LD) with 
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PCMTD1, which has lately been found to play an intertermediate role in apoptosis and 
inflammation. The differences in the association might be attributed to the smaller sample 
size of the current study (200 PACG samples, 200 controls) as compared to the original 
study (3771 PACG samples and 18,551 controls) (Vithana et al., 2012). All three SNPs 
have also been screened in the Indian PACG cohort, which identified an association of 
rs1015213 in PCMTD1 with PACG but not the other two polymorphisms (Duvesh et al., 
2013). The SNPs in COL11A1 and PLEKHA7 have also been reported to be associated 
with higher risk of PACG in the Chinese, where the incidence of PACG is twice as high as 
compared to other Asian populations (Chen et al., 2014b).  
4.3 Familial Screening and Case Control Association Analysis: Age 
Related Macular Degeneration 
Two families with AMD were screened for the candidate gene CFH, in which no 
involvement of the gene variants was found in the current families. Although linkage 
studies for AMD using large families and twin studies has helped to identify the AMD 
susceptibility genes, it has always been difficult to map the plausible genes mainly due to 
the late onset of the disease (Swaroop et al., 2009). The familial studies have helped in the 
discovery of disease causing genetic variants in two major AMD causing genetic loci which 
harbour CFH and ARMS2/HTRA1. Besides the familial studies, case-control association 
studies have contributed tremendously in defining the genetic component of the disease. A 
summary of the SNPs genotyped for AMD in the Pakistani cohort and their pathways; is 
given in Figure 4.2. 
Drusen are the hallmark of AMD in whose formation and accumulation, the components 
of the inflammatory pathway and complement system have been shown to be involved 
(Seddon et al., 2005; Yucel et al., 2012). Polymorphisms in CFH, C3, C2, CFB and few 
other genes have also been reported to be associated with AMD in various populations 
around the world (Deangelis et al., 2011). Besides CFH, variants in ARMS2/HTRA1 have 
also been found to be associated with AMD (Rivera et al., 2005; Klein et al., 2005b).  In 
the current AMD cohort no association was found with the CFH polymorphism rs1061170, 
which is a well-established AMD causative variation in various populations, especially in 
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Europeans and also Indians (Kaur et al., 2006). These results are suggestive of differences 
in the genotype and allele frequency distribution of this polymorphism among and within 
various populations (Rodriguez De Cordoba et al., 2004; Chen et al., 2006). The 
association of the CFH polymorphism appears to be varied specially among the Asian and 
white populations (Tsai et al., 2008). The risk allele of the SNP was found to be lower in 
Asians (Chen et al., 2012; Tsai et al., 2008), whereas it is higher in Europeans (Sofat et al., 
2012). It has recently been reported by the AMD Gene Consortium (Fritsche et al., 2013) 
that there were great differences in effect sizes of the CFH polymorphism when the data 
were stratified on the basis of ethnic background, and the strongest association was found 
in Europeans. Other genes of the complement pathway have also been found to be 
associated with AMD, including C2/CFB and C3 (Fuse et al., 2006; Yates et al., 2007; 
Gold et al., 2006). SNPs that had been previously reported to be significantly associated 
with AMD and are located 100kb upstream of the C2/CFB and C3 genes (Fritsche et al., 
2013) were screened in the current study, but these SNPs were not found to be associated 
with AMD in the current Pakistani cohort, although the variants in these genes have been 
reported to significantly contribute to AMD susceptibility (Swaroop et al., 2009).   
A gene other than the complement pathway genes that has been shown to have a major 
contribution in AMD is ARMS2 (Swaroop et al., 2009). In the current population, the case-
control association analysis identified that the risk allele (T) of the ARMS2/HTRA1 
rs10490924 SNP confers higher risk of developing wet AMD as compared to dry AMD, 
which is in agreement with the study of Sobrin et al (2011). In another study conducted by 
Schwartz et al (2012), it was observed that the variant allele T conferred higher risk towards 
advance bilateral wet AMD. The effect size of the rs10490924 SNP was much higher in 
the current wet AMD cohort (OR=3.57) as compared to the multicentre study conducted 
by Sobrin et al. (2011) although they obtained similar results the effect size was between 
1.34-1.56. ARMS2 is located in the outer mitochondrial membrane and encodes protein 
(age-related maculopathy susceptibility protein 2) of mitochondria (Kanda et al., 2007). 
An indel polymorphism (372_815del443ins54) in the gene has been reported to remove 
the polyadenylation signal, resulting in a higher turnover of the mRNA (Fritsche et al., 
2008). With advancing age, loss in the functional efficiency of the mitochondria occurs, 
resulting in the formation and accumulation of ROS, mutations in the mitochondrial DNA 
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Figure 4.2 Summary of the SNPs genotyped for Age Related Macular Degeneration. ECM; Extracellular Matrix
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and onset of apoptosis (Lin and Beal 2006). It has been observed that in the aging retina 
and particularly in the macular region, cytochrome C deficient cones accumulate as well 
as a higher rate of mitochondrial deletions are detected (Mcbride et al., 2006). The SNP 
rs10490924 has been implicated in mitochondrial dysfunction, which consequently 
increases the susceptibility of the photoreceptors to age associated degenerative changes 
that might be due to the change in the coding sequence (A69S) of ARMS2, affecting its 
conformation and thus interaction of the protein (Kanda et al., 2007).  
A SNP, rs4420638, 14 kb upstream of the gene APOC1 and co-inherited with APOE is 
previously shown to be significantly associated with AMD in the studied population 
(Fritsche et al., 2013) was also screened in the current study, but the SNP was not found to 
be associated with AMD in the current cohort. APOE was initially considered as a plausible 
gene for AMD for two main reasons. First, it was found to be present in drusen associated 
with AMD (Wang et al., 2010) and secondly, due to its involvement in Alzheimer’s (Baird 
et al., 2006), which has many common features with AMD such as the presence of β 
amyloid in the plaques of patients with Alzheimer’s as well as in drusen of patients with 
AMD. In addition, both are diseases that occur at higher age (Ohno-Matsui 2011). The 
gene is involved in the transport of lipids and cholesterol metabolism (Schmidt et al., 
2002), which are essential components of drusen (Wang et al., 2010) and hence the 
involvement of APOE in AMD cannot be ignored, despite the non-association of 
rs4420638 in the current cohort, which could be due to racial differences.    
Microglial cells are present in the retina that respond to oxidative stress by the formation 
of drusen (Combadiere et al., 2007) by the expression of APOE (Xu et al., 2006), proteins 
of the complement system (Bellander et al., 2004), inflammatory components, CX3CR1and  
β amyloid precursor protein (Haass et al., 1991).  These cells are also found to play a 
proangiogenic role in the retina (Checchin et al., 2006), and moreover, in the absence of 
CX3CR1, they secrete VEGF which results in neovascularisation (Combadiere et al., 2007) 
resulting in wet AMD. The risk allele (A) of the chemokine receptor CX3CR1 (Tuo et al., 
2004) SNP rs3732378, and the heterozygous genotype of SNP rs3732379 confer increased 
risk of AMD in the Pakistani population, which is in agreement with previous studies 
(Yang et al., 2010). It is postulated that the variation (rs3732378) in CX3CR1 affects the 
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migratory properties of the microglial cells in the retina, and accumulation in the 
underlying layers of the retina result in drusenogenesis (Combadiere et al., 2007). 
Moreover, lower levels of CX3CR1 have been detected in the macula of patients with 
AMD and both variants, rs3732379 and rs3732378, might be responsible for decreased 
ligand affinity and receptor binding. It is further postulated by Tuo et al (2004) that 
decreased levels of CX3CR1 might be due to the interaction of SNPs present in the 
promoter region that are in LD with the above mentioned SNPs and thus the presence of 
the variant alleles of these SNPs might affect the transcription activity.  
Under stressful conditions, VEGF plays a very important role in the maintenance of the 
vasculature and has been found to be extensively expressed in the eyes of the AMD patients 
where it induces the formation of new vessels in the retina (Shibuya 2008). Moreover, the 
binding of VEGF with its receptor generates a signal cascade that affects NOS3 expression 
(Gelinas et al., 2002; Hood et al., 1998). The expression of NOS3 results in the synthesis 
of NO, which maintains the vascular tone, inhibits apoptosis (Kota et al., 2012) and is a 
key regulator of ocular blood flow (Bhutto et al., 2010). In the promoter region of VEGF 
there are eight SNPs (rs833061 [-460C>T], rs833062 [-417T>C], rs59260042 [-
1210C>A], rs79469752 [-1203C/T], C-160T, rs28357093 [-141A>C], rs1570360 [-
116G>A]) which have previously been reported to be associated with diabetic retinopathy 
(Churchil et al., 2008), and recently found to be involved in neovascularisation in Pakistani 
diabetic patients with retinopathy (unpublished data). Keeping in view the involvement in 
the Pakistani diabetic retinopathy patients, the SNPs were also screened in the current 
AMD cohort. However, none of the SNPs were found to be associated with AMD in this 
cohort, although the risk allele of rs1570360 [-116G>A] showed a trend towards 
association (after correction for multiple testing p=0.07) with AMD but did not reach the 
level of significance. The 27bp intron 4 VNTR polymorphism of NOS3 was also screened 
in the current AMD cohort, and it was observed that the risk allele ‘a’ was significantly 
associated with wet AMD. The risk allele of the NOS3 polymorphism has previously been 
reported to be associated with macular edema in the Japanese (Awata et al., 2004). The 
NO produced results in the vasodilatation of the ocular vessels but free radicals produced 
in oxidative stress deactivate the NO function, which further catalyses the lipid 
peroxidation resulting in enhancement of stress in the ocular tissue (Beckman et al., 1990). 
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The minor allele ‘a’ has been shown to be associated with lower production of NO, which 
under oxidative stress can increase the damage to the cells (Zhang et al., 2008). Previously 
NO has been found in lower amounts in the plasma of AMD patients (Totan et al., 2001) 
and reported to have an adverse effect on vascular functions (Bhutto et al., 2010).  
In the current cohort the SNP rs243866 in MMP2 and SNP rs17576 in MMP9 were also 
screened to determine their association with AMD. Both these SNPs were found to be 
associated with AMD (wet and dry AMD combined) and with the dry AMD in the 
subgroup analysis. However, the association remained significant only for rs243866 after 
correction for multiple testing, although SNP rs17576 had a mild association with both wet 
AMD and dry AMD, before the correction for multiple testing, which might be the reason 
that overall the SNP is strongly associated with AMD. It is hypothesised that the risk allele 
(A) and genotype (AA) of MMP2 rs243866 increases the predisposition towards dry AMD.  
Both MMPs belong to the subgroup of gelatinases that cleaves the collagenases (Sethi et 
al., 2000). The MMPs maintain the balance of extracellular matrix (Birkedal-Hansen et al., 
1993), which in the eyes includes the interphotoreceptor matrix (IPM) and the BM 
(Plantner 1992). The MMP2 and MMP9 proteins are abundantly found in the IPM. It is 
postulated that disproportion of these MMPs against their tissue inhibitors TIMPs in the 
IPM can cause a pathological condition (AMD) in the retina. MMP2 and MMP9 proteins 
have been found in higher levels in the RPE associated ECM in patients of AMD (Plantner 
et al., 1998b; Plantner et al., 1998a). The SNP rs17579 has also been screened in Chinese 
Han, but was not found to be associated with AMD (Zeng et al., 2014). The MMP activity 
is controlled by expression of the tissue inhibitors of MMPs and posttranslational 
modifications and thus by the control of expression level (Sternlicht and Werb 2001). The 
SNP rs243866 is located in the promoter region of MMP2 (-1575 position) and has been 
found to be associated with reduced transcriptional activity (Harendza et al., 2003). 
Various studies found SNPs near the tissue inhibitor metalloproteinase 3 (TIMP3) gene to 
be significantly associated with AMD. The protein remodels the extracellular matrix in the 
retina (Francis and Klein 2011). The mutated gene causes Sorby’s fundus dystrophy, which 
is an early onset degeneration of the macula (Weber et al., 1994). The previously associated 
SNP rs5749482 in TIMP3 was studied in the current AMD cohort, but no association of 
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the SNP was found. Although the variation in the SNP has previously been reported as not 
associated with AMD (Stone et al., 2001), Abecasis et al (2004) speculate that the 
variations in the gene might be involved in interacting with some other variants in AMD 
susceptible genes and also suggest environmental influences to cause the late effects of the 
disease (neovascularisation).      
Several Interleukins have been reported to play a key role in the pathogenesis of AMD 
(Seddon et al., 2005; Klein et al., 2005a). IL-6 was previously shown to be involved in 
increasing the risk of AMD independently (Seddon et al., 2005), moreover, IL-10 has been 
postulated to suppress neovascularisation in wet AMD by regulating  macrophages, which 
are known to be anti-angiogenic factors (Apte et al., 2006). This interleukin is suggested 
to suppress the influx of macrophages by having inhibitory effect on the cytokines that 
attract macrophages (Ferguson et al., 1994). In the current cohort the risk allele ‘C’ and the 
homozygous genotype ‘CC’ of the SNP rs16944 in ILβ was found to increase the risk of 
wet AMD with an effect size of 1.57 and 3.23, respectively. However, the ‘CT’ genotype 
of the SNP is associated with both wet and dry AMD, and the homozygous ‘CC’ genotype 
was associated with dry AMD, but the association did not remain significant after the p 
value was corrected for multiple testing. In a study conducted by Tsai et al. (2008), it was 
postulated that the risk allele of the associated interleukin (IL-8) also increased the risk of 
developing wet AMD in the Taiwanese. This SNP (rs16944) has previously been shown to 
be associated with schizophrenia (Shirts et al., 2006) and bipolar disorder (Papiol et al., 
2008). The SNP is in the promoter region of the gene (-511) and has been shown to increase 
the expression of the gene in combination with another variant in the promoter region of 
the gene at -31 position (Hulkkonen et al., 2000; Hall et al., 2004).    
SNP rs1800629 located in the promoter region of the ubiquitously expressed cytokine 
tumor necrosis factor-alpha (TNF-α) was also screened in the current AMD cohort, but no 
association of the polymorphism was found. The protein is involved in various processes 
such as inflammation, immune-regulation and apoptosis (Vassalli 1992) and the 
polymorphism has been associated with elevated TNF-α production (Wilson et al., 1997), 
which has been associated with various complications in the eyes such as diabetic 
retinopathy (Yoshioka et al., 2006; Limb et al., 1999) and glaucoma (Huang et al., 2009). 
145 
 
This polymorphism was also found to be associated with PEXG in the Pakistani population 
(Khan et al., 2009) but the same polymorphism was not associated with PEXG in 
Europeans of Caucasian descent (Mossbock et al., 2009). The difference in the associations 
might be due to the difference in the distribution of the genotypes among various 
populations of the world (Mossbock et al., 2009).       
4.4 Conclusion 
In the present study the genetic cause of familial and sporadic cases with glaucoma and 
AMD were studied in the Pakistani population. This is the first time that a genetic screening 
of AMD and whole genome screening of familial glaucoma in Pakistan has been 
conducted, which has resulted in the identification of possible novel genes and a possible 
novel locus linked to glaucoma. The association analysis of sporadic glaucoma and AMD 
was also conducted for various polymorphisms, which were found to be significantly 
associated with various populations in GWAS. Some of those polymorphisms were found 
to be associated with the current population, either playing a pathogenic or a protective 
role; whereas the rest of them were not associated with the disease, indicating genetic 
heterogeneity. These differences among different association studies might be due to 
geographical and ethnic variations in the studied populations.  
4.5 Future Perspective 
Glaucoma and AMD are both complex disorders and their complexity is attributed to the 
contribution of numerous genes with varying degrees of effects. Although high throughput 
techniques like GWAS have resulted in discovery of interesting genes but due to 
restrictions such as differences in phenotyping and screening methods, replicating such 
studies becomes difficult. Moreover, in the current study several genes could not be 
functionally validated. Also genes implicated by functional studies could not be found to 
be associated in genetic studies. Therefore the requirement is to characterize these diseases 
at the molecular level using high throughput techniques. For such complex disorders, 
whole genome sequencing is the method of choice for understanding their genetic etiology. 
Functional studies would further be required for the validation of the genetic data, followed 
by validation through proteomic approaches, animal models and replication studies in 
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different populations. Only then it would be possible to unravel the causative agents of 
these complex disorders and their underlying molecular mechanisms that will further help 
in developing better therapeutic interventions. 
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Annexure 1 Product size and primer sequences used to amplify the exons and intron-exon 
junctions of MYOC and OPTN   
Gene Exon Primer sequence 5’ to 3’ Product size (bp) 
MYOC 1_A 
F-CAGGCACCTCTCAGCACAG 
406 
R-AGCCCCTCCTGGGTCTC 
MYOC 1_B 
F-ACCCAACGCTTAGACCTGG 
432 
R-TGTAGCAGGTCACTACGAGCC 
MYOC 2 
F-CAACATAGTCAATCCTTGGGC 
255 
R-AACACAGCACTAGACATGAATAAAGAC 
MYOC 3_A 
F-GCATGATCATTGTCTGTGTTTG 
521 
R-GCTGTAAATGACCCAGAGGC 
MYOC 3_B 
F-GAGAAGGAAATCCCTGGAGC 
500 
R-CCAGGAGCCCTGAGCATC 
OPTN 4_A 
F-GGGGGACAGCTCTATTTTCA 
224 
R-CTGCTCACCTTTCAGCTGGT 
OPTN 4_B 
F-AAACCTGGACACGTTTACCC 
146 
R-TAGTGCAAAGGGATGGCATT 
OPTN 5_A 
F-TCCACTTTCCTGGTGTGTGA 
218 
R-TTTTCCAAGCTCTTCCTTCAA 
OPTN 5_B 
F-CAGAAGGAAGAACGCCAGTT 
160 
R-CATCACAATGGATCGGTCTG 
OPTN 6_A 
F-ATGGTGCCCAGCCTTAGTTT 
201 
R-CGCTGGAGTTCAGCTTGAG 
 
OPTN 
6_B 
F-CCAGGTGGTGAGGCTACAAG 
219 
R-CAATCCTTGGCTTGTGTTGA 
 
OPTN 
7 
F-TGGGTTGCATGTCACAAAAA 
206 
R-GACAGCCCGAGTCTTCCTTC 
 
OPTN 
8_A 
F-TTGGAATTTTTCTGATGAAAACC 
154 
R-CTGATTCCCTTCCCTTAGGC 
OPTN 8_B 
F-CAGATGGGGCCAAGAATTAC 
214 
R-CTTTAAATGGGTGAACTGTATGG 
OPTN 9 
F-CCCAATTGTAAACAATGTTCTTTTT 
244 
R-GTGTGTGGGTGTGGTAGTGG 
Larger exons were split into two amplicons A & B. F; Forward, R; Reverse  
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Annexure 1 cont. 
Gene Exon Primer sequence 5’ to 3’ 
Product 
size (bp) 
OPTN 10 
F-TGGTTCAGCCTGTTTTCTCC 
235 
R-TCAAAGGAGGATAAAATTGCTCTC 
 
OPTN 11 
F-TTAAAAGCCACTGCGACGTA 
239 
R-GCTGCCCTTCTGACTCAACA 
 
OPTN 12 
F-ATTTTCCCCAGGATTCCATT 
194 
R-AACGTTCAACAGTTTCTGTTCATT 
OPTN 13 
F-ACTAAAACAGGCAGAATTATTTCAA 
242 
R-AGCTGGGGTTTTGGAAGGT 
 
OPTN 14 
F-CGCATAAACACTGTAAGAATCTGC 
236 
R-GATGTGAGCTCTGGGTCCTC 
 
OPTN 15 
F-TGTCATGTTTCGGGGTTGTA 
213 
R-TGAAGTGGAATTTTTCTTCAAGC 
OPTN 16 
F-CGCCATCTGTTCTTCAAGTG 
232 
R-ACCAACAGTTTTGGGGAGGT 
F; Forward, R; Reverse  
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Annexure 2 Product size and primer sequences used to amplify exons and intron-exon 
junctions of WRD36 and CYP1B1   
Gene Exon Primer sequence 5’to 3’ Product size (bp) 
CYP1B1 1_A 
F-GGAGTCCGGGTCAAAGC 
577 
R-AAAGTACCTACCACGCCACC 
CYP1B1 1_B 
F-GTCACTGAGCTAGATAGCCT 
844 
R-GGACAGTTGATTTATGCTCACC 
CYP1B1 2 
F-AGACCACGCTCCTGCTACTC 
168 
R-GAGCGAACGAGAGGTGAGC 
WDR36 1 
F-CTAGGCAACGTGCTGGAGAC 
463 
R-GAGTTAGAGGCCAAGGAGGG 
WDR36 2 
F-GAGGTTATATCTTAATCTTCAGGTG 
211 
R-TTACCTTGGCTTCCTTATATGC 
WDR36 3 
F-CAAGGTGATTTCCTATCCTTAGTTTG 
409 
R-TAGTTCCAGAGTGTGCTGGG 
WDR36 4 
F-AACAGAAGCATCTCAGGATTAGC   
321 
R-TTTACAGGCAAAATCTCTGGC 
WDR36 5 
F-AAATTACATTTACAAGTTGCCTCTC 
475 
R-CCTCTGATACAGGGGACCAAC 
WDR36 6 
F-TGTAGCTGATATTGTTTTCCTCC 
185 
R-TCCTGAAACTGAAGGATTTTCC 
WDR36 7 
F-TTTGATAACACCTAATAATGATGCG 
350 
R-TTGCCTTTTACTCCAGTATTCATTC 
WDR36 8 
F-TGAATACTGGAGTAAAAGGCAAAG 
492 
R-TGCAATCATGTCACCTGCTG 
WDR36 9 
F-GCTTGCAGATCAGATGGAAC 
247 
R-CAAACCTCATACTGGGCACC 
WDR36 10 
F-TTCCCTTTAAAGTGTCCCAAAC 
274 
R-TTGATGAAACTTCCTCCAGTTG 
WDR36 11 
F-TTTCTGACTTAAATGGGAATATCTTG 
278 
R-AAAACAGCATACAGTAGGAAATAAATG 
WDR36 12 
F-AGTGTCTGAAATATTGGATGCC 
375 
R-TTTGTGGCTTTGGGTTATGC 
WDR36 13 
F-GCTTTGGAAAGCATAAAGTGC 
306 
R-TGATTATAACCCATCTTCAACTTTAG 
Exon 1 was split into two amplicons A & B, F; Forward, R; Reverse  
 
190 
 
Annexure 2 cont. 
Gene Exon Primer sequence 5’to 3’ Product size (bp) 
WDR36 14-15  
F-TGTGTATTGTTCAGAGAGAAACACTG 
620 
R-GGATAACACACCCAAACAAAAG 
WDR36 16  
F-TGAAGCCTGCATTATCTTTTC 
318 
R-AAAGCATATAACCCATTAACTATCGG 
WDR36 17  
F-GACTTTCTGATCAATGCTGGTG 
437 
R-GCTGTCTACATTATCAAGCAGATG 
WDR36 18  
F-GCATATTCGCACTCTGACTTACTC 
551 
R-TGCACTAAACTTTGCCTTTGG 
WDR36 19  
F-CATTGAAGAAGGTGTTTTGGG 
577 
R-CATCCAAATGTCTGCTGAGTG 
WDR36 20-21  
F-GAAATTAAATATGAGAAACTGTTGGC 
541 
R-TGAGAACGCTGATATTTCCTTC 
WDR36 22  
F-TCAATTATTTTGGGTTTCATTCTAC 
413 
R-AGATAGCACTGCCCCAGAAG 
WDR36 
23  
F-TGTCTTTTGTGGTTCCTTGG 
326 
R-TCACATTGACACTTGGAAAATAAG 
F; Forward, R; Reverse 
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Annexure 3 Standard PCR reagent concentrations  
Reagent Stock 
Concentration 
Working 
concentration 
Reaction 
volume (25µl) 
Annealing 
temperature 
dNTPs 25mM 0.2mM 0.2µl 
58 oC 
Buffer 10X 1X 2.5µl 
MgCl2 25mM 1.5mM 1.5µl 
Forward Primer 10µM 0.2µM 0.5µl 
Reverse primer 10µM 0.2µM 0.5µl 
Taq polymerase 5U/µl 1U 0.2µl 
gDNA - 100ng/µl 2µl 
PCR water - - 17.6µl 
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Annexure 4 Product size and primer sequence and PCR products for candidate genes in the 
homozygous regions of GLC 2, GLC 4 and GLC 8  
Gene Exon Primer Sequence  Product size 
(bp) 
TMEM74 1 
F-CTGGCCTACAACTCCCG 
R-ATTCGAGGTACGGATGTGTC 
340 
 2_A 
F-AGGAGCAACACTCCTGGAAG 
R-TCCCCAGGGTGATTATGC 
523 
 2_B 
F-TGCAGCCAGGAATTAGAAAC 
R-AGTTTTGCAGACTCTTTGGAAG 
515 
 2_C 
F-GGCGTCATCCTGTCCTG 
R-AAGAAATAATTTGTAGACTGGGTC 
501 
 2_D 
F-CAGCCACACCTATCCTTCTG 
R-TGACCCTGGCTAATATCTGG 
507 
 2_E 
F-ATGTTGGGCTTTCCTTATTG 
R-TGTGAGTGGGAGGTGAGTTC 
616 
PXDN 1 
F-CCCTCGGGGATTCAGAG 
R-TTCGGAGGTTCCCTTCTG 
518 
 2 
F-GCAAATGTGTAGCGATGTTTG 
R-TGAGTTCTACCTACAGATAAACAATG 
212 
 3 
F-AATGTGACCTTTTCCAAGGC 
R-CAATAATTCATAAGCAGCACG 
260 
 4 
F-TTTCCGTCTGAAGTTTGACC 
R-ACTCCACTGGTCCCTACAAG 
210 
 5 & 6 
F-TGATATCTGAATTTGAAATGACTAGG 
R-GAATCAGATTGTTATCAACATTTCAC 
709 
 7_A 
F-CTGATGGATGGATGGACAAG 
R-TGATGGTTGCCACTGAGC 
213 
 7_B 
F-CTCAAACACACTTCACTGCG 
R-GTCTGTGTCTGCATGTGTGTC 
664 
 8 
F-CATCTGTGGTTTCCTTTTGG 
R-TGTGGTTTGGGTGTCTGAG 
290 
 9 
F-GGGTGAGGTACGTCTTTGTG 
R-AGGCAGATAGTGAGGGACG 
291 
 10 
F-AAACCATGTCAAACCGGG 
R-GCTAGTGGAGGGGTGAGG 
388 
Larger exons were split into two or more amplicons A, B, C, D & E, F; Forward, R; Reverse 
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Annexure 4 Cont. 
Gene Exon Primer Sequence  Product size 
(bp) 
 11 
F-AGACGTCTGCCAAGACTGTG 
R-GTGGAAATGTGTGCTTCCTG 
399 
 12 
F-CAGGAGTTCTCCATGCG 
R- CAACGCTTTATAACGAAGAGTAAC 
319 
 13 
F- GCAGGGGATTTTGTTCTTC 
R- CAGCCCGTCTACCTTGTATC 
244 
 14 
F- CCCAACCCTAGGTCAGATAAC 
R- ACACTAGGGACCTGCGG 
297 
 15 
F- ATGCCTTGTGGCTAATGATG 
R- TAATCACTCCCACCTTCACC 
271 
 16 
F- AGCAATGATTATATTTTGGGG 
R- GTTCAACCCCGTTACTCAG 
298 
 17_A 
F- CCCTCACACATCCTCCAG 
R- CTGTCCGTCGGAGAAGC 
486 
 17_B 
F-GAGAATGGCTTCAACACCC 
R-CATAGTAGATGGTGTCGCCG 
736 
 17_C 
F-TCAACCAGCTCACCTCCTAC 
R-TTGCAGTAGACCCTGTAGTCG 
826 
 17_D 
F-CGGCGACACCATCTACTATG 
R-AGGTTCCCATCTTGACCTTC 
735 
 18 
F-AGCATTGTGGAGAGATGCAG 
R-AGAAGATACCAGGGCCTCAG 
465 
 19 
F-GTGACCTGTGAGTCTCCTGC 
R-AGCAGTCACCAAAACCAGG 
322 
 20 
F-CTTAATTTCCCCGAGGTCAG 
R-AGGATGCCGGTCCTACTG 
260 
 21 
F-CCAGGAAACCTTGAAATGAG 
R-AGGGCTGTGCTGCTGTG 
268 
 22 
F-GCCAAGCTGTTACTCTGAAG 
R-GGACTCTCGGACTTGCG 
225 
 23 
F-GAGCTGACAGGCTTTGCTC 
R-ACCCGATCTCACGATGG 
243 
Exons 17 was split into 4 amplicons A, B, C & D. F; Forward, R; Reverse 
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Annexure 5 Product size and primer sequences for the gene SH3PXD2B 
Exon Primer sequence  Product 
size (bp) 
1 
F-AGCTCCAGGTTCCCTGC 
R-GGAGGCAGAAGTTTTCCAAG 
262 
2 
F-AACCCACGTCTTTCTGACTCT 
R-TGGACTCTAAAGCTGTAGTGGAA 
266 
3 
F-AAATGTCCTAGATGATGTTTAGTGC 
R-AGGGCTCTGGGAACTGTAAC 
206 
4 
F-CTGAGAGCTTGTCCCTGTTC 
R-TTTTATTGTTGAGCATCTTGTAGC 
221 
5 
F-TGGGTTTGCTTTTGTGTTTG 
R-GCTAAGTGAAGTGCGGTCTC 
452 
6 
F-TCACGTCAATACATGGCAAG 
R-CCTGGTGCACAGTTGGTG 
164 
7 
F-GCTCTGACTCCTGCTCTTTC 
R-TTCCAAATGTTTCATGTCCC 
270 
8 
F-ATTCACTGGTACAGTGGCTG 
R-AGGCCAAAAGAAGAGATTGG 
295 
9 
F-GGATTACGGCATCCCAAG 
R-GTCCCTGTGACCCCAAAC 
255 
10 
F-GTGATTCCCAGTAGGAGCAA 
R-TCTGGGCCTCTGTTTTCTTA 
445 
11 
F-ATAGACCCGACCTGGCAC 
R-CTAGTGGACACCCCTCACAG 
189 
12 
F-ACAGGGTCGCAGGAGTG 
R-GACAGGGGAGAAGTAGGAGG 
257 
13_A 
 
F-CAAACCATTCCATCTGCTG 
R-ATCGGCAAAATCACGCC 
564 
13_B 
 
F-TCAGCAGGCTACGAGGAG 
R-GGCAGGCCTGAGCTTAC 
507 
13_C 
 
F-GAGAAGCCAGATGCCACTC 
R-TGGAGAGAAAAGGTTTGGC 
556 
13_D 
 
F-AAACCTCTTCGTCATCCAGG 
R-AATACGTGGGTAAAGCCAGC 
494 
Exon 13 was split into 4 amplicons A, B, C & D. F; Forward, R; Reverse 
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Annexure 6 Homozygous regions obtained in the affected members of family GLC 2, GLC 
4 and GLC 8 
Family GLC 2 
Chromosome Flanking SNP Boundaries (Mbs) Size (Mbs) 
Chr. 3  rs2372548-rs12715538 43,801,895-58,931,816 15.1 
Chr. 7 rs2354332-rs4727933 138,534,971-147,937,132 9.4 
Chr. 15 rs1104848-rs12914158 56,112,714-58,070,608 1.9 
Chr. 15 rs2970374-rs1816625 60,108,779-61,437,557 1.3 
Chr. 15 rs2044029-rs9920103 71,679,959-78,435,527 6.7 
Family GLC 4 
Chr. 1 rs7512461-rs16861320 102408762-168665346 66.25 
Chr. 2 rs4954099-rs6758983 134757957-175192260 40.43 
Chr.10 rs4980024-rs10886726 80839269-122386632 41.54 
Family GLC 8 
Chr. 3 rs17746160-rs2710779 148,533,397-192,100,439 43.56 
Chr. 4 rs1315962-rs6535574 111,033,550-148,928,801 37.89 
Chr. 6 rs6927090-rs6456313 25,214,5-20,251,699 19.99 
Chr.11 rs11602762-rs7121949 116,129,53-312,881,60 19.67 
SNP, single nucleotide polymorphism; Mbs, mega bases 
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Annexure 7 Unsolved glaucoma Families A; JOAG family GLC4, B; Late glaucoma onset family GLC6, C; Late glaucoma onset 
family GLC7, D; Late glaucoma onset family GLC 9, E; A PACG family GLC10 and F; Late glaucoma onset family GLC11.  
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Annexure 7 Continued.  G; Late onset POAG family GLC12, H; A PACG GLC13, I; A PACG family GLC14, J; A JOAG family 
GLC15, K; Recessive PCG Family GLC1 
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